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Abstract 
Influenza virus replication relies on the functionality of its trimeric RNA dependent RNA 
polymerase complex under the conditions provided by the infected cell. PB2 is an essential 
component of this complex and is known to be a key factor for influenza virus host range. 
Given its importance, the interplay of PB2 with the cellular host proteome was investigated in 
several studies and various interaction partners such as protein phosphatase 6 (PP6) have 
been reported. However, these studies were mostly performed with laboratory/mouse-
adapted strains or in the context of transiently transfected cells. 
Here, a combined affinity-purification/mass spectrometric approach was performed to identify 
novel interaction partners of PB2 of seasonal and highly pathogenic viral strains in infected 
human alveolar epithelial cells (A549). The subsequent analysis of selected cellular 
interaction partners aimed to determine the influence of these proteins on the replication 
cycle of these non-laboratory adapted viral strains. Furthermore, differences in their 
relevance for the seasonal and the highly pathogenic influenza viruses were investigated in 
order to gain further insights into the basis of the diverse replication characteristics of these 
viruses in human cells. 
By generation and use of recombinant influenza viruses carrying a Strep-tag at the C-
terminus of their PB2 protein, affinity purification upstream of mass spectrometry (MS) 
enriched PB2 and its interaction partners while non-specific contaminants got reduced. To 
further increase specificity, and thereby confidence in the results, Stable isotopic labelling by 
amino acids in cell culture (SILAC) quantification method was employed and an internal 
control, namely A549 cells infected with un-tagged seasonal virus, was included. The mass 
spectrometric analysis resulted in a list of 487 protein groups that were significantly changed 
and more abundant in tagged samples in comparison to the internal control. The list included 
already described polymerase regulator like ANP32A as well as proteins like SLC12A2 that 
have not been shown to interact with PB2 so far. After addition of more stringent filter criteria, 
the list was further condensed resulting in 22 hit proteins. A selection of 13 proteins was 
further analyzed, and co-precipitation with PB2 was confirmed for 9 proteins. Moreover, 
polymerase activity assay in hit protein overexpressing cells revealed an inhibitory or 
stimulatory effect of 11 proteins on polymerase activity. Five of these proteins showed 
different effects on the polymerase activity of the seasonal or the highly pathogenic influenza 
virus strain. 
Out of the proteins shown to have an influence on polymerase activity and to co-precipitate 
with PB2 in an overexpression setting, HSPA8 was selected for further investigation. HSPA8 
belongs to the 70 kilo Dalton heat shock protein (HSP70) family. Besides its various roles in 
cellular homeostasis, HSPA8 was previously shown to interact with influenza virus M1 
protein and was proposed to play a role in the nuclear export of viral ribonucleoprotein 
(vRNP). Co-precipitation of endogenous HSPA8 with PB2 was demonstrated by 
immunoprecipitation from lysates of A549 cells infected with seasonal or highly pathogenic 
influenza virus. In addition, confocal microscopy showed HSPA8 relocates into the nucleus of 
infected A549 cells. While the influence of HSPA8 on the highly pathogenic strain remained 
unclear due to inconclusive results, its importance for seasonal influenza virus life cycle was 
demonstrated. Overexpression of HSPA8 resulted in increased polymerase activity. On the 
other hand, HSP8 knock down resulted in reduction of viral replication and viral polymerase 
activity of up to ~ 70 % and ~ 40 %, respectively. Intriguingly, the knock down of HSPA8 led 
to a strong decrease of PB2 protein expression. However, this was only observed for 
seasonal PB2. These results indicate a role of HSPA8 as a PB2 chaperone, necessary for 
protein stability of seasonal but not highly pathogenic influenza virus. 
 
Zusammenfassung 
Die Replikation von Influenzaviren ist angewiesen auf die Funktionalität des trimeren RNA 
abhängigen RNA Polymerase Komplexes im Kontext der infizierten Zelle. PB2 ist ein 
essentieller Bestandteil dieses Komplexes und bekannt für seine Schlüsselrolle in der 
Bestimmung des Wirtsspektrums von Influenzaviren. Aufgrund der Bedeutung von PB2 
wurde das Zusammenspiel des zellulären Wirtsproteoms mit dem viralen Protein bereits in 
mehreren Studien untersucht und verschiedene PB2-Interaktionspartner, wie zum Beispiel 
die Protein Phosphatase 6 (PP6), wurden identifiziert. Diese Studien wurden allerdings meist 
mit Labor/Maus-adaptierten Influenzastämmen oder im Kontext von transient transfizierten 
Zellen durchgeführt.  
Diese Arbeit diente der Identifizierung neuer Interaktionspartner von PB2 eines saisonalen 
und eines hochpathogenen Influenzavirus Stammes im Kontext infizierter humaner alveolar 
Epithelzellen (A549) unter Einsatz massenspektrometrischer Analysen von 
affinitätschromatographisch gereinigten Proteinkomplexen. Die anschließende Untersuchung 
ausgewählter zellulärer Interaktoren hatte zum Ziel deren Einfluss auf den Replikationszyklus 
der nicht Labor-adaptierten Stämme zu bestimmen. Außerdem sollten mögliche 
Unterschiede in Ihrer Relevanz für das saisonale und das hochpathogene Influenzavirus 
identifiziert werden um Hinweise auf die Grundlage für das verschiedene 
Replikationsverhalten dieser Viren in humanen Zellen zu erlangen. 
Die Erzeugung und Nutzung von Influenzaviren die einen Strep-tag am C-Terminus ihres 
PB2 Proteins tragen ermöglichte eine affinitätschromatographische Anreicherung von PB2 
und seiner Interaktionspartner gegenüber unspezifischer Kontaminationen. Um die Spezifität 
weiter zu erhöhen wurde die sogenannte „Stable isotopic labelling by amino acids in cell 
culture (SILAC)“ Quantifizierungsmethode angewendet. Darüber hinaus wurde eine interne 
Kontrolle, A549 Zellen infiziert mit einem saisonalen Stamm ohne Strep-tag am PB2 Protein, 
in die Untersuchung mit einbezogen. Die massenspektrometrische Analyse zeigte eine 
signifikante Anreicherung von 487 Proteingruppen in Strep-tag Proben im Vergleich zur 
internen Kontrolle. Diese Kandidatenliste enthielt sowohl bereits bekannte Polymerase-
regulatoren wie ANP32A, als auch Proteine, wie z.B. SLC12A, die noch nicht als 
Interaktionspartner von PB2 beschrieben wurden. Das Hinzufügen weiterer Filterkriterien, 
resultierte in einer 22 Proteine umfassenden Hitliste. Eine Auswahl an 13 Proteinen wurde 
tiefer gehend analysiert und eine Komplexbildung mit PB2 konnte für 9 Proteine bestätigt 
werden. Darüber hinaus offenbarte ein Polymerase-Aktivitäts-Assay in Hit-Protein über-
exprimierenden Zellen einen stimulierenden bzw. hemmenden Effekt von 11 Proteinen. Fünf 
dieser Proteine zeigten einen regulatorischen Einfluss auf die Polymerase-Aktivität des 
saisonalen und des hochpathogenen Stammes. 
Aus den Proteinen, die nach Überexpression mit PB2 kopräzipitierten und einen Einfluss auf 
die Polymerase-Aktivität zeigten, wurde das Protein HSPA8 zur weiteren Untersuchung 
ausgewählt. HSPA8 gehört zur Familie der 70 kDa Hitzeschockproteine (HSP70) und erfüllt 
mehrere Aufgaben in der Aufrechterhaltung der Zellhomöostase. Darüber hinaus interagiert 
HSPA8 mit dem Influenzavirusprotein M1. Dieser Interaktion wurde eine Rolle im nuklearen 
Export von viralen Ribonukleoproteinen (vRNPs) zugeschrieben. Kopräzipitation von 
endogenem HSPA8 mit PB2 wurde mit Hilfe von Immunopräzipitation in A549 Zellen nach 
Infektion mit saisonalem oder hochpathogenem Influenzavirus gezeigt. Darüber hinaus zeigt 
eine Untersuchung mit Hilfe konfokaler Mikroskopie die Relokalisation von HSPA8 in den 
Kern infizierter A549 Zellen. Während ein Einfluss von HSPA8 auf den hochpathogenen 
Influenzastamm aufgrund uneindeutiger Ergebnisse nicht abschließend geklärt werden 
konnte, wurde seine Bedeutung für den Vermehrungszyklus des saisonalen Stammes 
aufgezeigt. Eine Überexpression von HSPA8 führte zu einer Steigerung der Polymerase-
Aktivität. Die Erniedrigung des HSPA8 Spiegels mittels transfizierter siRNA resultierte 
wiederum in einer Verringerung der viralen Replikation um rund 70 % und einer Verringerung 
der Polymerase-Aktivität um rund 40 %. Interessanterweise führte die Erniedrigung des 
HSPA8 Spiegels auch zu stark verminderter PB2-Expression. Dies wurde jedoch nur im 
Falle des saisonalen Influenzastammes beobachtet. Dieser Befund deutet auf eine Rolle von 
HSPA8 als PB2-Chaperon, notwendig für Proteinstabilität von saisonalen aber nicht 
hochpathogenen Influenzaviren, hin. 
 
 
Contents 
Contents ........................................................................................................................ I 
List of Figures .............................................................................................................. III 
List of Tables ................................................................................................................ V 
List of Abbreviations ................................................................................................... VII 
1 Introduction .......................................................................................................... 2 
1.1 Influenza virus ........................................................................................ 2 
1.1.1 Disease .................................................................................... 2 
1.1.2 Taxonomy ................................................................................ 2 
1.1.3 Morphology and structure ......................................................... 3 
1.1.4 Replication ............................................................................... 6 
1.2 The trimeric polymerase complex ........................................................... 8 
1.2.1 Viral polymerase structure ........................................................ 9 
1.2.2 Transcription and replication ................................................... 10 
1.2.3 Regulation by host cell factors ................................................ 11 
1.2.4 The polymerase component PB2 ............................................ 12 
1.3 Low pathogenicity and highly pathogenic influenza viruses .................. 14 
1.3.1 Low pathogenicity and highly pathogenic influenza viruses in 
birds ....................................................................................... 14 
1.3.2 Avian influenza viruses in humans .......................................... 15 
1.3.3 Differences and similarities of seasonal H3N2 and HPAI H5N1 
viruses in humans .................................................................. 17 
1.4 Heat shock proteins ............................................................................. 19 
1.4.1 HSPA8 ................................................................................... 20 
1.4.2 HSPA8 and influenza ............................................................. 22 
1.5 Mass spectrometry ............................................................................... 24 
1.5.1 MS principles .......................................................................... 24 
1.5.2 Stable isotopic labelling by amino acids in cell culture (SILAC)26 
1.6 Aim of this study ................................................................................... 28 
2. Materials and Methods....................................................................................... 30 
2.1 Materials .............................................................................................. 30 
2.1.1 Chemicals and Consumables ................................................. 30 
2.1.2 Kits ......................................................................................... 32 
2.1.3 Enzymes ................................................................................ 33 
2.1.4 Cell lines ................................................................................. 33 
2.1.5 Bacterial strains ...................................................................... 33 
2.1.6 Virus strains............................................................................ 33 
2.1.7 Plasmids ................................................................................. 34 
2.1.8 Antibodies .............................................................................. 36 
2.1.9 Primer..................................................................................... 36 
2.1.10 siRNA ..................................................................................... 37 
Contents II 
 
2.1.11 Cell culture media ................................................................... 38 
2.1.12 Media for bacteria ................................................................... 39 
2.1.13 Buffer and solutions ................................................................ 39 
2.1.14 Technical equipment .............................................................. 42 
2.1.15 Software and web tools .......................................................... 43 
2.2 Methods ............................................................................................... 44 
2.2.1 Cell culture ............................................................................. 44 
2.2.2 Infectious work ............................................................................ 45 
2.2.3 Molecular biology methods .......................................................... 48 
2.2.4 Biochemical Methods ............................................................. 55 
2.2.5 Cell biology Methods .............................................................. 56 
2.2.6 SILAC Mass spectrometry analysis ........................................ 59 
3. Results .............................................................................................................. 64 
3.1 Proteomic analysis of the PB2 interactome of influenza 
A/Panama/2007/99 (H3N2) and A/Thailand/(KAN-1)/04 (H5N1) viruses65 
3.1.1 Generation and functional characterization of PB2-Strep viruses 
for co-precipitation experiments .............................................. 65 
3.1.2 Experimental setup ................................................................. 68 
3.1.3 MS data evaluation ................................................................. 70 
3.1.4 Protein classification ............................................................... 73 
3.1.5. Hit protein classification and network analysis ........................ 75 
3.2 Data validation ..................................................................................... 79 
3.2.1 Co-immunoprecipitation .......................................................... 79 
3.2.2 Polymerase activity assay ...................................................... 81 
3.3 Characterization of HSPA8 as a novel PB2 interaction partner ............ 85 
3.3.1 Co-precipitation of PB2 with Endogenous HSPA8 .................. 86 
3.3.2 HSPA8 relocates into the nucleus in infected cells ................. 87 
3.3.3 siRNA mediated depletion of HSPA8 expression influences 
A/Panama/2007/99 and A/Thailand/(KAN-1)/04 replication .... 90 
3.3.4 Knock down of HSPA8 leads to a depletion of 
A/Panama/2007/99 PB2 ......................................................... 92 
4. Discussion .............................................................................................................. 94 
4.1 Mass spectrometric analysis revealed the PB2 interactome of non-
laboratory adapted seasonal and highly pathogenic avian influenza virus 
strains .................................................................................................. 94 
4.2 HSPA8 is a novel regulator of the non-laboratory adapted seasonal 
influenza virus polymerase ................................................................. 105 
Bibliography .............................................................................................................. 114 
Supplementary information ....................................................................................... 125 
Appendix ................................................................................................................... 137 
 
 
 
List of Figures III 
 
 
List of Figures 
Figure 1.1. Electron microscopy and schematic illustration of influenza A virus 
structures ............................................................................................................. 4 
Figure 1.2. Replication cycle of influenza A viruses ...................................................... 7 
Figure 1.3. Structural details of the trimeric polymerase complex.................................. 9 
Figure 1.4. Ribbon diagram and subunit domain structure of the polymerase protein 
PB2.................................................................................................................... 13 
Figure 1.5. Laboratory-confirmed cases of avian influenza virus in humans ................ 16 
Figure 1.6. Hemagglutinin, species specificity and pathogenicity ................................ 17 
Figure 1.7. Model for the substrate binding and release cycle of HSPA8.. .................. 21 
Figure 1.8. Model of the HSPA8 related nuclear export of vRNPs............................... 23 
Figure 1.9. Principle of stable isotopic labeling by amino acids in cell culture (SILAC).27 
Figure 2.1. Generation of pHW2000-PB2-Strep plasmids ........................................... 49 
Figure 3.1. PB2 sequence information of constructed influenza A viruses .................. 65 
Figure 3.2. Growth characteristics of WT and Strep-PB2 viruses ................................ 66 
Figure 3.3. Recombinant PB2-Strep proteins co-precipitate viral NP .......................... 67 
Figure 3.4. Workflow of SILAC experiments ................................................................ 69 
Figure 3.5. Precipitation control for SILAC experiments .............................................. 70 
Figure 3.6. Correlation of protein ratios between replicates......................................... 71 
Figure 3.7. Significance and t-test difference of identified proteins .............................. 72 
Figure 3.8. Comparison of MS data with different PB2/polymerase complex interactome 
screens .............................................................................................................. 73 
Figure 3.9. Functional classification of proteins in the filtered protein list..................... 74 
Figure 3.10. STRING network of PB2 interactome screen hit proteins ........................ 78 
Figure 3.11. Validation of the co-precipitation of A/Thai/04 PB2 with selected hit 
proteins .............................................................................................................. 80 
Figure 3.12. Validation of the co-precipitation of A/Pan/99 PB2 with selected hit 
proteins .............................................................................................................. 81 
Figure 3.13. Schematic representation of the influenza polymerase activity assay ..... 82 
Figure 3.14. Functional investigation of MS data by polymerase activity assay ........... 83 
Figure 3.15. Co-precipitation of PB2 with endogenous HSPA8 ................................... 86 
List of Figures IV 
 
Figure 3.16. HSPA8 relocates into the nucleus at late time points of A/Pan/99-WT 
infection ............................................................................................................. 88 
Figure 3.17. HSPA8 relocates into the nucleus at late time points of A/Thai/04-WT 
infection ............................................................................................................. 89 
Figure 3.18. Depletion of HSPA8 influences A/Pan/99-WT and A/Thai/04-WT 
replication .......................................................................................................... 91 
Figure 3.19. Knock down of HSPA8 leads to a depletion of A/Pan/99 PB2 ................. 93 
Figure 4.1. Cellular functions of HSPA8 .................................................................... 105 
Figure 4.2. Proposed model for the role of HSPA8 in the influenza virus replication 
cycle ................................................................................................................ 110 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
List of Tables V 
 
List of Tables 
Table 1.1. vRNA segments and encoded proteins of influenza A/Pan/99 and A/Thai/04
 ............................................................................................................................ 5 
Table 2.1. Composition of SDS polyacrylamide gels ................................................... 55 
Table 2.2. Amount of expression plasmids transfected per well of a 12-well plate used 
for polymerase activity assay ............................................................................. 58 
Table 2.3. Steps for desalting of peptides ................................................................... 62 
3.1. Infection state of light, intermediate and heavy A549 cells in the 4 conducted 
SILAC experiments ............................................................................................ 68 
Table 3.2. List of hit proteins ....................................................................................... 75 
Table 3.3. Combined results of the co-immunoprecipitation and polymerase activity 
assay experiments ............................................................................................. 84 
Table 4.1. Experimental setups of proteome screens used for comparison with our 
filtered protein list ............................................................................................... 99 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 VI 
 
 
 
 
 
 
 
 
 
 
 
 
 
List of Abbreviations VII 
 
List of Abbreviations 
2DE Two-dimensional gel electrophoresis 
A/Pan/99 A/Panama/2007/1999 
A/Thai/04 A/Thailand/1(KAN-1)/2004 
A549cells Human alveolar epithelial cells 
aa Amino acid 
ACN Acetonitrile 
APH Amphipathic helicase 
AP-MS Affinity-purification mass spectrometry 
ATP Adenosine triphosphate 
Bcl-2-associated athanogene BAG 
C Cytosine 
CCT Chaperonin containing TCP-1 
CID Collision induced dissociation 
Co-IP Co-Immunoprecipitation 
CPE Cytopathic effects 
cRNA Complementary RNA 
csRNA Capped small RNA 
dd Double distilled 
DMEM Dulbecco’s modified Eagle medium 
E Glutamic acid 
ESI Electrospray ionization 
FDR False discovery rate 
FT Fourier transformation 
FTICMS Fourier transform-ion cyclotron 
Fw Forward 
G Guanosine 
GO Gene ontology 
H/L Heavy to light 
HA Hemagglutinin 
HEK293T cells Human embryonic kidney 293T 
HeLa cells Henrietta Lacks cells 
HPAIV Highly pathogenic avian influenza virus 
Hsc70 Heat shock cognate 71 kDa protein 
HSP Heat shock protein 
HSPA1A Heat shock 70 kDa protein 1A 
HSPA8 Heat shock cognate 71 kDa protein 
HSV-1 Herpes simplex virus type 1 
IAA Iodoacetamide 
IFNβ Interferon β 
IMPα Importin-α 
IMPβ1 Importin-β1 
IVPI Intravenous pathogenicity index 
K Lysine 
KEGG Kyoto Encyclopedia of Genes and Genomes 
LC Liquid chromatography 
LCAR Low-complexity acidic region 
List of Abbreviations VIII 
 
LPAIV Low pathogenicity avian influenza virus 
LRR Leucine-rich repeat 
LRT Lower respiratory tract 
LTQ Linear ion trap quadrupole 
M/L Intermediate to light 
m/z Mass-to-charge ratio 
M1 Matrix protein 1 
M16I Methionine to isoleucine substitution at position 16 
M2 Matrix protein 2 
MALDI Matrix-assisted laser desorption/ionization 
MAVS Mitochondrial antiviral signaling protein 
MBCS Multibasic cleavage site 
MCL Markov Cluster algorithm 
MCM Minichromosome maintenance 
MDCK cells Madin-Darby Canine Kidney cells 
MEM Minimal essential medium 
MINT Molecular interaction database 
ml Minutes 
MOI Multiplicity of infection 
mRNA Messenger RNA 
mRNP Messenger ribonucleoprotein 
MS Mass spectrometry 
MS/MS Tandem mass spectrometry 
MS1 First MS scan 
MS2 Second MS scan 
NA Neuraminidase 
Na Sodium 
NB Non-bound 
NCBI National Center for Biotechnology Information 
NCR Non-coding region 
NEF Nucleotide exchange factors 
NEP Nuclear export protein 
NLS Nuclear localization sequences 
NP Nucleoprotein 
NS1 Non-structural protein 1 
nt Nucleotides 
NT Non-target 
NTP Nucleoside triphosphate 
OIE World organization for animal health 
ON Overnight 
p.i. Post infection 
p.t. Post transfection 
PA Polymerase acidic protein 
PA-X Polymerase acidic protein X 
PB1 Polymerase basic protein 1 
PB1-F2 Polymerase basic protein 
PB2 Polymerase basic protein 2 
PB2-S1 Polymerase basic protein 2 S1 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
 IX 
 
PlasmID Plasmid information database 
Pol I RNA polymerase I 
Pol II DNA-dependent RNA polymerase II 
PPI Protein-protein interactions 
PTMs Post-translational modifications 
R Arginine 
rev Reverse 
RNA Ribonucleic-acid 
sa Sialic acids 
SAα2,3 α-2,3-linked sialic acid 
SAα2,6 α-2,6-linked sialic acid 
SDS PAGE Sodium dodecyl sulfate polyacrylamide gel electropho-resis 
sec Seconds 
sHSP Small heat shock protein 
SILAC Stable isotopic labelling by amino acids in cell culture 
snoRNA Small nucleolar RNA 
snRNA Small nuclear RNA 
SOC Super optimal broth with catabolite repression 
ss Single-stranded 
STRING Search Tool for the Retrieval of Interacting Genes/Proteins 
TOF Time-of-flight 
U Uridine 
UPS Ubiquitin-proteasome system 
URT Upper respiratory tract 
vRNA Viral RNA 
vRNP Viral ribonucleoprotein 
WCL Whole cell lysate 
WHO World health organization 
 
 
 
 
  
 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Introduction 2 
 
 
1 Introduction 
1.1 Influenza virus 
1.1.1 Disease 
Influenza, or colloquially “the flu”, is an acute respiratory disease caused by the influ-
enza virus 1. Strains circulating in humans replicate mainly in the upper respiratory tract 
including the nose and throat, and the lower respiratory tract, including the trachea, 
bronchial epithelium and lung 2. Influenza viruses are transmitted from person to per-
son via aerosolized droplets which are shed from infected persons by coughing or 
sneezing, or by contact with contaminated hands and surfaces. 
After an incubation period of one to three days, infected individuals start to show the 
typical clinic signs of influenza disease 3. These include sudden onset, fever, cough, 
headache, muscle and joint pain, sore throat, runny nose and severe malaise 1. Most 
people recover within a week without medical treatment. However, influenza can also 
lead to severe illness and death, particularly among children under 5 years of age, el-
derly people over 65 and individuals with chronic medical conditions. 
Influenza viruses circulate worldwide. In temperate climates the disease occurs in sea-
sonal epidemics with peaks in infection rates during the winter months, whereas in 
tropical regions epidemics can occur throughout the year 1. According to the World 
Health Organization (WHO), influenza viruses cause 3 to 5 million cases of severe ill-
ness and up to 250.000 to 500.000 deaths each year. 
1.1.2 Taxonomy 
Influenza viruses belong to the Orthomyxoviridae family which is comprised of 7 gene-
ra: Thogotovirus, Isavirus, Quaranjavirus, influenza virus A, B, and C, and the recently 
identified influenza virus D 4. The influenza virus genera contain only 1 species each, 
influenza A, B, C or D virus, and are classified based on the antigenicity of the nucleo-
protein (NP) and matrix protein 1 (M1) 5. 
The 4 influenza virus species also differ in their ability to infect host species. In addition 
to its natural reservoir, water birds, influenza A viruses are also able to infect other bird 
species, such as poultry and a wide range of mammals: cats, dogs, whales, pigs, bats 
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and humans 6. The host spectrum of influenza B, C and D viruses is much more re-
stricted. Influenza D viruses have only been isolated from swine and cattle so far 4, 
whereas influenza B virus infection is restricted to seals and humans 7. In addition to its 
ability to replicate in dogs and pigs, influenza C viruses can also infect humans, how-
ever causing usually only mild symptoms in humans 8. 
The influenza A virus species can be further divided into subtypes according to the 
surface proteins hemagglutinin (HA) and neuraminidase (NA). To date, 11 different NA 
and 18 HA subtypes have been identified 9. However, only the subtypes H1N1 and 
H3N2 are currently circulating in the human population 1. In 1980, a common nomen-
clature for influenza viruses was established by the WHO 10. The name includes the 
virus genus, the host of origin (if the strain was not isolated from a human case), the 
geographical region where the virus was isolated, the strain number or name and the 
year of isolation. In the case of influenza A viruses, the subtype based on HA and NA is 
also included. For example, influenza A/Panama/2007/1999 (H3N2) represents a hu-
man H3N2 virus that was isolated in 1999 in Panama. Due to the frequency of human 
infections and the risk that influenza A virus poses to human health, it will be the main 
focus of the study presented in this thesis. 
1.1.3 Morphology and structure 
Influenza viruses contain an envelope and a segmented, single-stranded (ss) ribonu-
cleic-acid (RNA) genome of negative polarity. The envelope is a lipid bilayer derived 
from the host cell during budding of progeny virions from the cell membrane. The newly 
formed virions have a spherical or filamentous shape (figure 1.1.A) and vary from 
around 100 nm in diameter for spherical virions up to 20 μm in length for the filamen-
tous form 11,12.  
Influenza A virions contains 8 unique genome segments of viral RNA (vRNA) (figure 
1.1.B). Each of these segments is associated with multiple nucleoprotein monomers 
and one monomer of each of the viral polymerase proteins: polymerase acidic protein 
(PA), polymerase basic protein 1 (PB1) and polymerase basic protein 2 (PB2) 13,14. 
Together, each vRNA-NP-polymerase complex is referred to as one viral ribonucleo-
protein (vRNP) (figure 1.1.C). The NP monomers in the internal region of the vRNP 
interact with each other, forming an antiparallel double helix that is closed by a loop 15. 
The genomic RNA ends at the opposite side are not associated with NP. However, 
they are partially complementary and can form a double stranded panhandle structure 
that is bound to the trimeric polymerase complex 16,17. The panhandle is formed by         
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interactions between the highly conserved 5`-end and 3`-end non-coding regions 
(NCRs) that contain promoter elements for the viral polymerase 18,19. 
 
 
Figure 1.1. Electron microscopy and schematic illustration of influenza A virus struc-
tures. A ZPC-TEM micrograph for inactivated influenza A/NewCaledonia/20/99 (H1N1). 
Adapted from 20. B Schematic model of influenza A virus particle. The 8 single stranded RNA 
(ssRNA) genomic segments encode the structural proteins PB2, PB1, PA, HA, NP, NA, M1, M2 
and NEP, the putative structural protein NS1 and the non-structural protein PB1-F2 that is only 
present in infected cells but not in incoming virions. Adapted from 21. C Schematic representa-
tion of an influenza vRNP. The viral ssRNA is associated with multiple copies of NP and a sin-
gle trimeric polymerase complex composed of PA (green), PB1 (blue) and PB2 (purple). The 
polymerase complex is bound to the double stranded panhandle structure at the complementary 
genomic ends (5’- and 3’-end depicted in dark grey and yellow, respectively). Contacts between 
NP monomers form an antiparallel double helix that is joined by a closed loop region. Adapted 
from 22,23. 
Each of the 8 genome segments of influenza A virus encode one major viral protein. In 
addition, segments 7 and 8 encode the matrix protein 2 (M2) and nuclear export protein 
(NEP) that are derived from splice variants of the matrix protein 1 (M1) and non-
structural protein 1 (NS1) viral messenger (mRNA), respectively 24,25. These 10 pro-
1 Introduction 5 
 
 
teins represent the minimal number of proteins expressed by influenza A viruses. De-
pending on the viral strain, up to 7 additional proteins can be expressed from segments 
1, 2, 3 and 7 either by alternative splicing (e.g. polymerase basic protein 2 S1 (PB2-
S1)), ribosomal frame shift (e.g. polymerase acidic protein X (PA-X)) or through the 
usage of an alternative start codon (e.g. polymerase basic protein F2 (PB1-F2)) 26-30. 
 
Table 1.1. vRNA segments and encoded proteins of influenza A/Pan/99 and A/Thai/04. 
Adapted from 31. 
Genome 
Segment 
Protein 
name 
Protein length (aa) 
 
Protein function 
 
  A/Pan/99 A/Thai/04  
1 PB2 759 759 
Subunit of the viral polymerase; involved 
in the recognition of 5`-capped host pre-
mRNAs 
2 PB1 757 757 
Catalytic subunit of the viral polymerase;   
responsible for RNA chain elongation 
 PB1-F2 90 90 
Virulence factor; induces mitochondria-
associated apoptosis 
3 PA 716 716 
Subunit of the viral polymerase; RNA 
endonuclease activity for cap snatching 
4 HA 566 568 
Receptor binding; mediates membrane 
fusion for release of vRNPs 
5 NP 498 498 
Major component of vRNPs; controls the 
nuclear cytoplasmic vRNA transport 
6 NA 469 449 
Cleaves sialic acids for the release of 
progeny virions 
7 M1 252 252 
Main component of the viral membrane; 
multiple roles in virion assembly and in-
fection 
 M2 97 97 
Membrane protein that forms a proton 
channel; important for genome unpack-
ing during virus entry 
8 NS1 230 225 
Antagonist of antiviral host cell response; 
regulates viral and host gene expression 
 NEP 121 121 Mediates vRNP export from the nucleus 
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The viral strains used in this study, A/Panama/2007/1999 (H3N2) and 
A/Thailand/1(KAN-1)/2004 (in this thesis denoted as A/Pan/99 and A/Thai/04), are 
known to express at least 11 proteins (table 1.1). The proteins forming the trimeric pol-
ymerase complex, PB2, PB1 and PA, are encoded by segments 1, 2 and 3, respective-
ly. Together with NP, expressed from segment 5, and the vRNA, they form vRNPs and 
are thereby structural components of influenza virions. Segment 7 encodes the struc-
tural proteins M1, which forms a layer between vRNPs and the viral envelope, and M2, 
a pH-dependent proton channel embedded in the envelope 32,33. The spike-like struc-
tures on the lipid envelope are formed by the viral surface glycoproteins HA and NA. 
Binding of sialic acids (sa), which act as receptors for influenza viruses, and fusion of 
the viral and cellular envelope during endocytosis are mediated by the homotrimeric 
protein HA 34. It is synthesized as a precursor protein (HA0) that is post-translationally 
cleaved into HA1 and HA2. This cleavage is necessary to activate the fusion potential 
of HA and is thereby crucial for virus infectivity 35. Whereas the HA protein is responsi-
ble for viral entry, tetrameric NA mediates the release of progeny viruses from the cel-
lular membrane by cleavage of sialic acids 36. Another structural protein, NEP, is en-
coded by segment 8 and mediates the nuclear export of newly formed vRNPs in the 
late phase of infection 37,38. The NS1 protein, which is expressed from the same seg-
ment, acts as an antagonist of the antiviral host response 39. The non-structural protein 
PB1-F2 enhances virus-induced cell death by suppressing the mitochondrial inner-
membrane potential 40. 
1.1.4 Replication 
Influenza viruses are, like all other viruses, obligate intracellular pathogens that rely on 
the metabolism of their host cell for replication. The viral replication cycle involves 3 
major steps: (1) viral attachment to the host cell, entry and uncoating, (2) viral gene 
expression and replication and (3) virion assembly, budding and release (figure 1.2).  
(1) Influenza viruses attach to their host cell by binding to sialic acids on the cell sur-
face, mediated by the viral protein HA 41. Upon receptor binding, the viral particle en-
ters the cell by clathrin-dependent and -independent endocytosis 42. The acidic envi-
ronment of the endosome triggers a conformational change of the HA protein that re-
sults in the exposure of the fusion peptide, which ultimately leads to fusion of the viral 
and endosomal membranes 43. The low pH also results in the opening of proton chan-
nels in the viral envelope formed by M2, and a subsequent acidification of the virion 
interior 44. 
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Figure 1.2. Replication cycle of influenza A viruses. Schematic representation of the Repli-
cation cycle of influenza A viruses, which is described in detail in the text. Adapted from Das et 
al. 45. 
This allows the vRNPs to dissociate from the M1 proteins and to be released into the 
host cell cytoplasm 46, enabling their subsequent transportation into the nucleus.      
Nuclear import of vRNPs is mediated by the cellular importin-α – importin-β1 (IMPα-
IMPβ1) pathway, in association with nuclear localization sequences (NLS) in the pro-
teins of the vRNPs 47. 
(2) Viral transcription as well as genome replication takes place in the nucleus of the 
infected cell. Both processes are catalyzed by the trimeric RNA-dependent RNA poly-
merase. After transcription, viral protein translation (which takes place in the cytoplasm 
and is catalyzed be the cellular translation machinery) and genome replication new 
vRNPs are formed. For further details about these processes see section 1.2.2. 
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Newly formed vRNPs are transported out of the nucleus in an exportin-1 (CRM1)-
dependent manner. The CRM1 export machinery interacts with vRNPs in a ‘daisy-
chain’ complex with viral NEP and M1, both transported into the nucleus after transla-
tion. CRM1 is bound to NEP that in turn is associated with M1, which interacts with 
vRNPs 48. After nuclear export, newly-formed vRNPs are transported through the cyto-
plasm to the plasma membrane on microtubule networks, in association with RAB11-
positive recycling endosomes 22. At the plasma membrane the vRNPs unite with the 
post translationally modified (e.g. glycosylated, lipidation or phosphorylation) proteins 
HA, NA and M2, which are located at lipid raft domains 11,49. 
(3) Assembly and budding of viral particles occurs at cholesterol-rich lipid raft domains 
in the plasma membrane of the infected cell where NA and HA accumulate, the so 
called budozones 50-52. During assembly the M1 protein acts as a linker between the 
viral envelope and the viral genome, by binding to vRNPs as well as the cytoplasmic 
tails of NA and HA. Furthermore, M1 acts as a linker between HA and M2 52. The M2 
protein, found at the edges of the budozones, mediates virus budding and scission by 
its amphipathic helicase (APH) region 52. During M2-APH region mediated, cholesterol-
dependent membrane curvature, M2 is found at the neck of the growing bud 52. Con-
striction of the neck by M2 and cleavage of sialic acids by the NA protein ultimately 
leads to scission and release of progeny viral particles from the cell surface 36,52. 
1.2 The trimeric polymerase complex  
The viral RNA-dependent RNA polymerase is a trimeric complex that is composed of 
the viral proteins PA, PB1 and PB2. The complex is bound to the double stranded pan-
handle structure of each viral genomic RNA segment and, together with NP, forms the 
vRNP (for further details see section 1.1.3) 13,14. Viral transcription as well as genome 
replication is catalyzed by the viral polymerase. Each component of the polymerase 
has distinct functions in these processes. PA and PB2 are involved in cap-snatching 
from cellular RNAs, which is essential for viral transcription. While PB2 binds the 5`-cap 
of nascent host capped RNAs via its cap-binding domain, the endonuclease PA 
cleaves the RNA downstream of the cap 53. The capped RNA fragment is then used as 
a primer to initiate viral transcription. PB1, the catalytic subunit of the viral polymerase 
complex, is responsible for RNA chain elongation 54. 
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1.2.1 Viral polymerase structure 
PB1 forms the center of the trimeric polymerase complex. It interacts with the N-
terminal domain of PB2 via its C-terminal extension and is sandwiched between the C-
terminal and N-terminal domains of PA (see figure 1.3.A and B) 23. The core of the pol-
ymerase complex is composed of PB1, the N-terminal region of PB2 and the C-
terminal domain of PA, while its flexible peripheral appendices are formed by the N-
terminal endonuclease domain of PA, and the cap-binding, mid-link, 627 and NLS do-
mains of PB2 23 (for further details on PB2 structure see 1.2.4). 
 
Figure 1.3. Structural details of the trimeric polymerase complex. A Front view and B side 
view of the polymerase structure surface model. PA, PB1 and PB2 subunits are depicted in 
green, blue and pink, respectively. The PA C-terminal (PA-C) and endonuclease (PA-endo) 
domains as well as the PB2 627-domain (PB2-627) and cap-binding (PB2-cap) domain are 
indicated. The 3′ terminus of vRNA is shown in yellow and the 5′ terminus in grey. C Model of 
the inactive, vRNA unbound, state and the D transcription pre-initiation state of the viral poly-
merase. The PB2 cap-binding domain and the PA endonuclease domain undergo rearrange-
ments upon vRNA binding which results in a cap-snatching compatible conformation. 3’- and 5’-
termini of the vRNA are depicted in yellow and NP is shown in light grey. Adapted from              
te Velthuis et al. 23. 
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The 5`- and 3`-termini of the genomic double stranded panhandle structure bind to dis-
tinct but spatially close sites in the polymerase complex. The 5`-end interacts with a 
pocket at the interface of PB1 and the C-terminal domain of PA, while the 3`-end binds 
on the surface of the polymerase at a site that is composed of amino acid (aa) residues 
from all 3 polymerase subunits 23. Consistent with reports that cap-snatching is activat-
ed by vRNA binding to the polymerase, the determination of X-ray crystallographic 
structures of the polymerase complex revealed a conformational change in the com-
plex upon binding to vRNA. The peripheral endonuclease domain of PA and the cap-
binding domain of PB2 undergo major rearrangements, which result in a cap-snatching 
compatible orientation (figure 1.3.C and D) 23. The polymerase active site is accessible 
via several channels; the template exit and entry channel, both located on the same 
side of the polymerase, the nucleoside triphosphate (NTP) entry channel and the prod-
uct exit channel 23. Another important feature is the priming loop located in the central 
cavity. This PB1 β-hairpin protrudes into the active site and has been shown to be im-
portant for primer independent replication initiation 55. 
1.2.2 Transcription and replication  
Viral transcription as well as genome replication takes place in the nucleus of the in-
fected cell. The synthesis of viral mRNA, known as primary transcription, is independ-
ent of de novo viral protein synthesis but dependent on capped primers 56. These are 
obtained from the 5`-end of cellular RNAs in a process called cap-snatching 57. First, 
PB2 binds to the 5`-cap of cellular capped RNA; this is followed by cleavage of the 
RNA 10 to 13 nucleotides (nt) downstream of the cap by PA 53. The preferred sub-
strates for cap snatching are small nuclear RNAs (snRNA), small nucleolar RNAs 
(snoRNA) and capped small RNAs (csRNA) 23. Subsequently, the 3`-end of the capped 
primer and the 3`-end of the vRNA template enter the polymerase active site via the 
product exit channel and the template entry channel, respectively 23. After transcription 
initiation by the addition of a Guanosine (G) or a Cytosine (C) to the 3`-end of the pri-
mer, PB1 catalyzes the transcription of viral mRNAs and then adds a poly(A) tail by 
stuttering along the uridine-rich sequence at the 5`-end of the vRNA 58. Stuttering is 
proposed to be due to steric hindrance of the polymerase caused by the 5`-end of the 
vRNA template 23. The assembly of the newly synthesized viral mRNA into host-like 
messenger ribonucleoprotein (mRNP) structures is likely mediated by the binding of 
their 5`-cap to the nuclear cap-binding complex 23. 
Processed viral mRNAs are transported to the cytoplasm and translated by the host 
cell translation machinery. Whether or not the trimeric polymerase complex is a stable 
1 Introduction 11 
 
 
component of viral mRNAs also during their export to the cytoplasm is still a matter of 
debate 59-61. Early transcription from incoming vRNPs leads to the expression of the 
early gene products PA, PB1, PB2 and NP, which are then subsequently transported 
into the nucleus 62. While PB2 is imported by the importin α/β pathway on its own, PB1 
and PA form a dimeric complex in the cytoplasm which is subsequently imported by 
RanBP5 63. The involvement of cellular chaperone proteins such as Hsp90 in the nu-
clear import of polymerase proteins has been proposed 64. In the nucleus, the PB1-PA 
dimer and PB2 assemble to form the polymerase complex which then subsequently 
forms new vRNPs in combination with viral RNA and NP. These newly created vRNPs 
then serve as a template for transcription of the late genes HA, NA, NEP, M2 and 
M1 62. 
Replication of the viral genome, on the other hand, occurs in two steps and is primer 
independent. First a full-length genomic complementary RNA (cRNA) with positive po-
larity is synthesized. This is initiated by the formation of pppApG dinucleotides on resi-
dues Uridine (U) 1 and C2 at the vRNA 3`-end, which is dependent on structural sup-
port by the priming loop, and is catalyzed by the resident polymerase 23. This newly 
synthesized cRNA serves in the second step as the template for the generation of new-
ly formed full-length genomic vRNA. In this phase initiation begins on residues U4 and 
C5 and is independent of the priming loop. To allow for synthesis of a full-length cRNA 
copy, the pppApG dinucleotide is transferred to U1 and C2 residues 23. The second 
stage of the replication cycle requires newly translated NP and polymerase proteins to 
form vRNPs with the newly synthesized genomic vRNA, thereby protecting the viral 
genome from degradation 65 and enabling it to be packaged in new virions. 
1.2.3 Regulation by host cell factors 
As an obligate intracellular parasite, influenza virus and its polymerase are dependent 
on the function of cellular proteins for replication. Several host cell factors have been 
described to interact with the polymerase complex and to regulate viral transcription 
and replication. Unlike other RNA viruses, influenza virus genome replication occurs in 
the nucleus and not in the cytoplasm of infected cells. More precisely, viral genomic 
transcription and replication is proposed to occur in DNase insensitive nuclear regions 
like the nuclear matrix, or close to the chromatin. The targeting of the viral polymerase 
to these nuclear regions is suggested to be mediated by its interactions with the nucle-
ar matrix protein NXP2/MORC3, the chromatin remodelers CHD1 and CHD6 and the 
DNA-dependent RNA polymerase II (Pol II) function modulator CLE/C14orf166 23. 
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The viral polymerase complex was also shown to interact with the serine-5 phosphory-
lated form of the C-terminal domain of the large subunit of Pol II, a form that is known 
to recruit cellular capping enzymes, hence facilitating its access to nascent capped 
host RNAs 66. In addition, this interaction brings the viral RdRp close to the cellular fac-
tors involved in splicing and assembly of mRNPs, thus promoting viral mRNA pro-
cessing. Since mRNAs for the viral proteins M1, NS1 and PB2 undergo splicing to al-
low for expression of M2, NEP and PB2-S1, it is not surprising that factors of the cellu-
lar splicing machinery, namely RED, SMU1, NS1-BP, SFPQ/PSF, hnRNPK and 
SF2/ASF, have been shown to be important for replication of influenza viruses 23. 
The Pol II interacting cellular helicase minichromosome maintenance (MCM) complex, 
which is involved in Pol II elongation and DNA replication, was also demonstrated to 
participate in vRNA replication through interaction with PA. MCM seems to trigger the 
shift from initiation to elongation during viral RNA replication 67. 
The second step of the replication cycle, vRNA synthesis from cRNA, was shown to be 
boosted through the interaction of the viral polymerase with the cellular factors of the 
protein family ANP32, ANP32A and ANP32B which are involved in cell death, mRNA 
export and transcription regulation by chromatin remodeling. PB2 627-domain related 
host restriction was assigned to species differences in ANP32A protein 68. Also specific 
importin-α was shown to influence viral RNA replication in a host dependent manner by 
its interaction with PB2 (see section 1.2.4 for further information on ANP32A and im-
portin-α) 69. 
Stimulation of viral RNA replication by recruitment of NP to nascent vRNA during vRNP 
assembly or by promoting NP interactions with the viral RNA polymerase was shown to 
be mediated by the transcription factor HTAT-SF1, the spliceosome RNA helicase 
UAP56 (also known as DDX39B or BAT1) and the translation stimulator FMR1 23. 
1.2.4 The polymerase component PB2 
The 759 aa long protein PB2 is part of the cap-snatching process and is an important 
factor in host range determination 70,71. PB2 consists of several domains (figure 1.4). 
The N-terminal third mediates the interaction with the PB1 protein of the polymerase 
complex and includes the lid domain 23. In addition, the N-terminal region also contains 
a mitochondrial localization signal. PB2 that accumulates in mitochondria interacts with 
the mitochondrial antiviral signaling protein (MAVS) and thereby inhibits MAV-mediated 
interferon β (IFNβ) expression 72. However, the mitochondrial localization signal, and 
the resulting accumulation of PB2 in the mitochondria, has so far only been found in 
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seasonal influenza viruses and not in H5N1 viruses. The remaining 2/3 of the PB2 pro-
tein contain the mid domain, the cap-binding domain, the cap-627 linker, the 627-
domain and the C-terminal nuclear-localization signal domain 23. 
 
 
Figure 1.4. Ribbon diagram and subunit domain structure of the polymerase protein PB2. 
A The trimeric polymerase complex (PB1 and PA in light grey) is associated with the 3’- and 5’-
termini (depicted in yellow and dark grey, respectively) of the viral RNA. B The PB2 subunit is 
composed of the N terminus, N-linker, lid domain, mid domain, PB2-cap domain, cap-627-linker, 
627-domain and a nuclear localization signal (NLS). Adapted from 23,73. 
The 627-domain is named after the amino acid position 627 which is linked to the host 
range of influenza viruses 71. PB2 proteins from mammalian influenza isolates general-
ly harbor a lysine (K) at position 627, whereas in avian isolates glutamic acid (E) is 
usually found at that position 71. The role of the 627-domain in host adaptation was 
linked to differences between avian and mammalian ANP32A protein 68. In comparison 
to mammalian ANP32A, the avian ANP32A protein possesses an additional 33 aa long 
sequence between its leucine-rich repeat (LRR) domain and its low-complexity acidic 
region (LCAR). When this 33 aa sequence was inserted into overexpressed mammali-
an ANP32A, the poor activity of avian RdRp in mammalian cells was rescued, while 
deletion of this sequence from overexpressed avian ANP32A abrogated avian          
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polymerase activity in mammalian cells 68. It was observed, that infection of humans 
with avian H5N1 or H7N9 subtypes leads to the rapid selection of mammalian type 
K627 in PB2, which adapts the avian polymerase for the shorter mammalian ANP32A 
protein 68. For further details on the 627-domain and host range determination see sec-
tion 1.3.3. 
Freshly translated PB2 is transported into the nucleus via the importin α/β pathway, 63 
and a physical interaction between importin-α and PB2 has previously been demon-
strated69. A study on this interaction revealed that mutation of the PB2 NLS results in 
the reduced, but not completely abrogated nuclear localization of this protein 69. While 
the formation of the trimeric polymerase complex was not altered by the mutated PB2 
protein, polymerase activity was abolished. Insertion of the ectopic SV40 TAg NLS into 
the mutant PB2 protein restored the diminished nuclear localization, but did not rescue 
polymerase activity 69. Hence, it was concluded that the decrease in polymerase activi-
ty was not due to the reduced transport of PB2 into the nucleus. It was proposed that 
importin-α, in addition to its role in PB2 nuclear import, is also important for optimal viral 
RNA synthesis 69. It was also observed that co-purification of human α-importins with 
the PB2 protein of avian H5N1 strains was reduced compared to the co-purification of 
human α-importins with PB2 of seasonal H3N2. This correlates with the reduced repli-
cation capacity of the avian influenza RdRp in human cells and suggests a role for PB2 
interaction with importin-α in host range determination 69. 
1.3 Low pathogenicity and highly pathogenic influenza 
viruses 
1.3.1 Low pathogenicity and highly pathogenic influenza viruses in 
birds 
Influenza strains that have evolved in birds are known as avian influenza viruses. On 
the basis of their pathogenicity in chickens, avian influenza viruses can be divided into  
low pathogenicity avian influenza virus (LPAIV) and highly pathogenic avian influenza 
virus (HPAIV) strains 74. Whereas LPAIV strains normally only cause mild disease in 
poultry and wild birds, infection with HPAIV leads to a severe disease with a case fatali-
ty rate up to 100 % 75. Only influenza viruses bearing H5 or H7 on their surface are 
known to be highly pathogenic in birds, and these HPAIV strains always arise by muta-
tions of H5 or H7 in low pathogenicity strains. Amino acid changes in the proteolytic 
cleavage site of the HA protein have been associated with a shift in pathogenicity 74. 
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The world organization for animal health (OIE) defines an avian influenza virus isolate 
as highly pathogenic if it results in a case fatality rate of >75 %, or an intravenous 
pathogenicity index (IVPI) of >1.2 in experimentally infected chickens. Also low patho-
genicity H5 and H7 strains that have a HA proteolytic cleavage site sequence similar to 
HPAIV are considered to be highly pathogenic 74. However, H5 and H7 isolates of both 
low and high pathogenicity are notifiable. If HPAIV is detected, the whole livestock will 
be depopulated and other flocks in the surrounding area will also either be culled or 
quarantined to prevent the spread of disease. Besides the enormous economic loss 
caused by HPAIV outbreaks in birds, an outbreak of both low pathogenicity and highly 
pathogenic avian influenza virus also harbors the risk of introducing the infection into 
the human population. 
1.3.2 Avian influenza viruses in humans 
Certain avian influenza viruses have the potential to cross the species barrier into hu-
mans. For example, infection of humans with avian influenza viruses of the subtype 
H5N1, H7N9, H7N7 and H9N2 have been reported 76. In patients infected with H7N9 or 
HPAI H5N1 viruses, the disease often has an aggressive clinical course. 
After an incubation period of 2-17 or 1-10 days for H5N1 or H7N9, respectively, pa-
tients can develop high fever, cough and lower respiratory tract disease 77,78. Some 
patients also show atypical symptoms including diarrhea, vomiting, abdominal pain and 
bleeding from the nose and gums 79. Complications can include hypoxemia, bacterial 
and fungal secondary infections and multiple organ failure 76. The case fatality rate of 
influenza virus disease in humans caused by avian H5N1 or H7N9 subtypes is much 
higher compared to infection with seasonal Influenza viruses. 
The first cases of H5N1 infection in humans were reported in 1997 in Hong Kong dur-
ing an H5N1 outbreak in poultry. Since then, a total number of 860 human H5N1 cases 
with 454 deaths (resulting in a case fatality rate of ~53 %) have been recorded by the 
WHO 80,81. On the other hand, with 613 deaths since the first human case in China in  
2013, H7N9 subtypes exhibit a case fatality rate of ~39% in humans 82. So far, all 1,566 
human cases of H7N9 infections have been reported from China. In comparison, the 
case fatality rates of the 1957 and 1968 influenza virus pandemics were around 0.1 %, 
and the devastating influenza virus pandemic in 1918-19 had an approximate case 
fatality rate of >2.5 % 83. 
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Figure 1.5. Laboratory-confirmed cases of avian influenza virus in humans. A Human 
cases of H5N1 infection since 2003 by month of onset. The different colors represent the coun-
try where the infection occurred. B Human cases of H7N9 infection since 2013 by week of on-
set. All cases were detected in China. Depicted are laboratory confirmed infections (blue) and 
lethal cases (red). Adapted from 84. 
Avian influenza viruses are mainly transmitted from infected animals to humans. Pa-
tients had either direct contact (e.g while slaughtering) or indirect contact (e.g. whilst 
visiting a poultry market) with infected poultry. The limited cases of human-to-human 
transmission have been attributed to close contact between the index patient and sub-
sequent cases 85,86. For example, the mother and aunt of an 11-year old index patient 
from Thailand were both infected after providing bedside care for the sick girl whilst in 
the hospital 85. Both mother and daughter succumbed to the disease. Tragic cases like 
this are however rare and sustained human-to-human transmission is yet to be report-
ed. Health authorities nonetheless monitor patients infected with avian influenza virus-
es very closely. In 2012 a study published by Herfst et al. showed that only 9 aa substi-
tutions in the genome of a highly pathogenic H5N1 virus isolated from a human case 
could be sufficient to facilitate airborne transmission from ferret to ferret, the best avail-
able small animal model for influenza research in mammals 87. Even though none of 
the ferrets died after infection with the mutated airborne virus, this study illustrates the 
potential of avian influenza viruses to become transmissible via aerosols between 
mammals.  
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1.3.3 Differences and similarities of seasonal H3N2 and HPAI H5N1 
viruses in humans 
HA  
All known influenza viruses, with the exception of influenza viruses found in bats, at-
tach to their host cells by binding of HA (embedded in the virus envelope) to sialic acids 
present on the surface of susceptible cells. Sialic acids are composed of nine-carbon 
backbone sugar units which are attached to the end of longer sugar chains that line the 
surface of vertebrate cells 88. Human adapted influenza viruses preferentially bind to 
sialic acids that are anchored to the sugar chain by an α-2,6-linkage (SAα2,6), which 
are abundant on the human respiratory epithelia 89,90. In contrast, avian influenza virus-
es prefer α-2,3-linked sialic acids (SAα2,3) that can be found in the avian intestinal 
tract as well as in the lower respiratory tract of humans 91,92 (figure 1.6.A). 
 
 
Figure 1.6. Hemagglutinin, species specificity and pathogenicity. A Structure of sialic acid 
and its linkage to the last galactose of sugar chains which are present mainly on proteins and 
lipids on vertebrate cell membranes. Human viruses preferentially bind to α-2,6-linked sialic 
acids (human virus receptor linkage) whereas avian viruses prefer α-2,3-linked sialic acids (avi-
an virus receptor linkage). Adapted from 93. B HA cleavage site of LPAI and HPAI viruses. The 
cleavage of the precursor protein HA0 into HA1 and HA2 by cellular proteases is essential for 
viral infectivity. HA proteins of LPAIV contain a monobasic cleavage site that can only be 
cleaved by extracellular trypsin-like proteases present in the respiratory and intestinal tract of 
poultry. The introduction of additional basic amino acid residues into this cleavage site allows 
the HA protein to be cleaved by intracellular furin-like proteases that are ubiquitously expressed. 
The acquisition of a multibasic cleavage site enables the virus to spread systemically and be-
come highly pathogenic in poultry. Adapted from Schrauwen et al. 94. 
Whereas seasonal influenza viruses can infect the upper respiratory tract (URT) as well 
as the lower respiratory tract (LRT) in humans through binding of HA to SAα2,6 on for 
example epithelial cells of the pharynx or on type II pneumocytes of the lung, H5N1 
viruses attach to SAα2,3 on type II pneumocytes, alveolar macrophages and non-
ciliated bronchiolar cells in the human LRT 92,95. Hence, the preference of avian HA for 
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SAα2,3, which usually acts as a species barrier between birds and humans, facilitate a 
LRT manifestation, e.g. pneumonia, in humans that become infected with avian 
H5N179. While infection with seasonal influenza virus is usually limited to the respirato-
ry tract, patients infected with H5N1 can also present with symptoms including diar-
rhea, vomiting and seizures, that hint at a systemic spread of the virus 1,79. This suspi-
cion is supported by isolation of the H5N1 virus from cerebrospinal fluid, rectal, throat 
and serum specimens from a 4-year old boy that died from the infection and the detec-
tion of viral RNA in rectal and blood samples of several other fatal human cases 96,97 . 
In avian species, infection with a highly pathogenic influenza virus strain is always ac-
companied by a systemic spread of the virus, whereas infection with a low pathogenici-
ty strain is restricted to the respiratory and intestinal tracts 98. This shift in tissue tro-
pism, and resulting shift from low pathogenicity to highly pathogenic, is known to be 
due to the acquisition of a multibasic cleavage site (MBCS) in the HA protein of LPAI 
viruses 99,100. While the HA protein of LPAIV can only be cleaved by extracellular tryp-
sin-like proteases present in the intestinal and respiratory tract in poultry, the acquisi-
tion of a MBCS enables the HA to be cleaved by ubiquitous intracellular furin-like pro-
teases and the virus to be spread systemically (figure 1.6.B) 101,102. However, the asso-
ciation between systemic spread, pathogenicity and the presence of a MBCS in HA is 
less clear in mammals. None of the pandemic or seasonal human influenza virus 
strains carry a MBCS in HA. The introduction of a multibasic cleavage site into the HA 
protein of a human seasonal H3N2 strain didn`t lead to a systemic virus spread or an 
increase in virus pathogenicity in ferrets 103. In contrast, the presence of a MBCS is 
indispensable for the systemic spread of H5N1 in ferrets 104. And even though all H5N1 
isolates from human cases harbor a multibasic cleavage site, the severity of the dis-
ease in humans varies from mild to lethal 105. Hence, the presence of a MBCS does not 
entirely correlate directly with an aggressive clinical disease course in humans. 
PB2 
The adaptation of the polymerase complex of avian influenza viruses to mammalian 
host factors is of great importance for interspecies transmission, since it allows for effi-
cient replication in the new host. Several mutations in the proteins of the viral polymer-
ase complex have been described to increase avian influenza polymerase activity in 
mammalian cells, for example L472V and L598P in the PB1 protein 106. However, most 
of these adaptive mutations were found in the PB2 protein 107. This includes the most 
prominent and intensively studied mutation E27K. 
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PB2 proteins from mammalian influenza virus isolates generally contain a lysine (K) at 
position 627, whereas in avian isolates glutamic acid is usually found at this position 71. 
The importance of the aa at position 627 for host adaptation is supported by the finding 
that the polymerase activity of an avian influenza virus RdRp in human embryonic kid-
ney 293T (HEK293T) cells, is dramatically increased after the exchange of glutamic 
acid with lysine at position 627 108. In addition, the substitution of the mammalian-type 
PB2 enables H5N1 avian influenza viruses to replicate in a broader range of mammali-
an cells and at lower temperatures 109. PB2 K627 is also linked to an increased viru-
lence of a human H5N1 isolate in mice 110. The role of the 627-domain in host adapta-
tion was linked to differences between the avian and mammalian ANP32A protein 68 
(see section 1.2.4). 
Even though all these data underline the importance of lysine at position 627 in PB2 for 
avian influenza viruses in mammalian hosts, differences in amino acids at this position 
alone are not solely responsible for the effective infection of humans with avian influen-
za viruses and the clinical outcome of the disease. Several avian influenza virus iso-
lates from human cases lack the E627K substitution in their PB2 protein 79. For exam-
ple the HPAIV strain used in this study, A/Thailand/1(KAN-1)/2004, that was originally 
isolated from a 6-year old boy who succumbed to the infection, harbors the avian-type 
E627 PB2 111,112. To compensate for the lack of PB2-K627, A/Thai/04 acquired an 
adaptive mutation in the nuclear export protein, namely a methionine to isoleucine sub-
stitution at position 16 (M16I), to enhance its polymerase activity in mammalian 
cells 112. The acquisition of the M16I substitution only in human isolates of HPAIV with 
avian-type E627 but not with mammalian-type K627, underlines the importance of the 
polymerase, and especially the PB2 protein, for adaption of HPAIV to humans. 
1.4 Heat shock proteins 
Members of the heat shock protein (HSP) family are ubiquitous proteins that can be 
found in every organism 113. The gene families that encode heat shock proteins are 
highly conserved among species and were originally named after their expression in 
response to heat shock 114 (gene names are used throughout the thesis to describe the 
genes as well as the proteins for clarity reasons). However, they are not only induced 
by heat stress but also after exposure to other stressful conditions such as cold, nico-
tine, ischemia, UV light, anoxia, heavy metal ions, surgical stress and viral agents 114. 
HSPs are important for the stabilization and three-dimensional refolding of (damaged) 
proteins during stress 115. HSPs functions in protein folding, assembly, translocation 
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and degradation are however not only essential under stressful conditions but also dur-
ing optimal cellular growth 115.  
Heat shock proteins can be grouped into 6 major families based on their approximate 
molecular weight: HSP100, HSP90, HSP70, HSP60, HSP40 and                            
small HSPs (sHSP) 116. Each family is part of the protein “life cycle”. For example, while 
HSP60 is important for the early stages of protein folding, HSP90 acts at the late stag-
es of protein folding and targets substrates for proteolysis 117. The HSP100 family dis-
sembles misfolded proteins containing aggregates and delivers substrates to proteas-
es 117. HSP70 family members have a coordinating function by directing protein sub-
strates for folding, translocation, unfolding, disaggregation or degradation 117. Hence, 
even though their name highlights their role during cellular stress, members of the heat 
shock protein families are also constitutively expressed and play a fundamental role in 
cellular homeostasis. 
1.4.1 HSPA8  
HSPA8, also known as heat shock cognate 71 kDa protein (Hsc70), belongs to the 
most abundant chaperone family, HSP70, and is a major cytosolic molecular chaper-
one 118. However, HSPA8 is also located in various cellular locations such as the nu-
cleus and close to the cellular membrane 118. 
HSPA8 consists of three regions: an N-terminal 44 kDa adenosine triphosphate 
(ATPase) domain, also known as ATP binding domain, a central 18 kDa substrate 
binding domain and a C-terminal 10 kDa “variable” or “lid” domain 118. Even though 
HSPA8 shares 85 % amino acid similarity with the stress inducible, well described heat 
shock 70 kDa protein 1A (HSPA1A), also sometimes referred to as HSP70, HSPA8 
differs greatly in its C-terminal domain which is involved in mediating substrate specific-
ity 118. The binding of HSPA8 to small hydrophobic stretches of substrate proteins is 
regulated in an ADP/ATP dependent manner (see figure 1.7) 119. First, the substrate is 
bound to HSPA8 in its ATP-bound “low affinity, fast-exchange rate” state. Then, the 
intrinsic ATPase activity of HSPA8 leads to the hydrolysis of ATP, in cooperation with 
co-chaperones. This initializes a conformational change in HSPA8 and the transition to 
its ADP-bound “high affinity, slow-exchange rate” state 119. The protein substrate is 
released after ADP is exchanged for a new molecule of ATP. ADP release is the rate 
limiting step in the ATPase reaction and is stimulated by nucleotide exchange factors 
(NEFs) 118. The BAG domain protein family has been described as one type of human 
NEF 120. The families 6 members, BAG1-6, are characterized by the presence of the 
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so-called BAG-domain at their C-terminus which is responsible for their binding to the 
ATPase domain of HSPA8. BAG-domain containing proteins compete with the ADP-
state stabilizing co-chaperone Hip for binding to the HSPA8 ATPase domain, and 
modulate chaperone activity 118. 
 
Figure 1.7. Model for the substrate binding and release cycle of HSPA8. Substrate binding 
and release is regulated in an ADP/ATP dependent manner. The substrate is bound with low 
affinity to the ATP-bound “high-exchange rate” state of HSPA8. In cooperation with co-
chaperones, the ATPase domain of the heat shock protein hydrolyses ATP, whereupon the 
substrate is bound with high affinity to the ADP-bound “slow-exchange rate” state. Release of 
ADP is stimulated by NEFs and the ADP/ATP exchange results in substrate liberation. Adapted 
from Liu et al. 118. 
HSPA8 was first described as a clathrin-uncoating ATPase during clathrin-mediated 
endocytosis 121. Clathrin binds membrane cavities, which are stimulated by binding of 
ligands to transmembrane receptors, and leads to the formation of endosomes. HSPA8 
mediates the release of clathrin by disrupting clathrin heavy chain interactions, which is 
important for fusion of the endosome with its target compartments 119. Ever since its 
discovery, additional functions of the HSPA8 chaperone in a variety of cellular pro-
cesses during optimal or stress conditions have been described. For example HSPA8 
is involved in facilitating the maturation of newly synthesized proteins, it plays a role in 
nuclear export and import of substrate proteins and reactivates heat denatured pro-
teins. HSPA8 is also part of the ubiquitin-proteasome degradation system 118: It inter-
acts with the E3 ubiquitin ligase CHIP, which leads to the coupling of ubiquitin chains to 
the chaperones substrate, resulting in its proteasomal degradation 119. The NEF protein 
BAG2 acts as an inhibitor of this CHIP mediated degradation process 118. HSPA8 has 
also been shown to play a role in the replication cycle of a variety of viruses. For ex-
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ample, HSPA8 is important for the formation of the pre-replicative site of herpes sim-
plex virus type 1 (HSV-1) 122, functions as a receptor for Japanese encephalitis virus 123 
and interacts with the RNA-dependent RNA polymerase of turnip mosaic virus 124. 
In contrast to other family members, HSPA8 is constitutively expressed and only mod-
erately induced during cellular stress 118. However, while HSPA8 shuttles between the 
cytoplasm and the nucleus, (with a preference for cytoplasmic localization under opti-
mal growth conditions) HSPA8 concentrates in the nucleus during stress 118. This nu-
clear localization of HSPA8 has also been observed in cells infected with influenza vi-
rus 125. 
1.4.2 HSPA8 and influenza 
The role of HSPA8 in influenza virus infection has been most extensively investigated 
in the context of vRNP nuclear export. Watanabe et al. showed that HSPA8 interacts 
with the influenza virus M1 protein 125. This interaction is mediated by the N-terminal 
half of the HSPA8 substrate binding domain and the C-terminal half of M1 126. An in-
volvement of the ATPase activity of the heat shock protein was shown to be unlike-
ly 126. Immunofluorescence staining of MDCK and HeLa cells infected with the influenza 
virus strain A/WSN/33 (H1N1) or A/PR8/33 (H1N1), respectively, revealed that HSPA8 
was dominantly localized in the nucleus during infection 125. However, the change in 
localization of HSPA8 was only observed at late time points of infection (9 hours post 
infection (p.i)), correlating with M1 expression and localization, and not at early time 
points (3 hours p.i). The importance of HSPA8 in the viral replication cycle was demon-
strated by the reduced viral titers observed in HSPA8 siRNA treated cells 125. 
The observation that M1 and NP failed to be exported from the nucleus in HSPA8 
knock down cells led to the assumption that the heat shock protein is involved in the 
nuclear export of vRNPs 125. The presence of HSPA8 in purified vRNP fractions and 
purified virions also argues for a virus supportive role of this factor 62. It was proposed, 
that HSPA8 mediates the export of vRNPs through the CRM1-dependent pathway (see 
figure 1.8.) 62. Further investigations revealed that HSPA8 not only does not interact 
with the nuclear export protein of influenza virus, it also competes with NEP for binding 
to M1 126. The observation that the binding between M1 and HSPA8 is stronger than 
the binding between M1 and NEP, further implies an important role for HSPA8 in the 
nuclear export of vRNPs 126. A role for HSPA8 in the nuclear import of incoming vRNPs 
could not, however, be detected 62. 
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Figure 1.8. Model of the HSPA8 related nuclear export of vRNPs. vRNP bound M1 binds to 
HSPA8 which in turn interacts with CRM1 via its nuclear export signal. The CRM1-HSPA8-M1-
vRNP complex is exported from the nucleus, CRM1 is released, and part of HSPA8 is potential-
ly incorporated into newly formed virions. Adapted from Watanabe et al. 62. 
Bortz et al. described a decrease in polymerase activity of the viral strains A/WSN/33 
(H1N1) or A/VN/1203/04 (H5N1) after siRNA depletion of HSPA8 127. A549 cells were 
co-transfected with HSPA8 siRNA and polymerase activity assay reporter genes. After 
the knock down, cells were infected with A/VN/1203/04 or A/WSN/33 and polymerase 
activity was determined by the measurement of reporter gene expression. 
In this experimental setup, HSPA8 knock down lead to a decrease in influenza virus 
polymerase activity. However, this effect was not seen in the classical influenza virus 
polymerase activity assay in 293T HSPA8 knock down cells. In this assay cells were 
not infected with influenza virus but transfected with plasmids expressing the viral PA, 
PB1, PB2 and NP, in addition to plasmids encoding the polymerase activity assay re-
porter genes 127. Hence, Bortz et al. concluded that the requirement of HSPA8 for opti-
mal polymerase function only in influenza virus infected cells, may be due to the role of 
HSPA8 in the cellular response to stress, rather than to a specific function for HSPA8 
in influenza virus polymerase activity 127. 
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1.5 Mass spectrometry 
Mass spectrometry is an analytical technique which allows for the identification, quanti-
fication and determination of chemical and structural properties of molecules. It can be 
used to analyze small molecule compounds, complex peptide and protein mixtures and 
even whole cellular proteomes. A proteome is defined as the complete set of proteins 
expressed by an organism or cell at a given time point under defined conditions 128. 
The proteome is larger than the genome since proteins encoded by the same gene can 
undergo different post-translational modifications (PTMs) to generate several protein 
variants. In addition, the proteome of even a single cell can change dramatically in re-
sponse to different stimuli, which further increases the complexity of proteome stud-
ies 129. Mass spectrometry analysis can decipher this complexity and provides more 
detailed information compared to other techniques such as two-dimensional gel elec-
trophoresis (2DE) 129. Hence, mass spectrometry represents a powerful tool for the 
analysis of protein expression, modifications or interactions. 
1.5.1 MS principles 
Mass spectrometry (MS) analysis is based on the ionization of molecules and meas-
urement of their mass-to-charge ratio (m/z). Hence, a mass spectrometer consists of 
an ion source, a mass analyzer and an ion detector. First the ion source ionizes the 
molecules. The most common techniques utilized for the ionization of peptides are 
electrospray ionization (ESI), where the sample is in a liquid phase, and matrix-
assisted laser desorption/ionization (MALDI), where the sample is associated with a 
solid matrix. After ionization the molecules are guided through the mass analyzer 
where they are sorted according to their mass-to-charge ratios. There are different 
types of mass analyzers: ion trap, time-of-flight (TOF), Fourier transform-ion cyclotron 
(FTICMS), quadrupole and Orbitrap analyzers. Since each analyzer has its own ad-
vantages and disadvantages, the choice depends on the type of experiment that will be 
performed and the specific demands that come with it. Parameters like dynamic range, 
speed of analysis, sensitivity, mass accuracy and resolution need to be taken into ac-
count. The dynamic range of the instrument is the range over which ion signal and ana-
lyte concentration is directly proportional. Speed refers to the number of spectra that 
can be generated per unit of time. The sensitivity of a mass spectrometer is defined by 
the lowest amount of analyte that can be detected, whereas mass resolution describes 
the lowest difference in m/z ratios that can be distinguished. Mass accuracy is the dis-
crepancy between the measured and the true m/z ratio.  
1 Introduction 25 
 
 
For the analysis of proteins by MS, two different approaches can be used. In top-down 
proteomics (mainly used for the analysis of simple mixtures or individual proteins) the 
whole protein is analyzed, whereas in the bottom-up approach peptides of proteolytical-
ly digested proteins are introduced to the MS analyzer. Peptide identification is 
achieved by alignment of the received peptide spectra with a peptide spectral library, or 
by comparing the detected peptide masses with those predicted from a sequence da-
tabase. Computational tools enable the assembly of identified peptides into protein 
sequences. Bottom-up proteomics is used for the analysis of complex protein mixtures 
and was employed in the experiments described in this thesis. An important aspect that 
needs to be considered is the possibility that peptides may have the same mass even if 
they have different sequences. To clearly identify peptides nonetheless, a technique 
called tandem mass spectrometry (MS/MS) can be employed. After a first MS scan 
(MS1) of peptide ions, a subset of peptides are selected based on their determined m/z 
ratio. These peptides are further fragmented by collision induced dissociation (CID) and 
analyzed in a second MS scan (MS2). The combination of spectra information from 
MS1 and MS2 allows for high accuracy peptide identification 130. 
The tandem MS employed in this study was performed using the linear ion trap quad-
rupole (LTQ)-Orbitrap XL, a hybrid mass spectrometer with two sequential mass ana-
lyzers. The Orbitrap is used for the full scan of the peptide mixture (MS1) and is char-
acterized by a high dynamic range, mass resolution and accuracy. The following scan 
(MS2) is conducted by the very sensitive and fast linear ion trap quadrupole. The tech-
nical process of tandem MS analysis by LTQ-Orbitrap starts with peptide ionization by 
ESI which results in the production of positively charged molecules. These peptide ions 
are trapped in the electrostatic field of the Orbitrap and start to oscillate around the 
central electrode. At this stage ions with different mass-to-charge ratios oscillate at 
different frequencies around the electrode, resulting in their separation. The oscillation 
amplitude represents the signal intensity which correlates with the amount of peptide. 
Fourier Transformation (FT) is then used to obtain the precursor ion spectrum (M1) 
from the detected signals 131. 
The precursor ions with the five most intense peaks are selected for the second MS 
scan. These selected precursor ions are isolated, fragmented into smaller peptides by 
collision with inert gas molecules and then analyzed in the linear ion trap quadrupole, 
thereby generating the MS2 spectra. 
As mentioned above, high-throughput MS/MS is employed for complex samples of pro-
teolytically digested proteins. This technique results in millions of spectra which cannot 
be interpreted manually. Therefore, in order to process raw MS data a search engine 
1 Introduction 26 
 
 
has to be used. The MS data obtained in this study were analyzed using MaxQuant 
software, a set of algorithms which enable the identification and quantification of pro-
teins. After the correction of systemic inaccuracies in measured peptide masses and 
the assembly of the mass and intensity of the peptide peaks into 3D peak hills, the pep-
tide and peptide fragment masses of MS1 and MS2, respectively, are searched in an 
organism specific sequence database 132. To avoid false positives, a target-decoy-
based false discovery rate (FDR) approach is applied 132. The FDR represents the per-
centage of random identifications and indicates the quality of peptide identification 133. 
In addition to the target sequences, the organism specific database also includes their 
reverse counterparts and contaminants to support correct peptide identification 132. The 
assembly of peptide hits to protein hits results in the identification of proteins 132. 
1.5.2 Stable isotopic labelling by amino acids in cell culture (SILAC) 
Stable isotopic labelling by amino acids in cell culture (SILAC) is a method for quantita-
tive MS and was developed by Matthias Mann and coworkers 134. It enables the assig-
nation of peptide signals to a specific sample set in a sample mixture and allows the 
difference in protein abundance between the different sample sets to be detected and 
relatively quantified (see figure 1.9). The method is based on the incorporation of non-
radioactive amino acid isotopes into cellular proteins during cell growth. In order to 
achieve this, cells are grown in medium lacking specific natural amino acids, which are 
replaced by the same but isotopically labeled amino acids. To assure incorporation of 
isotopically labelled amino acids and complete labelling of cellular proteins, essential 
amino acids are isotopically labelled. Even though isotopically labelled forms of all 20 
naturally occurring essential and non-essential amino acids are commercially available, 
L-lysine (K) and L-arginine (R) are the preferred choices. The most commonly used 
enzyme in proteomics (trypsin) cleaves proteins immediately after lysine and arginine 
residues. Therefore, except for the C-terminal peptide, labelling of all peptides is en-
sured when isotopically labelled arginine and lysine are used in combination with tryp-
sin for proteolytic digestion. 
Proteins from cells labelled with different combinations of isotopically distinguishable 
arginine and lysine are identical except for a small mass difference of a few Dalton. 
The cells themselves also behave the same and exhibit no differences in protein com-
position 134,135. After complete labelling of cellular proteins, differently labelled cells are 
lysed and mixed in same protein proportions prior to further sample preparation for 
mass spectrometry. 
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Figure 1.9. Principle of stable isotopic labeling by amino acids in cell culture (SILAC). 
Cells are grown in media containing different isotopically labelled amino acids. Proteins from 
differentially labeled cells (light, intermediate and heavy) are identical except for a small differ-
ence in mass. Lysates of cells in different states are mixed in equal proportions and the mass 
shift in peptides derived from different cells states is detected by MS. Comparison of signal in-
tensities allows for relative protein quantification. In this example, the peptide is most abundant 
in cells containing ‘heavy’ (R10K8) labeled amino acids. 
During MS, peptides that share the same aa sequence but originate from differentially 
labelled cells (also referred to as different states) appear in groups but exhibit a small 
shift of their mass-to-charge ratios. This mass shift enables the differentiation of these 
peptides, their assignment to their original state and the direct comparison of their sig-
nal intensities, thereby facilitating relative protein quantification 136. In the experiments 
described in this thesis triplex-SILAC was employed. Cells were therefore either grown 
in medium containing light (R0K0), intermediate (R6K4) or heavy (R10K8) amino acid 
isotopes of L-lysine and L-arginine (see section 2.2.6 for further details). 
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1.6 Aim of this study 
PB2 is part of the trimeric polymerase complex of influenza viruses. Together with PA, 
PB2 provides capped primers derived from cellular RNA which are indispensable for 
transcription of viral genes 57. Hence, PB2 is a key factor in the replication process of 
influenza viruses and is furthermore known to be an important factor in the determina-
tion of influenza virus host range 57,71,137. Hence, the interplay of PB2 with the cellular 
host proteome is of particular interest and has been previously investigated in several 
interaction studies. However, most of these studies either used laboratory/mouse-
adapted influenza strains, which do not necessarily reflect characteristics of human 
influenza isolates, or were performed in the context of transiently transfected cells 138-
144. Studies performed in which viral proteins are expressed in non-infected cells do not 
also evaluate the influence of other viral proteins and of cellular proteins that are poten-
tially differentially regulated and expressed in infected cells. Hence, the PB2 interac-
tomes determined in previous studies may not reflect all aspects of the PB2-host pro-
teome interplay in the context of naturally occurring strains in infected cells. 
The main aim of this study was therefore to systematically identify cellular interaction 
partners of the PB2 protein of seasonal and highly pathogenic influenza virus strains in 
the context of infected cells. Therefore, a SILAC based affinity-purification mass spec-
trometry (AP-MS) screen was performed to determine the interactome of PB2 in sea-
sonal A/Pan/99 (H3N2) or highly pathogenic A/Thai/04 (H5N1) infected human alveolar 
epithelial cells (A549). Selected proteins, preliminarily identified as PB2 interaction 
partners, were further validated and their impact on polymerase activity was examined. 
It was hoped that new functional interactions of cellular proteins with PB2 could be de-
scribed and that these findings may increase our understanding of the differences be-
tween seasonal and highly pathogenic influenza virus replication in human cells. 
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2. Materials and Methods 
2.1 Materials 
2.1.1 Chemicals and Consumables 
1702 Plunger Assembly Hamilton, Bonaduz (Switzerland) 
0.5 ml reaction tubes Sarstedt, Nümbrecht 
1.5 ml reaction tubes Sarstedt, Nümbrecht 
15 ml reaction tubes Roth, Karlsruhe 
50 ml reaction tubes TPP, Trasadingen (Switzerland) 
6-well plates TPP, Trasadingen (Switzerland) 
12-well plates PAA Laboratories, Cölbe 
24-well plates PAA Laboratories, Cölbe 
96-well plates BRAND GmbH, Wertheim 
96-well PCR Plate, Skirted, Low-Profile, 
Natural 
STARLAB, Hamburg 
Acetic acid Roth, Karlsruhe 
Acetonitril Roth, Karlsruhe 
Acrylamide/Bis-acrylamide solution 30% 
(29:1) 
Roth, Karlsruhe 
Agarose NEEO Ultra Quality Roth, Karlsruhe 
Ammonium carbonate Roth, Karlsruhe 
Ammonium chloride Roth, Karlsruhe 
Ammonium peroxodisulfate (APS) Roth, Karlsruhe 
Ampicillin Roche, Mannheim 
Bacto-Agar Becton-Dickenson, Heidelberg 
Β-Mercaptoethanol Roth, Karlsruhe 
Boric acid Roth, Karlsruhe 
Bovine albumin fraction V Roth, Karlsruhe 
BSA, 30% PAA Laboratories, Cölbe 
Calcium chloride Merck, Darmstadt 
Cell culture dishes Greiner, Solingen 
Cell culture dishes Nunc, Roskilde (Denmark) 
Cell culture flasks and dishes TPP, Trasadingen (Switzerland) 
Cell dissociation buffer Gibco (Life Technologies), Darmstadt 
Cell scraper TPP, Trasadingen (Switzerland) 
Clear view™ Snap-Cap microtubes, low 
retention 
Sigma-Aldrich, Taufkirchen 
CL-XPosure film Thermo Fisher Scientific, Bonn 
Coomassie brilliant blue R250 Roth, Karlsruhe 
Corning Axygen® AM-96-PCR-RD 
AxyMat™ PCR Microplate Sealing Mat 
Capitol Scientific, Austin (USA) 
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4',6-diamidino-2-phenylindole (DAPI) Merck, Darmstadt 
DEAE-Dextran Sigma-Aldrich, Taufkirchen 
Dialyzed FBS Invitrogen (Life Technologies), Darmstadt 
Dimethylsulfoxid (DMSO) Sigma-Aldrich, Taufkirchen 
Dithiothreitol (DTT) Roth, Karlsruhe 
DNA Fast Ruler Fermentas, St. Leon-Rot 
DNA Mass Ruler Fermentas, St. Leon-Rot 
DNA 6x loading buffer Fermentas, St. Leon-Rot 
EASY-Column, 2cm, C18-A1 Proxeon (Thermo Fisher Scientific), 
Dreieich 
EASY-Column, 2cm, C18-A2 Proxeon (Thermo Fisher Scientific), 
Dreieich 
EDTA Roth, Karlsruhe 
Embryonated chicken eggs Valo Biomedia GmbH, Osterholz 
Scharmbeck 
Empore™ Octadecyl C18 47mm extrac-
tion disc 
Sigma-Aldrich, Taufkirchen 
Ethanol Roth, Karlsruhe 
Ethidium bromide Roth, Karlsruhe 
Fetal bovine serum (FBS) Biochrom, Cambridge (UK) 
Formaldehyde 10 % (methanol-free) Polysciences Inc., Eppelheim 
Formaldehyde 37 % Roth, Karlsruhe 
Formic acid Sigma-Aldrich, Taufkirchen 
Glutamine Roth, Karlsruhe 
Glycerol Roth, Karlsruhe 
Glycin Roth, Karlsruhe 
HEPES Roth, Karlsruhe 
IGEPAL® CA-630 Fluka Biochemika, Milano (Italy) 
Iodoacetamide Sigma-Aldrich, Taufkirchen 
Isopropanol Roth, Karlsruhe 
Kanamycin Roth, Karlsruhe 
L-Arginine (none labelled) Cat. 
#201004102 
Silantes, München 
L-Arginine (13C6) Cat. # 201204102 Silantes, München 
L-Arginine (13C6, 15N4) Cat. # 201604102 Silantes, München 
L-Lysine (none labelled) Cat. # 
211004102 
Silantes, München 
L-Lysine (D4) Cat. # 211104112 Silantes, München 
L-Lysine (13C6, 15N2) Cat. # 211604102 Silantes, München 
Lipofectamine® 2000 Invitrogen, Darmstadt 
Lipofectamine® LTX Invitrogen, Darmstadt 
Lipofectamine® RNAiMAX Invitrogen, Darmstadt 
Magnesium sulfate Roth, Karlsruhe 
Methanol Roth, Karlsruhe 
Midori Green Advance Biozyme Diagnostik, Oldendorf 
Milk powder Roth, Karlsruhe 
Mowiol 4-88 Roth, Karlsruhe 
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Nitrocellulose-membrane Whatman (GE Healthcare), Freiburg 
Opti-MEM® Gibco (Life Technologies), Darmstadt 
Parafilm American National Can, Chicago (USA) 
Paraformaldehyde Roth, Karlsruhe 
Pefabloc Roth, Karlsruhe 
Penicillin/Streptomycin PAA Laboratories, Cölbe 
PicoTip emmiter silica tip New Objective Inc., Woburn (USA) 
Pierce™ 20X Tris-HEPES-SDS Buffer Thermo Fisher Scientific, Bonn 
Ponceau S Sigma-Aldrich, Taufkirchen 
Precise™ Tris-HEPES gels Thermo Fisher Scientific, Bonn 
Prestained protein ladder Fermentas, St. Leon-Rot 
Protein G Agarose Roche, Mannheim 
ProteoMass Cal Mix Sigma-Aldrich, Taufkirchen 
Rotisolv® Ultra LC-MS (MS grade water) Roth, Karlsruhe 
SimplyBlue™ SafeStain Invitrogen™ (Thermo Fisher Scientific), 
Carlsbad (USA) 
Sodium acetate Roth, Karlsruhe 
Sodium chloride Roth, Karlsruhe 
Sodium deoxycholat Roth, Karlsruhe 
Sodium dodecyl sulfate (SDS) Serva, Heidelberg 
Sodium orthovanadate Sigma-Aldrich, Taufkirchen 
Strep-Tactin® Superflow® 50 % suspen-
sion 
IBA Lifesciences, Göttingen 
Super Signal Dura chemiluminescence Pierce, Bonn 
TEMED Serva, Heidelberg 
TPCK-Trypsin Sigma-Aldrich, Taufkirchen 
Trifluoroacetic acid (TFA) Roth, Karlsruhe 
Tris Roth, Karlsruhe 
Triton-X 100 Serva, Heidelberg 
Trypsin (cell culture) Gibco (Life Technologies), Darmstadt 
Trypsin (mass spectrometry) Sigma-Aldrich, Taufkirchen 
Tween® 20 Roth, Karlsruhe 
Vivaspin® 500 Sartorius, Göttingen 
Whatman paper Whatman (GE Healthcare), Freiburg 
2.1.2 Kits 
BCA Protein Assay Kit Pierce, Bonn 
BigDye® Terminator 3.1 Kit Applied Biosystems, Darmstadt 
Cell Proliferation Kit I (MTT) Roche, Mannheim 
Dual-Luciferase® Reporter Assay System Promega, Mannheim 
Expand™ High Fidelity PCR System Roche, Mannheim 
Gateway™ LR Clonase™ II Enzyme mix Thermo Fisher Scientific, Bonn 
Invisorb® Spin DNA Extraction Kit STRATEC Molecular GmbH, Berlin 
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Invisorb® Spin Plasmid Mini Two Mini-
prep Kit 
STRATEC Molecular GmbH, Berlin 
Phusion Green High-Fidelity DNA Poly-
merase 
Thermo Fisher Scientific, Bonn 
QIAamp Mini Elute Virus spin Kit QIAGEN, Hilden 
Qiagen® OneStep RT-PCR Kit QIAGEN, Hilden 
QIAfilter Plasmid Maxi Kit QIAGEN, Hilden 
QIAquick® PCR Purification Kit QIAGEN, Hilden 
RevertAid RT Reverse Transcription Kit Thermo Fisher Scientific, Bonn 
2.1.3 Enzymes 
DpnI Fermentas, St. Leon-Rot 
RNasin Promega, Mannheim 
T4 DNA Ligase Fermentas, St. Leon-Rot 
T4 Polynucleotide kinase Thermo Fisher Scientific, Bonn 
2.1.4 Cell lines 
A549 cells Human alveolar epithelial cells 
HEK293T cells Human Embryonic Kidney cells 
MDCKII cells Madin-Darby Canine Kidney cells 
2.1.5 Bacterial strains 
Escherichia coli (E.coli), strain DH5α fhuA2 lac(del)U169 phoA glnV44 
Φ80`lacZ(del)M15 gyrA96 recA1 relA1 
endA1 thi-1 hsdR17 
Escherichia coli (E.coli), strain XL1-Blue 
(Stratagene) 
recA1 endA1 gyrA96 thi-1 hsdR17 
supE44 relA1 lac [F`proAB lac Iq ZδM15 
Tn10 (Tetr)] 
2.1.6 Virus strains 
A/Panama/2007/1999 H3N2 recombinant  
A/Panama/2007/1999 PB2-Strep H3N2 recombinant A/Panama/2007/1999 de-
rived virus with a Twin-
Strep-tag® at the C-
terminal end of the PB2 
protein 
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A/Thailand/1(KAN-1)/2004 H5N1 recombinant  
A/Thailand/1(KAN-1)/2004 PB2-
Strep 
H5N1 recombinant A/Thailand/1(KAN-1)/2004 
derived virus with a Twin-
Strep-tag® at the C-
terminal end of the PB2 
protein 
2.1.7 Plasmids 
pCAGGS-A/Thailand/1(KAN-1)/2004-NP V. Czudai-Matwich, Dept. of Medicine, 
Philipps Universität Marburg, Marburg 
pCAGGS-A/Thailand/1(KAN-1)/2004-PA V. Czudai-Matwich, Dept. of Medicine, 
Philipps Universität Marburg, Marburg 
pCAGGS-A/Thailand/1(KAN-1)/2004-PB1 V. Czudai-Matwich, Dept. of Medicine, 
Philipps Universität Marburg, Marburg 
pCAGGS-A/Thailand/1(KAN-1)/2004-PB2 V. Czudai-Matwich, Dept. of Medicine, 
Philipps Universität Marburg, Marburg 
pCAGGS-EV J.-I. Miyazaki, Institute for Medical Genet-
ics, Kumamoto University Medical School, 
Kuhonji 
pcDNA3.1 Flag YFP EV U. Arnold, FG17, RKI, Berlin 
pcDNA-A/PR8/33-PA Ervin Fodor, Medical Sciences Division, 
University of Oxford, Oxford 
pcDNA-A/PR8/33-PB1 Ervin Fodor, Medical Sciences Division, 
University of Oxford, Oxford 
pcDNA-A/PR8/33-PB2 Ervin Fodor, Medical Sciences Division, 
University of Oxford, Oxford 
pcDNA-A/PR8/33-NP Ervin Fodor, Medical Sciences Division, 
University of Oxford, Oxford 
pcDNA3.1 Flag YFP hNKCC1 Addgene Plasmid #49085 
pcDNA5/FRT/TO V5 EV U. Arnold, FG17, RKI, Berlin 
pcDNA5/FRT/TO V5 HSPA2 Addgene Plasmid #19512 
pcDNA5/FRT/TO V5 HSPA8 Addgene Plasmid #19460 
pDONR221-AGR2 Harvard Medical School PlasmID Plasmid 
HsCD00042662 
pDONR221-CAST Harvard Medical School PlasmID Plasmid 
HsCD00043496 
pDONR221-EPHX1 Harvard Medical School PlasmID Plasmid 
HsCD00044569 
pDONR221-LXN Harvard Medical School PlasmID Plasmid 
HsCD00296066 
pDONR221-PABPC1 Harvard Medical School PlasmID Plasmid 
HsCD00045525 
pDONR221-PABPC3 Harvard Medical School PlasmID Plasmid 
HsCD00044176 
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pENTR223-BAG2 Harvard Medical School PlasmID Plasmid 
HsCD00368116 
pENTR223-GGH Harvard Medical School PlasmID Plasmid 
HsCD00369546 
pENTR223-RCN2 Harvard Medical School PlasmID Plasmid 
HsCD00383773 
pESG-IBA 105 IBA Lifesciences, Göttingen 
pEZYflag Addgene Plasmid #18700 
pEZYflag-AGR2 U. Arnold, FG17, RKI, Berlin 
pEZYflag-CAST U. Arnold, FG17, RKI, Berlin 
pEZYflag-EPHX1 U. Arnold, FG17, RKI, Berlin 
pEZYflag-LXN U. Arnold, FG17, RKI, Berlin 
pEZYflag-PABPC1 U. Arnold, FG17, RKI, Berlin 
pEZYflag-PABPC3 U. Arnold, FG17, RKI, Berlin 
pHW2000-A/Panama/2007/1999-NP A. Martini, FG17, RKI, Berlin 
pHW2000-A/Panama/2007/1999-PA A. Martini, FG17, RKI, Berlin 
pHW2000-A/Panama/2007/1999-PB1 A. Martini, FG17, RKI, Berlin 
pHW2000-A/Panama/2007/1999-PB2 A. Martini, FG17, RKI, Berlin 
pHW2000-A/Panama/2007/1999-PB2-
Strep 
U. Arnold, FG17, RKI, Berlin 
pHW2000-A/Thailand/1(KAN-1)/2004-
PB2 
M. Schwemmle, Dept. for Medical Micro-
biology and Hygiene, Universitätsklinikum 
Freiburg, Freiburg 
pHW2000-A/Thailand/1(KAN-1)/2004 
PB2-Strep 
U. Arnold, FG17, RKI, Berlin 
pHW2000-EV R. G. Webster, Dept. of Virology and Mo-
lecular Biology, St. Jude Children's Re-
search Hospital, Memphis 
pMAX-DEST Addgene Plasmid #37631 
pMAX-DEST-BAG2 U. Arnold, FG17, RKI, Berlin 
pMAX-DEST-GGH U. Arnold, FG17, RKI, Berlin 
pMAX-DEST-RCN2 U. Arnold, FG17, RKI, Berlin 
pPol-SapI-A-NS-Luc (Firefly) J. Stärk, FG17, RKI, Berlin 
pTK-Luc (Renilla) Promega, Mannheim 
pT7-V5-SBP-C1-EV U. Arnold, FG17, RKI, Berlin 
pT7-V5-SBP-C1-HshnRNPC1 Addgene Plasmid #64920 
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2.1.8 Antibodies 
Primary antibodies 
Identifier Species/Feature Source 
α-A-NP mouse/monoclonal AbD Serotec (Bio-Rad), Hercules (USA) 
α-A-PB2 goat/polyclonal Santa Cruz Biotechnology, Dallas 
(USA) 
α-A-PB2 rabbit/polyclonal Thermo Fisher Scientific, Bonn 
α-β-actin mouse/monoclonal Sigma-Aldrich, Taufkirchen 
α-cMyc (9E10) mouse/monoclonal Santa Cruz Biotechnology, Dallas 
(USA) 
α-Flag M2 mouse/monoclonal Sigma-Aldrich, Taufkirchen 
α-Hsc70 mouse/monoclonal Abcam, Cambridge (UK) 
α-Hsc70 rabbit/monoclonal Abcam, Cambridge (UK) 
α-Hsc70/HSP73 rat/monoclonal Enzo Life Sciences GmbH, Lörrach 
α-Strep mouse/monoclonal IBA Lifesciences, Göttingen 
α-V5 mouse/monoclonal AbD Serotec (Bio-Rad), Hercules (USA) 
Secondary antibodies 
Identifier Species Source 
Alexa Fluor™ 488 α-rat IgG donkey Invitrogen™ (Thermo Fisher Scientific), 
Carlsbad (USA) 
Alexa Fluor™ 594 α-rabbit 
IgG 
goat Invitrogen™ (Thermo Fisher Scientific), 
Carlsbad (USA) 
α-mouse IgG-HRP rabbit Dako, Santa Clara (USA) 
α-goat IgG-HRP rabbit Dako, Santa Clara (USA) 
α-rabbit IgG-HRP goat Cell Signaling Technology®, Danvers (USA) 
2.1.9 Primer 
Identifier Purpose of 
primer 
Target sequence 5`→ 3` 
A-PB2-Twin-
Strep-tag For 
Cloning  ATCAATTATAGCGCATGGAGTCATCCTCAATTCG 
BD-uni-PB2 Rev  Sequencing GGCCGCCGGGTTATTAGTAGAAACAAGGTCGTTT 
B-PB2-Pan-Twin-
Strep-tag Rev 
Cloning  CCAATTAGCTTATTTTTCGAACTGCGGGTGGCTCC 
B-PB2-Thai-
Twin-Strep-tag 
Rev 
Cloning  CCTATCAGCTTATTTTTCGAACTGCGGGTGGCTCC 
CMV For 
 
Sequencing CGCAAATGGGCGGTAGGCGTG 
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C-Twin-Strep-
tag-PB2-Pan For 
Cloning  GAAAAATAAGCTAATTGGGCAAGGAGACG 
C-Twin-Strep-
tag-PB2-Thai For 
Cloning  GAAAAATAAGCTGATAGGGCAAGGAGACG 
D-pHW2000 Rev Cloning  GAAAAATAAGCTAATTGGGCAAGGAGACG 
hGH-pA-R Rev Sequencing CCAGCTTGGTTCCCAATAGA 
LNCX For Sequencing AGCTCGTTTAGTGAACCGTCAGATC 
M13 Rev Sequencing CAGGAAACAGCTATGAC 
MB-CMV-seq For Sequencing AACAACTCCGCCCCATTGAC 
Pan-intern-PB2 
For 
Sequencing TTGTACAACAAAATGG 
PB2-2333 Rev Sequencing CAAGGTCGTTTTTAAA 
pCDNA3.1-
inverse-fw 
Cloning  TAATTAATTAAGTTTAAACCCGCTGATCAGCC 
pCDNA3.1-
inverse-rev 
Cloning  CTTGTAGAGCTCGTCCATGCCG 
pCDNA5-inverse-
fw 
Cloning  TAAGCGGCCGCTCGAGTCTAG 
pCDNA5/pT7-
inverse-rev 
Cloning  CGTAGAATCGAGACCGAGGAGAG 
pT7-inverse-fw Cloning  TAAGAATTCTGCAGTCGACGGTACC 
Thai-PB2-1751-
1764 For 
Sequencing GGAGTTTGAACCG 
2.1.10 siRNA 
Identifier Source Target sequence 5`→ 3` 
AllStars Negative Control 
siRNA 
Qiagen FlexiTube  
siRNA HSPA8 #6* Qiagen FlexiTube AAGGACCTAAATTCGTAGCAA 
siRNA HSPA8 #10* Qiagen FlexiTube GAGGTTGATTAAGCCAACCAA 
siRNA HSPA8 #11* Qiagen FlexiTube TGGGCATTCTCAATACTTGAA 
siRNA HSPA8 #12* Qiagen FlexiTube TTAAGCTGCTATAGTAAGTTA 
 
* component of HSPA8-siRNA Mix 
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2.1.11 Cell culture media 
DMEM/MEM culturing  
medium 
FBS 
Glutamine 
Pen/Strep 
DMEM or MEM 
10 % 
2 nM 
50 mg/mL 
ad 500mL 
 
Transfection 
DMEM/MEM 
FBS 
Glutamine 
DMEM or MEM 
10 % 
2 nM 
ad 500mL 
 
Infection DMEM/MEM BSA 
Glutamine 
Pen/Strep 
DMEM or MEM 
0.2 % 
2 nM 
50 mg/mL 
ad 500mL 
 
SILAC DMEM Dialyzed FBS 
Glutamine 
Pen/Strep 
L-Lysine (non labelled), (D4)or (13C6, 15N2) 
10 % 
2 mM 
50 mg/mL 
146 mg/L 
 L-Arginine (non labelled), (13C6) or 
(13C6, 15N4) 
SILAC DMEM 
84 mg/L 
 
ad 500mL 
 filter 0.22 µm  
 
SILAC Infection DMEM 
 
Glutamine 
Pen/Strep 
L-Lysine (non labelled), (D4)or (13C6, 15N2) 
L-Arginine (non labelled), (13C6) or 
(13C6, 15N4) 
SILAC DMEM 
 
2 mM 
50 mg/mL 
146 mg/L 
84 mg/L 
 
ad 500mL 
 filter 0.22 µm 
 
 
Freezing Media 
 
 
 
Avicel overlay medium 
SILAC DMEM 
Dialyzed FBS 
DMSO 
 
2.5 % Avicel RC-581 in H2O 
2x MEM 
30% BSA 
5 % NaHCO3 
1 % DEAE-Dextran 
 
20 % 
10 % 
 
4.86 mL 
4.86 mL 
66.7 µL 
100 µL 
100 µL 
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2.1.12 Media for bacteria 
2x YT medium  Trypton 
Yeast extract 
NaCl 
16 g/L 
10 g/L 
10 g/L 
 pH 7.2  
 
SOC medium 
 
Trypton 
Yeast extract 
NaCl 
KCl 
 
20 g/L 
5 g/L 
10 mM 
2.5 mM 
 autoclaving  
 MgCl2 20 mM 
 
MgCl2-Stock 
 
MgCl2 x 6 H2O 
MgSO4 x 7 H2O 
Glucose 
 
1 M 
1 M 
0.4 % (w/v) 
 
2x YT-agar with antibiot-
ics 
 
2 x YT medium 
Bacto-Agar 
 
 
1.5 % (w/v) 
 autoclaving and cooling 
down 
 
 Ampicillin or Kanamycin 100 g/L or 50 g/L 
2.1.13 Buffer and solutions 
PBS NaCl 
KCl 
Na2HPO4 
KH2PO4 
137 mM 
2.7 mM 
80.9 mM 
1.5 mM 
 
PBS+ 
 
PBS 
MgCl2 
CaCl2 
 
 
0.1 g/L 
0.13 g/L 
 
PBS+/+ 
 
PBS 
BSA 
MgCl2 
CaCl2 
 
 
 
0.2 % 
0.1 g/L 
0.13 g/L 
PEI Polyethylenimin 
 
2,58 µg/µL 
10x SDS buffer Tris 
Glycin 
SDS 
250 mM 
1.92 mM 
10 g/L 
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Separating gel buffer pH 8.8 Tris/HCl 1.5 mM 
 
Stacking gel buffer pH 6.8 
 
Tris/HCl 
 
0.5 M 
 
10x TBE buffer 
 
Tris 
Boric acid 
EDTA, pH 8.0 
 
0.89 M 
0.89 M 
10 mM 
 
2x SDS sample buffer 
 
H2O 
0.5 M Tris/HCl, pH 6.8 
10 % SDS (w/v) 
Glycerol 
Bromphenolblue 
β-Mercaptoethanol 
 
1.2 mL 
8.3 mL 
6 mL 
1.5 mL 
9 g/L 
5 % 
 
6 SDS sample buffer 
 
H2O 
0.5 M Tris/HCl, pH 6.8 
SDS  
Glycerol 
0.5 mM EDTA, pH8 
Bromphenolblue 
β-Mercaptoethanol 
 
1.2 mL 
9.8 mL 
1.7 g 
5 mL 
0.5 mL 
9 g/L 
5 % 
 
Semi-dry blotting buffer 
 
Tris 
Glycin 
SDS 
Ethanol 
 
40 mM 
30 mM 
1.3 mM 
20 % 
 
Coomassie staining solution 
 
Coomassie Roti® Blue (5x) 
Ethanol 
H2O 
 
20 % 
20 % 
60 % 
 
Coomassie destaining solution 
 
Methanol  
in H2O 
 
10 % 
 
Coomassie fixation solution 
 
Acetic acid 
Ethanol 
 
10 % 
30 % 
 
6x DNA sample buffer 
 
Bromphenolblue 
Xylencyanol 
Glycerol 
 
0.1 % (w/v) 
0.1 % (w/v) 
30 % 
 
Mowiol 
 
Mowiol 4-88 
Glycerol 
H2O 
 
2.4 g 
6 mL 
6 mL 
 incubation over night 
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 0.2 M Tris/HCl, pH 8.5 12 mL 
 heating to 60°C while stirring 
centrifugation for 15 min  
DABCO 
 
 
1.300g 
10 % 
Cell lysis buffer (mass spectrom-
etry) 
Tris/HCl, pH 8.0 
NaCl 
MgCl2 
IGEPAL 
Dithiothreitol 
Glycerol 
Sodium-Orthovanadat 
Pefabloc 
50 mM 
300 mM 
2 mM 
0.3 % 
1 mM 
10 % 
2 mM 
1 mM 
 
Buffer W 
 
Tris/HCl, pH 8.0 
NaCl 
EDTA 
 
 
100 mM 
150 mM 
1 mM 
Buffer E Tris/HCl, pH 8.0 
NaCl 
EDTA 
Desthibiotin 
100 mM 
150 mM 
1 mM 
10 mM 
 
1x Tris-HEPES SDS buffer 
 
20x Tris HEPES buffer diluted in MS grade 
water 
 
Alkylation buffer 
 
Iodoacetamide in MS grade 
water 
 
50 mM 
 
Destaining solution 
 
NH4HCO3 
Acetonitril 
 
200 mM 
40 % 
 
Enzyme reaction buffer 
 
NH4HCO3 
Acetonitril 
 
400 mM 
9 % 
 
Extraction buffer 
 
Acetonitril 
Trifluoroacetic acid 
 
50 % 
0.1 % 
 
Desalting buffer 
 
Formic acid 
Acetonitril 
 
0.5 % 
80 % 
 
IP-Lysis buffer 
 
Tris/HCl, pH 7.4 
NaCl 
IGEPAL 
EDTA 
Glycerol 
 
25 mM 
150 mM 
1 % 
1 mM 
5 % 
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2.1.14 Technical equipment 
Centrifuges 
Centrifuge 5417 R Eppendorf, Hamburg 
Heraeus™ Pico™ 17 Microcentrifuge Thermo Fisher Scientific, Bonn 
Labofuge 400R (rotor: 8179) Heraeus (Thermo Fisher Scientific), 
Bonn 
Megafuge 1.0R (rotor: 2704) Heraeus (Thermo Fisher Scientific), 
Bonn 
Multifuge 1S-R (rotor: 75002000) Thermo Fisher Scientific, Bonn 
Sorvall™ LYNX™ Superspeed-Centrifuge 
(rotors: F12-6x500, F14-6x250y, A27-8x50) 
Thermo Fisher Scientific, Bonn 
SpeedVac Univapo 150 H Uniequip, Planegg 
Thermocycler 
Personal Cycler Biometra, Göttingen 
Primus 96 PEQLAB (VWR), Erlangen 
Uno Thermoblock Biometra, Göttingen 
Microscopes 
Eclipse TS100 Nikon, Tokyo (Japan) 
Olympus CKX41 Olympus, Tokyo (Japan) 
Confocal laser scan microscope LSM 780 Zeiss, Oberkochen 
Other devices 
ABI Prism 3100 Genetic Analyzer Applied Biosystems, Foster City (USA) 
Advanced Fluorescence Imager Intas Science Imaging, Göttingen 
Binder (incubator) Thermo Fisher Scientific, Bonn 
Ecotron (incubator shaker) Infors HT, Bottmingen (Switzerland) 
FLUOstar® Omega Plate Reader BMG Labtech, Ortenberg 
Haake DC10-P21 Open-Bath Circulators 
with Integral Bath (Water) 
PSL Systemtechnik, Osterode am Harz 
HeraSafe HSP15 clean bench Heraeus (Thermo Fisher Scientific), Bonn 
HeraSafe KS12 Heraeus (Thermo Fisher Scientific), Bonn 
Curix 60 developer machine Agfa, Mortsel (Belgium) 
Easy Nano-LC2 Proxeon (Thermo Fisher Scientific), 
Dreieich 
Gel chamber Mini-Sub Cell GT Bio-Rad, Hercules (USA) 
Gel documentation Intas Science Imaging, Göttingen 
LTQ Orbitrap Discovery mass spectrome-
ter 
Thermo Fisher Scientific, Bonn 
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Mini-PROTEAN® 3 Bio-Rad, Hercules (USA) 
NanoDrop 8000 Thermo Fisher Scientific, Bonn 
Power Pack 200 and 300 Bio-Rad, Hercules (USA) 
Roto-Shake Genie Scientific Industries, Bohemia (USA) 
Spectrafluor Plus ELISA-Reader Tecan, Männedorf (Switzerland) 
Tecan Genios Pro ELISA-Reader Tecan, Männedorf (Switzerland) 
Thermomixer compact Eppendorf, Hamburg 
Trans-Blot SD Semi-Dry Transfer Cell Bio-Rad, Hercules (USA) 
TriStar LB941 Multimode Reader Berthold Technologies GmbH & Co.KG, 
Schöneiche bei Berlin 
Varocell 150 (incubator) Varolab GmbH, Giesen  
2.1.15 Software and web tools 
Software 
Adobe Photoshop CS6 image processing 
ChemoStar Professional software (Intas) gel documentation 
DNASTAR Lasergene 10 sequence analysis 
Endnote X7.4 reference manager 
Geneious R10 sequence analysis 
GraphPad Prism 7 tables and statistics 
Intas-Capture gel documentation 
LabImage 1D quantification of immunoblot protein bands 
Magellan™ data analysis 
MARS data analysis software data analysis 
MaxQuant 1.5.1.2 analysis of MS data 
Microsoft Office 2010 text and presentations 
MikroWin 2000 data analysis 
Proteome Discoverer 1.4 analysis of MS data 
Perseus 1.5.0.31 downstream biological analysis of MS data 
Web tools 
Bioinformatics & Evolutionary Genomics http://bioinformatics.psb.ugent.be/webtools/
Venn/ 
NCBI PubMed https://www.ncbi.nlm.nih.gov/pubmed 
PANTHER Gene List Analysis v11.1 http://pantherdb.org/ 
STRING: functional protein association 
networks v10.5 
https://string-db.org/ 
UniProt Knowledgebase http://www.uniprot.org/ 
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2.2 Methods 
2.2.1 Cell culture 
Cell passaging 
All cell types were cultured at 37°C and in 5 % CO2 and manipulated under sterile con-
ditions. Cells were subcultured every 3 – 4 days, depending on the cell line, when they 
reached 90 % to 95 % confluency. During subculture cells were washed in phosphate 
buffered saline (PBS) and detached by adding 1 mL trypsin-ETDA solution to a T75 cell 
culture flask. Detached cells were resuspended in fresh media and transferred into new 
flasks at the required density. MDCKII cells were cultured in complemented minimal 
essential medium (MEM) while A549 and HEK293T cells were cultivated in comple-
mented Dulbecco’s modified Eagle medium (DMEM). For the exact media composition 
see section 2.1.11. 
Transfection of eukaryotic cells with Lipofectamine® 2000 
The day prior to transfection, cells were subcultured to ensure they were still dividing 
when transfected. On the day of transfection, cells were washed once with PBS, de-
tached with trypsin-EDTA solution and resuspended in transfection D-MEM). Cells 
were pelleted at 800 g for 3 minutes (min) and resuspended in 10 mL fresh transfection 
D-MEM. In each well of the 6-well plate, 800 µL of cells (corresponding to approximate-
ly 0.7 x 106 cells) were seeded and 1.2 mL of fresh transfection D-MEM was added. 
Meanwhile, Lipofectamine® 2000 was diluted in 100 µL Opti-MEM at a concentration of 
1.5 µL per 1 µg of plasmid DNA, then the mixture was incubated at room temperature 
(RT) for 5 min. Plasmid DNA was diluted in 100 µL Opti-MEM then combined with the 
Lipofectamine® 2000-Opti-MEM mixture and incubated for 20 min at RT. The DNA-
Lipofectamine® 2000-solution was added dropwise to the cells and distributed by shak-
ing gently. Cells were incubated in 5 % CO2 at 37 °C for 48 hours (h) before further 
analysis. 
Transfection of eukaryotic cells with PEI 
Cells were subcultured the day prior to transfection to ensure they were still dividing 
when transfected. On the day of transfection, cells were harvested, pelleted at 800 g 
for 3 min, resuspended in fresh transfection D-MEM and seeded corresponding to a 
confluency of ~80 %. Plasmid DNA was diluted in Opti-MEM equivalent to 10 % of the 
seeding volume of the cells, and PEI was added at a concentration of 2 µL per 1 µg 
DNA. After 15 min of incubation at RT, the DNA-PEI mixture was added to the cells 
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and distributed by rocking the cell culture plate. Cells were incubated for 24 h before 
they were analyzed. 
Transfection of siRNA 
The effect of HSPA8 knock down was examined by transfecting A549 or 293T cells 
with HSPA8 FlexiTube siRNA mix using Lipofectamine® RNAiMAX according to manu-
facturers instructions. The siRNA mix was composed of 4 different, preselected siRNAs 
specific for the target gene (see section 2.1.10). Briefly, cells were seeded in transfec-
tion D-MEM such that they were~60 - 80 % confluent on the day of transfection. For 
each well of a 12-well plate, 25 pmol of siRNA was combined with Opti-MEM to a total 
volume of 50 µL, and in parallel 5 µL of Lipofectamine® RNAiMAX was combined with 
Opti-MEM also to a total volume of 50 µL. For each well of a 96-well plate, 2 pmol siR-
NA and 1µL of Lipofectamine® RNAiMAX was diluted in a total volume of 5 µL Opti-
MEM each. In both cases, the solutions of siRNA and RNAiMAX were mixed and incu-
bated for 5 min at RT before being added to the cells. 4 h after transfection, medium 
was replaced by fresh transfection D-MEM. Cells were transfected with either HSPA8 
siRNA mix or non-target control siRNA. The efficacy of the knock down was evaluated 
at different time points post transfection (p.t.) by SDS-PAGE and immunoblotting. 
2.2.2 Infectious work 
All experiments involving infectious A/Thailand/1(KAN-1)/2004 influenza virus were 
performed under BSL3 conditions. 
Infection of eukaryotic cells 
For infection with influenza A viruses, cells were seeded such that their confluency was 
80 - 90 % on the day of infection. Cells were either infected with a defined dilution (e.g. 
a 10-3 dilution) for viral titration or with a defined number of infectious virus particles per 
cell. To determine the amount of virus stock needed to reach a specific multiplicity of 
infection (MOI), the following formula was used: 
 
𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛 𝑜𝑜𝑜𝑜 𝑐𝑐𝑛𝑛𝑐𝑐𝑐𝑐𝑐𝑐 × 𝑀𝑀𝑀𝑀𝑀𝑀
𝑣𝑣𝑣𝑣𝑛𝑛𝑣𝑣𝑐𝑐 𝑡𝑡𝑣𝑣𝑡𝑡𝑛𝑛𝑛𝑛 [𝑃𝑃𝑃𝑃𝑃𝑃𝑛𝑛𝑚𝑚 ] = 𝑣𝑣𝑜𝑜𝑐𝑐𝑛𝑛𝑛𝑛𝑛𝑛 𝑜𝑜𝑜𝑜 𝑣𝑣𝑣𝑣𝑛𝑛𝑛𝑛𝑐𝑐 𝑐𝑐𝑡𝑡𝑜𝑜𝑐𝑐𝑠𝑠 [𝑛𝑛𝑚𝑚]  
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For infection, cells were washed once with PBS+ and then inoculated with the appropri-
ate virus dilution in PBS++. The total volume of the virus dilution was the minimum vol-
ume that could still cover the cells in the dish. After incubation for 45 min at RT under 
constant gentle shaking, in order to allow the viral particles to distribute evenly, cells 
were washed twice with PBS+ and infection media was added. 
For monocyclic infections, the media was free of TPCK-Trypsin, however TPCK-
Trypsin was added to the infection media in the case of multicyclic infections to assist 
cleaving of the viral HA and support virus propagation. The concentration of TPCK-
Trypsin was dependent on the cell type used for the experiment: 1 µg/mL for MDCKII 
cells and 0.225 µg/mL for A549 cells.  
For growth curve analysis, 10% of the total volume of media in the dish was removed 
at defined time points and replaced by fresh infection medium supplemented with 
TPCK-Trypsin. Supernatants were stored at -80°C until further analysis. 
Viral titration by plaque-forming assay 
Plaque-forming assay is a method for determining the amount of infectious virus parti-
cles in, for example, virus stocks or supernatants of infected cells. It is based on the 
cytopathic lytic effect of influenza viruses, which leads to the formation of visible 
plaques in an infected confluent cell monolayer. These plaques can be counted and the 
viral titer can be calculated. 
Briefly, confluent MDCKII cells were washed once with PBS+ and infected with 10-fold 
serial dilutions of the virus solution in PBS++. After a 45 min incubation at RT under 
constant gentle shaking, cells were washed twice with PBS+, and then overlaid with 
Avicel medium containing 1 µg/mL TPCK-Trypsin and incubated at 37 °C. 48 h post 
infection (p.i.), Avicel medium was removed and cells were washed twice with PBS, 
and then stained for at least 15 min with 0.1 % crystal violet diluted in 10% formalde-
hyde. The staining solution was then removed and cells were washed thoroughly with 
water and dried at RT. Viral titers were calculated using the following formula: 
 
𝑣𝑣𝑣𝑣𝑛𝑛𝑣𝑣𝑐𝑐 𝑡𝑡𝑣𝑣𝑡𝑡𝑛𝑛𝑛𝑛 [𝑃𝑃𝑃𝑃𝑃𝑃/𝑛𝑛𝑚𝑚] = 𝑁𝑁𝑜𝑜. 𝑜𝑜𝑜𝑜 𝑝𝑝𝑐𝑐𝑣𝑣𝑝𝑝𝑛𝑛𝑛𝑛𝑐𝑐
𝑑𝑑𝑣𝑣𝑐𝑐𝑛𝑛𝑡𝑡𝑣𝑣𝑜𝑜𝑛𝑛 𝑜𝑜𝑣𝑣𝑐𝑐𝑡𝑡𝑜𝑜𝑛𝑛 ∗ 1 𝑛𝑛𝑚𝑚𝑣𝑣𝑛𝑛𝑜𝑜𝑛𝑛𝑛𝑛𝑡𝑡 𝑜𝑜𝑜𝑜 𝑣𝑣𝑣𝑣𝑛𝑛𝑛𝑛𝑐𝑐 𝑐𝑐𝑜𝑜𝑐𝑐𝑛𝑛𝑡𝑡𝑣𝑣𝑜𝑜𝑛𝑛 𝑛𝑛𝑐𝑐𝑛𝑛𝑑𝑑 𝑜𝑜𝑜𝑜𝑛𝑛 𝑣𝑣𝑛𝑛𝑜𝑜𝑛𝑛𝑐𝑐𝑡𝑡𝑣𝑣𝑜𝑜𝑛𝑛 [𝑛𝑛𝑚𝑚]  
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Rescue of recombinant viruses 
To generate recombinant A/Pan/99 (H3N2) and A/Thai/04 (H5N1) wild type (WT) and 
PB2-Strep viruses, cells were transfected with the corresponding pHW2000 plasmid 
system. The pHW2000 plasmid contains viral cDNA inserted between an RNA poly-
merase I (Pol I) promoter and terminator sequence, which are flanked by an RNA pol-
ymerase II (Pol II) promoter and a polyadenylation site 145. The two transcription units 
are in opposing orientation on the plasmid, which allows for the synthesis of positive-
sense mRNA and negative-sense vRNA, both necessary for virus rescue, from one 
viral cDNA template 145. For A/Pan/99 rescue, 293T cells in a 6-well plate were trans-
fected with a mixture of eight pHW200 plasmids, each representing one viral segment. 
500 ng of each plasmid was used for transfection. For A/Thai/04 rescue, a mixture of 
293T and MDCKII cells in a 6-well plate was transfected. In addition to the 500 ng of 
each of the 8 pHW200 plasmids, 4 helper plasmids were co-transfected. The helper 
plasmids were pcDNA expression plasmids encoding PA, PB1, PB2 or NP of the viral 
strain A/Puerto Rico/8/34 (H1N1). These plasmids only allow the synthesis of mRNA 
and not vRNA. The expressed A/PR8/34 proteins boost the production of A/Thai/04 
viral particles in mammalian cells. 250 ng each of pcDNA-PA, -PB1 and -PB2, and 1 µg 
of pCDNA-NP were co-transfected into each well of a 6-well plate. For the rescue of 
A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep, the pHW2000-PB2-Strep plasmid for 
the corresponding virus was transfected instead of the WT plasmid. Transfected cells 
were incubated at 37 °C for 48 h before cell supernatants were collected. 
Confluent MDCKII cells in a 6-well plate were infected with the 293T cell supernatant 
containing either A/Pan/99 or A/Thai/04 rescued virus. These MDCKII cells were 
washed once with PBS before inoculation with 250µL of 293T cell supernatant for 45 
min at RT under constant gentle shaking. After removal of the supernatant, cells were 
washed twice with PBS+ and 2 mL of infection MEM containing 1 µg/mL TPCK-Trypsin 
was added to each well. After 48 h at 37 °C, MDCKII supernatant was collected and 
viral titers were determined by plaque-forming assay before being used for virus prop-
agation in embryonated chicken eggs. 
Infection of embryonated chicken eggs for virus propagation 
Influenza viruses replicate well in the allantoic cavity of embryonated chicken eggs. 
Hence, A/Pan/99-WT, A/Pan/99-PB2-Strep, A/Thai/04-WT and A/Thai/04-PB2-Strep 
viral stocks were produced in 10 day old eggs. Each MDCKII supernatant was diluted 
to a concentration of 800 PFU in 100 µL PBS++ per egg. The diluted virus suspension 
was inoculated into the allantoic cavity with a needle (canula 0.55 x 25 mm). After 48 h 
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of incubation at 37 °C, eggs were cooled overnight (ON) at 4 °C. The shell around the 
air cell of the egg was removed with tweezers and the allantoic fluid was harvested with 
a stripette while the yolk sac was protected from lesions with a spatula. The harvested 
virus suspension was centrifuged (3.000 rpm, 5 min, 4 °C) and a hemagglutination as-
say was performed (see 2.2.2). Allantoic fluids of eggs with similar haemagglutination 
titers (HA titer) were pooled, aliquoted in cryovials and stored at -80 °C. Viral titers 
were subsequently determined by plaque-forming assay.  
Hemagglutination assay 
The hemagglutination assay allows for a rapid estimation of the amount of virus parti-
cles present in a solution. The technique is based on the ability of viral HA to bind sialic 
acids on the surface of erythrocytes, thereby cross-linking them to each other, which 
leads to agglutination. However, discrimination between infectious and non-infectious 
particles is not possible. 
Virus containing solution was 1 in 2 serially diluted in a 96-well microtiter plate (V-
bottom) in PBS. Equal amounts of a 1 % chicken erythrocyte solution were then added, 
solutions were mixed and the plate was incubated at 4 °C for at least 30 min. If an ex-
amined solution contains approximately 105 to 106 viral particles, erythrocytes agglu-
tinate146. Whether the erythrocytes did or did not agglutinate can be determined by tilt-
ing the plate. If there are not enough viral particles for agglutination, red blood cells 
accumulated at the bottom of the well will stream in a “tear-drop” fashion. The recipro-
cal value of the dilution at which hemagglutination can still be observed (i.e no “tear-
drop” stream of erythrocytes) represents the HA titer. 
2.2.3 Molecular biology methods 
Generation of pHW2000-PB2-Strep plasmids 
For the rescue of A/Pan/99 and A/Thai/04 viruses expressing Strep-tagged PB2, the 
sequence of the Twin-Strep-tag® needed to be inserted into the corresponding 
pHW2000-PB2 plasmid. Based on the publication of Rameix-Welti et al. the tag se-
quence was fused to the sequence encoding the C terminus of PB2. To enable not only 
expression of the fusion protein but also packaging of the PB2 genomic segment into 
viral particles, a duplication of the last 109 nucleotides (nt) of the PB2 coding sequence 
was inserted between the stop codon of the tag sequence and the 5′ NCR 147. This  
143 nt long sequence represents the PB2 packaging sequence (figure 2.1.A). For the 
generation of the pHW2000-PB2-Strep plasmids a multi-step polymerase chain reac-
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tion (PCR) procedure was applied (figure 2.1.B). First, the Twin-Strep-tag® sequence 
was amplified from the pESG-IBA 105 plasmid. The used forward (fw) primer contained 
a sequence homologous to the end of the PB2 non-coding region, not including the 
stop codon, at the 5’-end. The reverse (rev) primer contained a sequence homologous 
to the start of the PB2 packaging signal. In addition the packaging signal sequence was 
amplified from the pHW2000-PB2 plasmid, using a reverse primer homologous to the 
pHW2000 sequence downstream of the packaging signal and a forward primer that 
contained a sequence homologous to the 5’ - end of the Twin-Strep-tag® sequence.  
 
 
Figure 2.1. Generation of pHW2000-PB2-Strep plasmids. The Twin-Strep-tag® sequence 
was inserted between the PB2 coding region and the PB2 packaging signal of A/Pan/99 or 
A/Thai/04 (A) using a multi-step PCR procedure (B). The detailed procedure is described in the 
text. 
The amplified sequences were fused by overlap PCR using both PCR products, the 
forward primer used for the amplification of the Twin-Strep-tag® sequence and the re-
verse primer used for the amplification for the packaging signal sequence. 
2. Materials and Methods 50 
 
 
The resulting fragment contained the sequence homologous to the end of the PB2 non-
coding region followed by the Twin-Strep-tag® with a stop codon, the PB2 packaging 
signal and the sequence homologous to the pHW2000 plasmid sequence. Finally, the 
pHW2000-PB2-Strep plasmid was generated by target primed plasmid amplification 
using pHW2000-PB2 as template and the overlap PCR product as primer. The follow-
ing reaction parameters were employed: 
 
Conventional PCR: 
 
Template DNA       100 ng 
Fw Primer        1 µL (0.5 µM) 
Rev Primer        1 µL (0.5 µM) 
dNTPs         0.4 µL (200 µM) 
5X Phusion Green GC Buffer     4 µL 
Phusion Green High-Fidelity DNA Polymerase (2 U/µL)  0.2 µL 
H2O         ad 20 µL 
 
Number of cycles Temperature Time 
1x 98 °C 30 sec 
35x 98 °C 
69 °C 
72 °C 
10 sec 
30 sec 
30 sec 
1x 72 °C 10 min 
1x 4 °C ∞ 
 
Overlap PCR: 
 
Template DNA 1 (PCR1)      10 ng 
Template DNA 2 (PCR2)      10 ng 
Fw Primer        1 µL (0.5 µM) 
Rev Primer        1 µL (0.5 µM) 
dNTPs         0.4 µL (200 µM) 
5X Phusion Green HF Buffer      4 µL 
Phusion Green High-Fidelity DNA Polymerase (2 U/µL)  0.2 µL 
H2O         ad 20 µL 
 
Number of cycles Temperature Time 
1x 98 °C 30 sec 
35x 98 °C 
71 °C 
72 °C 
10 sec 
30 sec 
30 sec 
1x 72 °C 10 min 
1x 4 °C ∞ 
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Target primed plasmid amplification: 
 
Template DNA       100 ng 
Primer (Overlap PCR)      100 ng 
dNTPs         1 µL (200 µM) 
5X Phusion Green HF Buffer      10 µL 
Phusion Green High-Fidelity DNA Polymerase (2 U/µL)  0.5 µL 
H2O         ad 50 µL 
Number of cycles Temperature Time 
1x 98 °C 1 min 
35x 98 °C 
66 °C 
72 °C 
10 sec 
30 sec 
95 sec 
1x 72 °C 10 min 
1x 4 °C ∞ 
 
Following the PCR reaction, a DpnI digestion was performed to degrade the remaining 
template DNA and transformation of bacteria was performed. 
Gateway cloning 
For fusion of human proteins of interest with a V5 or a FLAG tag, the gateway cloning 
method was used. Gateway cloning entry vectors encoding the protein of interest 
(pENTR223 or pDONR221, depending on availability) were acquired from Harvard 
Plasmid Information Database (PlasmID). Cloning into the destination vector pEZYflag 
or pMAX-DEST was performed using Gateway™ LR Clonase™ II Enzyme mix accord-
ing to the manufacturer’s instructions. 150 ng/µL of destination vector and 100 ng/µL 
entry clone were used per reaction. 
Generation of control vectors by inverse PCR 
If available, expression vectors encoding V5 or FLAG tagged proteins of interest were 
ordered. Since empty expression vectors coding only for the tag were needed for some 
experiments, the sequence of the protein of interest was deleted by inverse PCR. Pri-
mers adjacent to the protein sequence with the 3’-ends facing away from each other 
were designed and the expression vector was used as the template. The PCR product 
was the linearized tag vector lacking the sequence for the protein of interest. The fol-
lowing reaction parameters were employed: 
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Template DNA       250ng 
DMSO         1.5µL 
Fw Primer        2.5µL (0.5 µM) 
Rev Primer        2.5µL (0.5 µM) 
dNTPs         1µL (200 µM) 
5X Phusion Green HF Buffer      10µL 
Phusion Green High-Fidelity DNA Polymerase (2 U/µL)  0.5µL 
H2O         ad 50µL 
 
Number of cycles Temperature Time 
1x 98 °C 30 sec 
25x 98 °C 
72 °C 
10 sec 
20 sec/kb 
1x 72 °C 10 min 
1x 4 °C ∞ 
 
Following the PCR reaction, a DpnI digestion was performed to degrade the remaining 
template DNA. For plasmid self-ligation, PCR products needed to be phosphorylated 
since the primers used for the inverse PCR lacked the 5’-end phosphate group. 
DpnI digestion 
The restriction enzyme DpnI specifically degrades methylated DNA. Therefore, it is 
widely used to remove the remaining template DNA after a PCR reaction. The template 
DNA is of bacterial origin and is thereby methylated, whilst the newly PCR-generated 
DNA does not have any methylation modification. For the restriction reaction, PCR 
product was mixed with 2 µL DpnI and incubated for 2 h at 37 °C. 
Agarose gel electrophoresis 
Agarose powder was boiled in 1x TBE buffer, cooled down, then 6 µL of Midori green 
was added per 100 µL of dissolved agarose. DNA samples were supplemented with 6x 
loading buffer, then loaded onto the agarose gel. Separation of samples was performed 
in 1x TBE buffer at a constant voltage of 120 V. DNA was visualized on a transillumina-
tor with UV light and the size of the DNA fragments was determined by comparison to 
commercially available DNA ladders. 
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Purification of PCR products 
PCR products were purified either immediately after the PCR reaction, or after analyz-
ing the product by agarose gel electrophoresis, using QIAquick® PCR Purification Kit 
or Invisorb® Spin DNA Extraction Kit, respectively. Purification was performed accord-
ing to the manufacturer’s instructions and DNA was eluted with 40 µL double distilled 
(dd) H2O. 
5’-End phosphorylation and plasmid self-ligation 
Purified inverse PCR products were phosphorylated employing following parameters: 
 
Purified PCR product  40 µL 
10x PNK Buffer A  5 µL 
ATP (10 mM)   4 µL 
T4 Polynucleotide kinase 1 µL 
 
37 °C, 60 min 
 
Next, 5’-end phosphorylation products were again purified and a self-ligation reaction 
was performed for 2 h at RT: 
 
10x T4 ligase buffer   2 µ 
100 ng purified PCR product  x µL 
ATP (10 mM)    1 µL 
PEG 4000    1 µL 
T4 DNA Ligase   1 µ 
H2O     ad 20 µL 
Transformation of bacteria 
For transformation of bacteria, 50 µL of competent E.coli XL-1 Blue cells were thawed 
on ice and mixed with 5 µL of purified PCR product. After incubation for 30 min on ice, 
heat shock for the induction of DNA uptake was performed for 45 seconds (sec) at 42 
°C. Bacteria were incubated for another 2 min on ice before being mixed with 500 µL 
2. Materials and Methods 54 
 
 
super optimal broth with catabolite repression (SOC) medium and incubated for 1 h at 
37 °C under constant gentle shaking. Cells were plated on 2x YT agar plates supple-
mented with antibiotics (100 µg/mL Ampicillin or 50 µg/mL Kanamycin) and incubated 
at 37°C ON. 
Plasmid preparation 
Single colonies of transformed bacteria were picked and grown at 37 °C ON at 200 rpm 
in 5 mL (“mini culture”) or 200 mL (“maxi culture”) 2x TY medium containing the appro-
priate antibiotic (100 µg/mL Ampicillin or 50 µg/mL Kanamycin). Bacteria were pelleted 
and plasmid DNA was isolated employing the QIAfilter Plasmid Maxi Kit for maxi cul-
tures, or the Invisorb® Spin Plasmid Mini Two Miniprep Kit for mini cultures, according 
to the manufacturer’s instructions. DNA was eluted with 50 µL ddH2O (mini culture) or 
200 µL ddH2O (maxi culture). DNA concentration was determined using a NanoDrop 
8000. 
DNA sequencing 
DNA was sequenced by Sanger sequencing using the BigDye® Terminator 3.1 Cycle 
Sequencing Kit under the following conditions: 
 
Template DNA  200 ng 
Primer    0.5 µL (0.5 µM) 
BigDye 3.1 Mix  1 µL 
5x ABI reaction buffer 1.5 µL 
H2O   ad 10 µL 
 
Number of cycles Temperature Time 
1x 96 °C 2 min 
25x 96 °C 
55 °C 
60 °C 
10 sec 
5 sec 
4 min 
1x 4 °C ∞ 
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2.2.4 Biochemical Methods 
SDS polyacrylamide gel electrophoresis (PAGE) 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE) was per-
formed to separate proteins according to their molecular weight. Gels were prepared 
using the Mini-PROTEAN® 3 gel casting equipment according to table 2.1. 
After preparation and polymerization of the separation gel, the stacking gel solution 
was mixed and poured on top. Lanes were generated by insertion of a plastic comb 
with the designated number of teeth. 
Table 2.1. Composition of SDS polyacrylamide gels. Volumes sufficient for a single 1.5 mm 
gel with the stated acrylamide concentration. 
 separation gel stacking gel 
 7.5 % 10 % 12.5 % 5% 
30% Acrylamide/ Bisacrylamide (29:1) 2.5 mL 3.3 mL 4.1 mL 0.83 mL 
ddH2O 4.8 mL 4.0 mL 3.2 mL 2.8 mL 
1.5 M Tris/ Cl pH 8.8 2.5 mL 2.5 mL 2.5 mL - 
0.5 M Tris/ Cl pH 6.8 - - - 1.25 mL 
10% SDS 100 µL 100 µL 100 µL 50 µL 
10% APS 100 µL 100 µ 100 µ 50 µL 
TEMED 6 µL 6 µL 6 µL 6 µL 
 
Protein samples were mixed with 2x or 6x sample buffer and heated for 5 min at 95 °C 
prior to loading onto the gel. Separation of samples was performed in a vertical gel 
chamber in SDS-running buffer by application of an electric field with a current of 25 
mA per gel. 
Western transfer and immunoblot analysis 
In order to detect specific proteins, separated proteins were transferred from the SDS 
polyacrylamide gel onto a nitrocellulose membrane by semi-dry western blotting.A 
Trans-Blot® SD Semi-Dry Transfer Cell was used for this purpose as follows: anode, 
3x Whatman paper, SDS gel, nitrocellulose membrane, 3x Whatman paper, cathode. 
For protein transfer from a 1.5 mm gel, a constant current of 75 mA was applied for    
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80 min. Afterwards, membranes were blocked with 3 % milk powder in 1x TBST at RT 
for at least 30 min. Primary antibodies were diluted in 0.5 % milk powder in 1x TBST 
and incubation of membranes with primary antibody solution was performed ON at 4 °C 
under constant gentle shaking. Membranes were washed at least 3 times for 10 min 
with 1x TBST before incubation with the appropriate secondary horseradish-peroxidase 
conjugated antibody diluted in 0.5 % milk powder dissolved in 1x TBST. After 1 h, 
membranes were washed at least 6 times for 5 min each with 1x TBST prior to detec-
tion of the specific protein bands using an enhanced chemiluminescence protocol with 
SuperSignal™WestDura Extended Duration Substrate. Luminescence was detected 
using CL-XPosure™ x-ray films developed with a Curix 60 processor (Agfa) or with an 
Advanced Fluorescence Imager (INTAS) operated with the corresponding ChemoStar 
software (INTAS). 
2.2.5 Cell biology Methods 
Protein overexpression and endogenous co-immunoprecipitation 
For the overexpression co-immunoprecipitation (co-IP) assay, 293T cells in a 10 cm 
dish were transfected with a plasmid expressing the FLAG or V5 tagged protein of in-
terest, and with expression plasmids for PB1, PB2 and PA of either A/Pan/99 or 
A/Thai/04 using PEI (see section 2.2.1). In the case of the negative control samples, 
PB1, PB2, PA expression plasmids and the empty FLAG or V5 vector were transfect-
ed. 1.75 µg of each plasmid was used for transfection, resulting in a total DNA amount 
of 7 µg per 10 cm dish. Cells were lysed and further analyzed 24 h post transfection.  
In the case of endogenous co-IP, A549 cells in a 10 cm dish were infected at an MOI of 
5 with either A/Pan/99-WT or A/Thai/04-WT virus (see section 2.2.2). 16 hours post 
infection, cells were lysed and further analyzed. 
For lysis, cells were washed once with ice cold PBS, then lysed for 10 min on ice with 
500 µL IP-Lysis buffer per dish, transferred into a 1.5 mL reaction tube, and centrifuged 
for 10 min at 13.000 g at 4°C. 
For each sample, one reaction tube containing 20 µL Protein G Agarose beads and 
one reaction tube containing 30 µL Protein G Agarose beads were prepared by wash-
ing 3 times with 500 µL IP-Lysis buffer. Centrifugation in-between washing steps was 
performed at 3.000 rpm for 3 min at 4 °C. After washing, the cell lysate was added to 
the 20 µL bead reaction tube for pre-clearing, while 500 µL IP-Lysis buffer containing 2 
µg of either α-V5, α-FLAG M2, α-Hsc70 or α- cMyc antibody was added to the            
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30 µL bead reaction tube for coupling. Pre-clearing as well as coupling was performed 
at 4 °C on a rotating platform for at least 2 h. 
Both bead mixtures were centrifuged at 3.000 rpm for 3 min at 4°C and the coupling 
solution was discarded. 50µL of the pre-cleared lysate was mixed with 6x SDS sample 
buffer, boiled at 95°C for 5 min and stored at -20 °C as a sample for whole cell lysate 
(WCL). The remaining 450 µL of pre-cleared lysate was added to the antibody-coupled 
beads and incubated ON at 4 °C on a rotating platform. 
To remove non-bound proteins, Protein G Agarose beads were washed 3 times with 
ice cold PBS. For the last washing step, beads in PBS were transferred to a new reac-
tion tube to avoid elution of proteins bound unspecifically to the reaction tube. Immuno-
precipitated proteins and their interaction partners were eluted by incubation in 30 µL 
2x SDS sample buffer for 10 min at 95 °C. Whole cell lysate and immunoprecipitate 
were analyzed by SDS PAGE and immunoblotting (see section 2.2.4). 
Polymerase activity assay 
For the polymerase activity assay, also known as minigenome or minireplicon assay, 
cells need to be transfected with expression plasmids encoding the polymerase pro-
teins and the NP protein of the analyzed influenza strain (to enable the formation of a 
polymerase complex), a reporter plasmid under the control of the UTR of an influenza 
genome segment (for the determination of the polymerase activity) and a constitutively 
expressed reporter plasmid (to allow for normalization of protein expression). For this 
study, 293T cells were transfected in 12-well plates using PEI (see section 2.2.1). Per 
well, the amounts of expression plasmids specified in table 2.2 were transfected. 
To determine the influence of proteins of interest on influenza polymerase activity by 
overexpression assays, either 100 ng or 500 ng of the plasmid encoding the investigat-
ed protein were additionally transfected per well. The total amount of transfected DNA 
in each experiment was kept constant using empty expression plasmids corresponding 
to those containing the analyzed protein. So for positive controls, 500 ng of the analo-
gous empty vector was transfected. Cell lysis and luciferase activity measurement was 
performed 24 h p.t. using a Dual-Luciferase® Reporter Assay System Kit according to 
manufacturer’s instructions. A/Thai/04 lysates were diluted 1:10 in the kit lysis buffer 
before measurement of luciferase activity. 
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To determine the influence of HSPA8 on influenza virus polymerase activity by siRNA 
knock down, 293T cells were transfected with 25 pmol per well of either NT siRNA or 
HSPA8 siRNA mix using Lipofectamine® RNAiMAX (see section 2.2.1) 24 hprior to 
transfection with the minigenome expression system (table 3.2). For negative controls, 
Lipofectamine® RNAiMAX was added to cells without siRNA (mock transfection) and in 
the second step the PB2 expression plasmid was replaced by the corresponding empty 
expression vector. 24 h after transfection of the minigenome expression system, de-
termination of luciferase activity was performed as described above. 
 
Table 2.2. Amount of expression plasmids transfected per well of a 12-well plate used for 
polymerase activity assay. 
Expression Plasmid Amount for A/Pan/99  
[ng] 
Amount for A/Thai/04 
[ng] 
pHW2000-A/Pan/2007/99-PA 
pCAGGS-A/Thai/1(KAN-1)/04-PA 
50 
- 
- 
50 
pHW2000-A/Pana/2007/99-PB1 
pCAGGS-A/Thai/1(KAN-1)/04-PB1 
50 
- 
- 
50 
pHW2000-A/Pan/2007/99-PB2 
pCAGGS-A/Thai/1(KAN-1)/04-PB2 
50 
- 
- 
50 
pHW2000-A/Pan/2007/99-NP 
pCAGGS-A/Thai/1(KAN-1)/04-NP 
100 
- 
- 
50 
pPol-SapI-A-NS-Luc 50 50 
pTK-Luc 5 5 
 
Cell viability assay (MTT test) 
To identify possible effects of siRNA treatment on cell viability, a MTT test was per-
formed. Cells were seeded in 96 well plates and transfected with 2 pmol/well of either 
NT siRNA or HSPA8 siRNA mix using Lipofectamine® RNAiMAX as described in sec-
tion 2.2.1. Control cells were mock transfected and 4 hours p.t. medium was replaced 
by 100 %, 10 % or 1 % DMSO diluted in fresh transfection D-MEM. At 24, 48, 72, 96 
and 120 hours p.t. cell viability was analyzed using the Cell Proliferation Kit I according 
to the manufacturer’s protocol. 
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Immunofluorescence analysis 
The subcellular localization of HSPA8 in influenza virus infected cells was visualized by 
indirect immunofluorescence analysis using fluorochrome-coupled antibodies. A549 
cells were seeded on cover slips and infected with either A/Pan/99-WT or A/Thai/04-
WT virus at an MOI of 1 (see section 2.2.2). 4 or 8 hours post infection cells were 
washed twice with PBS and fixed ON at 4 °C in 4 % PFA. After removal of PFA, cell 
permeabilization was performed for 20 min at RT with 0.1 % IGEPAL® CA-630 diluted 
in PBS. Cells were washed 3 times with PBS and blocked for 1 hour in 1 % milk pow-
der in PBS, before being incubated with primary antibodies diluted in 1 % milk pow-
der/PBS for 1 hour at 37 °C. Next, cells were washed three times with PBS, then incu-
bation with suitable fluorophore-labelled secondary antibodies and DAPI, diluted in      
1 % milk powder/PBS, was performed for 30 min at RT in the dark. Cells were washed 
3 times with ddH2O and cover slips were mounted on glass slides using Mowiol 4-88. 
Antibody-staining of specific proteins was visualized using a Zeiss 780 confocal laser 
scanning microscope (LSM) equipped with a 63x oil immersion objective, with a numer-
ical aperture of 1.4. Images were captured and processed with Zeiss ZEN imaging 
software. 
2.2.6 SILAC Mass spectrometry analysis 
To identify the cellular interactome of influenza A/Pan/99 and influenza A/Thai/04, a 
stable isotopic labelling by amino acids in cell culture (SILAC) approach followed by 
high-resolution liquid chromatography (LC) tandem mass spectrometric analysis was 
utilized. The detailed workflow of the performed SILAC experiment is described in fig-
ure 3.2. 
SILAC labeling of A549 cells 
A549 cells were labelled with stable isotopic amino acids according to the protocol pub-
lished by Ong and Mann 148. A549 cells were grown in SILAC DMEM containing 10 % 
dialyzed FBS, 50 mg/mL Pen/Strep as well as light (L-lysine (K0) and L-arginine (R0)), 
intermediate (L-[D4] lysine (K4) and L-[13C6] arginine (R6)) or heavy (L-[13C6, 15N2] ly-
sine (K8) and L-[13C6, 15N4] arginine (R10)) labelled amino acids. Lysine was added at 
a concentration of 146 mg/L and arginine at a concentration of 84 mg/L. Cells were 
grown in cell culture flasks and passaged five times to ensure incorporation of labelled 
amino acids into cellular proteins (see section 2.2.1). To prevent integration of unla-
belled L-lysine or L-arginine by the use of trypsin during cell passaging, Cell Dissocia-
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tion Buffer was used for cell detachment. After five cell doublings, cells were frozen at -
80 °C in SILAC DMEM containing 20 % dialyzed FBS and 10 % DMSO. 
Monitoring labelling efficiency of cells 
Protein lysates were generated from light, intermediate and heavy SILAC labelled A549 
cells and prepared for, then analyzed by LC-MS as described below. Efficient labelling 
was demonstrated at the peptide level by use of Proteome Discoverer 1.4 software. 
Infection of SILAC labelled cells with influenza A virus 
Light, intermediate and heavy labelled A549 cells were seeded in SILAC DMEM at a 
density resulting in a confluency of 80 % to 90 % on the day of infection. For each cell 
type, 2x 10 cm dishes were infected at an MOI of 1.5 with either A/Pan/99-wt, 
A/Pan/99-PB2-Strep or A/Thai/04-PB2-Strep virus, diluted in PBS+ (see section 2.2.2). 
Cells were then incubated for 16 h at 37 °C in SILAC infection DMEM. 
Cell lysis, BCA test and co-precipitation 
Infected cells were washed twice with PBS, detached from the dish in 1 mL ice cold 
PBS using a cell scraper, and transferred to a 2 mL reaction tube. The dish was 
flushed with an additional 0.75 mL PBS to collect the remaining cells, which were also 
transferred to the reaction tube. After centrifugation at 2.000 rpm for 5 min at 4 °C, the 
supernatant was discarded and the cells were lysed in 1 mL ice cold cell lysis buffer for 
1 h at 4 °C on a rotating platform. After centrifugation at 13.000 rpm for 20 min at 4 °C 
the cleared lysates from the same SILAC and infection state were merged in a new 2 
mL reaction tube. The protein concentration of each state was determined by BCA as-
say at dilutions of 1:2 and 1:10 in triplicates according to the manufacturer’s protocol. 
Lysates from the 3 SILAC states were mixed in a 1:1:1 protein ratio and 50 µL of the 
mixture was prepared as an input sample for immunoblot analysis (see section 2.2.5). 
The remaining lysate was used for co-precipitation of PB2 with Strep-Tactin resin. For 
co-precipitation, 4 mL Strep-Tactin® Superflow® 50 % suspension was washed 3 
times with 5 mL cold Buffer W. Centrifugation in-between washing steps was per-
formed at 3.000 rpm for 3 min at 4 °C. After the last washing step Buffer W was dis-
carded, the cell lysate mixture was combined with the Strep-Tactin and precipitation 
was performed at 4 °C ON on a rotating platform. 
On the next day, the sample was centrifuged at 3.000 rpm for 3 min at 4 °C and 50 µL 
of the supernatant was prepared for immunoblot analysis as the non-bound (NB) sam-
ple. The remaining supernatant was discarded and the Strep-Tactin and bound pro-
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teins were washed 3 times with Buffer W. For the last washing step, Strep-Tactin in 
Buffer W was transferred to a new reaction tube to avoid elution of proteins bound un-
specifically to the reaction tube. Elution was performed 3 times with 2 mL Buffer E for 1 
h at 4 °C on a rotating platform. Eluate 1 to 3 were combined and concentrated at 
12.500 rpm at 4 °C using Vivaspin® 500 columns. The concentrated eluate was mixed 
with 6x SDS sample buffer, discharged from the BSL-3 laboratory and boiled at 95 °C 
for 10 min. 
Preparation of SILAC samples for LC-MS 
The sample obtained after Co-precipitation was alkylated by incubating it with 50 mM 
Iodoacetamide (IAA) for 30 min at RT in the dark, before proteins were separated by 
SDS PAGE. The gel was washed 3 times with MS grade water and stained for 1 h with 
SimplyBlue™ SafeStain. After removal of the redundant stain by washing with MS 
grade water ON, the visualized protein lane was cut into 10 slices, each of them cut 
into smaller pieces of approximately 1 mm, and transferred into a low retention reaction 
tubes. 
The small gel cubes were washed several times with destaining solution for 30 min at 
37 °C until they were fully destained. Afterwards the gel pieces were dehydrated with 
100 % acetonitrile (ACN) and in-gel digestion was performed. For this, one vial of MS 
grade trypsin was dissolved in 150 µL HCl and 1350 µL enzyme reaction buffer, before 
75 µL trypsin solution was added to each of the reaction tubes containing the dried gel 
cubes. After 30 min at 4 °C the gel pieces had fully absorbed the trypsin solution and 
an additional 37.5 µL were added. The mixture was incubated for a total of 90 min at 4 
°C, then 277.5 µL enzyme reaction buffer was added and in-gel digestion was per-
formed at 37 °C ON. Supernatants were transferred into new low retention reaction 
tubes and residual peptides were extracted out of the gel cubes by incubation with 100 
µL extraction buffer for 30 min at 37 °C whilst shaking. Combined peptide extracts were 
dried in a vacuum concentrator until samples were completely dry, then frozen at -20 
°C. 
After all 4experiments were conducted, dried samples were thawed and acidified to a 
pH of approximately 2, by resuspension in 1 % TFA. Desalting C18-Stage tips were 
prepared by stamping out round pieces out of an Empore™ Octadecyl C18 47mm Ex-
traction Disc and packing them into 200 µL pipette tips by use of a 1702 Plunger As-
sembly. Desalting of peptides was conducted through the use of centrifugation steps at 
2.000 g for 1 min (see table 2.3). Desalted peptides were dried in a vacuum concentra-
tor, dissolved in 20 µL 0.1 % FA and loaded into a 96 well plate for MS analysis. 
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                          Table 2.3. Steps for desalting of peptides. 
Step Solution added to C18-Stage tip 
Activation 100 µL MeOH 
Equilibration 1. 100 µL 0.1 % FA, 80 % ACN 
2. 100 µL 0.2 % TFA 
Loading Samples dissolved in 1 % TFA 
Washing 100 µL 0.2 % TFA 
Elution 100 µL 0.1 % FA, 80 % ACN 
Nano-LC and MS analysis 
Peptide samples were separated by reverse phase EASY-nano-LC 2 using a C18-A 
column. The nano-LC setup was connected to a LTQ Orbitrap Discovery™ mass spec-
trometer equipped with a nanoelectrospray ion source. 
Peptides were separated and eluted by applying a 65 min gradient from 2 % to 40 % 
between buffer A (0.2 % formic acid in water) and buffer B (0.2 % formic acid in ace-
tonitrile) at a flow rate of 300 nl/min with a spray voltage of 1.8 kV and 200 °C capillary 
temperature. 
Data dependent acquisition was performed using Xcalibur™ software 2.0 in positive ion 
mode. Full scan MS spectra (from m/z 300 to 1.700) were acquired in the FT-Orbitrap 
with a resolution of M/ΔM = 30.000. The 5 peptide ions with the highest intensity were 
sequentially isolated for fragmentation by collision induced dissociation (CID) in the 
linear ion trap. The Orbitrap lock mass feature was applied to improve mass accuracy. 
Data processing and evaluation 
Raw data acquired by MS analysis was processed using MaxQuant software version 
1.5.1.2. Proteins were identified using following parameters: Labelling standard; Label 
multiplicity 3; the 4 SILAC labels K4, K8, R6 and R10; Variable modifications Acetyl 
(Protein N-term), Oxidation (M) and Deamidation (NQ); Digestion mode specific; En-
zyme Trypsin/P; Max missed cleavages 2; Match type match from and to; Fixed modifi-
cation Carbmidomethyl (C); Re-quantify; Match between runs; Decoy mode revert; In-
clude contaminants. The false discovery rate (FDR) was set to 1 % and only protein 
groups identified by at least one unique peptide were kept for further analysis. Search-
es were performed against the Homo Sapiens data base of National Center for Bio-
technology Information (NCBI) with 91.670 entries as of 08.10.2015 and against the 
influenza A/Pan/99 (Q1NZ46; Q1NZ48; Q1NZ45; Q1NZ38; Q1NZ39; Q8AZB6; 
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Q1NZ40; Q1NZ41; Q1NZ43;) and influenza A/Thai/04 (H8PF41; H8PF42; H8PF44; 
H8PF45; Q5L4F7; H8PF47; Q5QF2; Q5QF24; Q5L4F5) database. For quantification, 
only unique and razor peptides were used with a minimum ratio count of 2.  
After retrieving a list of protein group identifications and quantifications from MaxQuant 
1.5.1.2, additional data analysis steps were performed to help interpret the results. The 
reproducibility of biological replicates was evaluated by scatter plot analysis and calcu-
lation of the Pearson correlation using Perseus software, version 1.5.0.31. In addition, 
statistical tests were performed by volcano plot analysis to identify protein groups that 
were significantly changed between PB2-Strep samples and the internal control. Signif-
icantly altered protein groups were subjected to gene ontology (GO) term analysis with 
the PANTHER Gene List Analysis v11.1 online tool, in order to gain insight into their 
biological function. 
To extract protein groups with the utmost probability of being PB2 interaction partners, 
the list of statistically significant protein groups was filtered based on the criteria that 
protein groups have to show a t-test difference of ≥ 1 in at least 2 out of the 4 experi-
ments. The resulting protein hit list was further analyzed using STRING: functional pro-
tein association networks v10.5, to visualize relationships between hit proteins. The 
obtained interaction network for the hit proteins was clustered using the Markov Cluster 
algorithm (MCL) with the inflation parameter set to 2. 
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3. Results 
As part of the influenza virus polymerase complex, PB2 plays a crucial role in the tran-
scription and replication of the viral genome, as well as in the determination of the viral 
host range 57,71,137. Consequently, the interaction of PB2 with the host cell proteome is 
of major interest. Preceding studies focusing on the host cell interactome of PB2 were 
either performed in the context of transiently transfected, non-infected cells, or with 
laboratory/mouse-adapted influenza virus strains 138-144. In contrast, this study aimed to 
identify PB2 cellular interaction partners not only in the context of infected cells but also 
using non-laboratory adapted seasonal (represented by A/Panama/2007/99 (H3N2)) 
and highly pathogenic (represented by A/Thailand/(KAN-1)/04 (H5N1)) viral strains 
from human isolates. 
Interactions of PB2 with cellular proteins were examined in a SILAC based affinity-
purification mass spectrometry (AP-MS) approach. Mass spectrometry enabled the 
highly sensitive detection of protein-protein interactions (PPI) under physiological con-
ditions in a relevant biological context 149, in this case human alveolar epithelial cells 
(A549) infected with influenza virus. Through the generation and use of influenza virus-
es carrying a Strep-tag at the C-terminus of their PB2 protein, affinity purification up-
stream of MS enriched PB2 and its interaction partners while non-specific contami-
nants were reduced. The use of triple SILAC labelling made it possible to perform a 
quantitative comparison between cells infected with PB2-Strep viruses and the internal 
control A/Pan/99-WT. This allowed the further exclusion of false positives and external 
protein contaminants and increased confidence in the identified interaction partners of 
PB2. 
The interactome screen and subsequent validation experiments revealed new and al-
ready described interactions of PB2 with cellular proteins, and demonstrated the impact 
of these proteins on polymerase activity. The obtained data also hinted at differences in 
the importance of these identified proteins on the polymerase activity of seasonal and 
highly pathogenic influenza virus strains. Further analysis of the PB2 interactor HSPA8 
revealed its relevance for replication, polymerase activity and the integrity of the PB2 
protein of A/Pan/99. 
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3.1 Proteomic analysis of the PB2 interactome of 
influenza A/Panama/2007/99 (H3N2) and 
A/Thailand/(KAN-1)/04 (H5N1) viruses 
3.1.1 Generation and functional characterization of PB2-Strep 
viruses for co-precipitation experiments 
The PB2 protein sequence of A/Pan/99 (H3N2) and A/Thai/04 (H5N1) differs in 40 
amino acids (aa) which correspond to 5.3 % of a total of 759 aa (figure 3.1.A). For ex-
ample, one of the differences is located at position 627 which is known to play a role in 
the adaptation of avian influenza viruses to the mammalian host (see section 1.3.3). 
Interestingly, PB2 of the A/Thai/04 strain isolated from a human case contains the avi-
an type glutamic acid and not the mammalian type lysine at this position.  
 
 
Figure 3.1. PB2 sequence information of constructed influenza A viruses. A Protein se-
quence comparison of A/Pan/99 and A/Thai04 PB2. Differences in aa sequence are highlighted 
in red. Host adaption relevant protein position 627 is framed in green. B Structure of the PB2 
genetic constructs, used to generate recombinant viruses expression Strep-tagged PB2, which 
is described in detail in the text. 
3. Results 66 
 
 
The plasmids encoding A/Pan/99 and A/Thai/04 PB2 were modified as described in 
section 2.2.3 to generate recombinant viruses that express Strep-tagged PB2. Thereby 
it is important to consider the packaging sequence of the genome segment coding for 
the protein to ensure not only expression of the fusion protein but also packaging of the 
genomic segment into viral particles. Thus, to generate recombinant A/Pan/99 (H3N2) 
and A/Thai/04 (H5N1) viruses that express a Strep-tagged PB2 protein the pHW2000 
constructs need to contain the PB2 coding sequence followed by the Twin-Strep-tag® 
sequence, the 143 nt long packaging sequence for the PB2 segment (a duplication of 
the last 109 nt of the PB2 coding sequence followed by the 5′ NCR) and a stop codon 
(see figure 3.1.B). The accuracy of the PB2-Strep constructs was analyzed and con-
firmed by Sanger sequencing. 
The use of recombinant A/Pan/99 (H3N2) and A/Thai/04 (H5N1) viruses that express a 
Strep-tagged PB2 protein has the advantage that protein specific antibodies are not 
needed for precipitation. Hence, interactions of host cell proteins with the epitope re-
gion of PB2 that would be interrupted by antibody binding are still intact and can be 
detected by downstream MS.  
 
 
Figure 3.2. Growth characteristics of WT and Strep-PB2 viruses. A549 cells were infected 
with A/Pan/99-WT, A/Pan/99-PB2-Strep (A), A/Thai/04-WT or A/Thai/04-PB2-Strep (B) viruses. 
Viral titers (log PFU/ml) at 24, 48 and 72 h were determined by standard plaque titration assay. 
Displayed values represent the mean +SD of N=2. 
After the successful rescue of recombinant viruses in 293T cells and subsequent virus 
propagation in embryonated chicken eggs, growth characteristics of the PB2-Strep 
viruses and the corresponding WT viruses were compared. Therefore A549 cells were 
infected and viral titers at 24, 48 and 72 h were determined by plaque-forming assay. 
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While A/Pan/99-PB2-Strep virus grew to similar but slightly higher titers (especially 
from 24 h onwards) as A/Pan/99-WT virus (see figure 3.2.A), growth of A/Thai/04-PB2-
Strep was attenuated compared to the WT virus at 48 and 72 h (figure 3.2.B). Howev-
er, given that the A/Thai/04-PB2-Strep virus did not replicate less efficient than the 
A/Pan/99-WT and A/Pan/99-PB2-Strep viruses, it was considered suitable for AP-MS 
analysis. In addition, this finding supported the decision to perform PB2 precipitation 
experiments at 16 h post infection, being in the time frame of monocyclic infection and 
ensuring the highest similarity between WT and PB2-Strep virus growth. 
 
 
Figure 3.3. Recombinant PB2-Strep proteins co-precipitate viral NP. A549 cells were in-
fected at an MOI of 1 with either A/Pan/99/-WT, -PB2-Strep, A/Thai/04-WT or -PB2-Strep virus-
es. 16 h p.i. cell lysates were combined with Strep-Tactin® Sepharose® and precipitation was 
performed overnight. The eluted proteins (eluate) of PB2-Strep (A) and WT (B) virus samples, 
as well as 5 % of the corresponding cell lysates (input) and non-bound (NB) proteins were ana-
lyzed by SDS PAGE. Immunoblotting analysis was performed with the indicated antibodies. 
To test the functionality of the tag, A549 cells were infected with WT and PB2-Strep 
viruses at an MOI of 1. After 16 h of infection, cells were lysed and precipitation with 
Strep-Tactin® Sepharose® was performed. Figure 3.3 shows the precipitation of Pan-
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PB2-Strep and Thai-PB2-Strep proteins (figure 3.3.A) whereas PB2-WT could not be 
detected in the IP fraction (figure 3.3.B), thus demonstrating the functionality of the tag 
in the context of infection. Viral NP, a known interaction partner of PB2, was used as a 
positive control for co-precipitation. NP was present in the eluate of Strep- but not WT-
virus lysates, indicating the applicability of the constructed Strep-tagged proteins for co-
precipitation experiments. In addition, the absence of the cellular protein actin after 
precipitation in PB2-Strep eluates underlined the specific precipitation of the tagged 
proteins and their interaction partners. 
3.1.2 Experimental setup 
To identify cellular interaction partners of the PB2 protein of the seasonal strain 
A/Pan/99 (H3N2) and the highly pathogenic strain A/Thai/04 (H5N1), a triple SILAC 
approach combined with high-resolution LC tandem mass spectrometry was employed. 
The workflow of the SILAC experiment is shown in figure 3.4. 
A549 cells were cultured in medium containing light (R0/K0), intermediate (R6/K4) or 
heavy (R10/K8) arginine and lysine isotopes. The small mass differences between pro-
teins derived from differentially labeled cells can be distinguished by MS. Hence, a 
peptide signal can be attributed to one SILAC state and thereby interaction partners of 
different viral strains can be distinguished. 
3.1. Infection state of light, intermediate and heavy A549 cells in the 4 conducted SILAC 
experiments. 
 
Experiment 
 
Light state 
 
Intermediate state 
 
Heavy state 
 
A 
 
A/Pan/99-WT 
 
A/Pan/99-PB2-Strep 
 
A/Thai/04-PB2-Strep 
B A/Pan/99-WT A/Thai/04-PB2-Strep A/Pan/99-PB2-Strep 
C A/Pan/99-WT A/Pan/99-PB2-Strep A/Thai/04-PB2-Strep 
D A/Pan/99-WT A/Thai/04-PB2-Strep A/Pan/99-PB2-Strep 
 
In total, 4 SILAC experiments were conducted, with each experiment representing a 
biological repeat. Labelled A549 cells were infected with A/Pan/99-WT (light state) as 
an internal control, A/Pan/99-PB2-Strep (intermediate state) or A/Thai/04-PB2-Strep 
(heavy state) at an MOI of 1.5. For replicates B and D, the virus used to infect cells in 
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each state was changed to account for differences caused by cell labeling. Thus, in-
termediate cells were also infected with A/Thai/04-PB2-Strep and heavy cells with 
A/Pan/99-PB2-Strep (see table 3.1). At 16 h post infection, cells were lysed and a 
sample from each state was taken and the protein concentration measured by BCA 
assay. Equivalent amounts of proteins from each state were then mixed and PB2-Strep 
was precipitated using Strep-Tactin® resin. 
 
 
Figure 3.4. Workflow of SILAC experiments. A549 cells were differentially labelled by cultiva-
tion in medium containing light (R0/K0), intermediate (R6/K4) or heavy (R10/K8) amino acid 
isotopes. Cells were infected with A/Pan/99/-WT, A/Pan/99-PB2-Strep or A/Thai/04-PB2-Strep 
at an MOI of 1.5. At 16 hours p.i. cells were lysed, proteins were mixed in a 1:1:1 ratio and PB2-
strep was precipitated with Strep-Tactin® resin. Eluted proteins were separated by size, digest-
ed with trypsin and the resulting peptides were analyzed using a LTQ-Orbitrap mass analyzer. 
A sample of the input mix, the non-bound fraction and eluate 1 to 3 was analyzed by 
SDS PAGE and immunoblotting in order to monitor co-precipitation efficiency. This is 
shown in figure 3.5, where it can be seen that PB2 and its known interaction partner 
NP are specifically precipitated, whilst the negative control protein actin is absent from 
the eluate fraction. Eluted proteins were then concentrated by membrane ultrafiltration 
and disulfide bounds were broken by β-mercaptoethanol. After alkylation of free thiol 
groups on cysteine residues by treatment with iodacetamide, proteins were separated 
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by SDS PAGE and visualized by Coomassie staining. The protein lane was cut into ten 
slices and proteins were subjected to in-gel digestion by trypsin. The resulting peptide 
mixture was separated by high-performance liquid chromatography on a Nano-LC and 
analyzed using a LTQ Orbitrap Discovery™ mass spectrometer (see section 2.2.6). 
 
Figure 3.5. Precipitation control for SILAC experiments. Cell lysates from light, intermediate 
and heavy states were mixed in equal protein amounts and loaded onto Strep-Tactin® resin. 
After washing, proteins were eluted 3 times with elution buffer. Samples of input, non-bound 
and eluate 1 to 3 were analyzed by SDS PAGE and immunoblotting using the indicated antibod-
ies. Shown is a single representative of the 4 SILAC replicates. 
3.1.3 MS data evaluation 
Evaluation of MS data was performed using MaxQuant software. In total, 2446 protein 
groups, including 18 viral proteins, were identified. A protein group consists of proteins 
which cannot be unambiguously identified by unique peptides, for example different 
protein isoforms. For quantification, only unique peptides and razor peptides (peptides 
which are shared between protein groups) were used with a FDR of 1% and a mini-
mum ratio count of 2, leading to the quantification of 1842 protein groups. Intermediate 
to light (M/L) and heavy to light (H/L) ratios (representing the abundance of a protein 
group in A/Pan/99-PB2-Strep or A/Thai/04-PB2-Strep samples proportional to its abun-
dance in the control sample A/Pan/99-WT) were calculated as the median of all peptide 
ratios assigned to a distinct protein group 150. For further data analysis using Perseus 
software, peptide ratios were specified as log2 values.  
Reproducibility between the 4 biological replicates A to D was verified by scatter plot 
analysis of M/L and H/L ratios (figure 3.6). The calculated Pearson correlation is a 
measure of linear correlation between two variables, in which 0 represents no linear 
correlation and 1 represents total positive linear correlation. In this study, the Pearson 
correlation ranged from 0.569 to 0.823 (figure 3.6.A) between replicates for A/Pan/99-
PB2-Strep and from 0.858 to 0.922 for A/Thai/04-PB2-Strep samples (figure 3.6.B). To 
identify protein groups that were significantly changed in abundance between         
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PB2-Strep samples and the internal control, a one sample t-test of M/L and H/L ratios 
was performed, and displayed by volcano plot analysis (figure 3.7).  
 
 
Figure 3.6. Correlation of protein ratios between replicates. Scatter Plot analysis of 4 bio-
logical replicates of A A/Pan/99-PB2-Strep and B A/Thai/04-PB2-Strep samples. Displayed are 
log2 values of M/L and H/L ratios of indicated replicates and the corresponding Pearson correla-
tion. Dots represent protein groups. 
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Protein groups with a p-value of < 0.05 and a t-test difference of > 0 are depicted as 
blue dots. They represent protein groups that are significantly changed and are more 
abundant in A/Pan/99-PB2-Strep (189 cellular protein groups) and/or A/Thai/04-PB2-
Strep (381 cellular protein groups) eluates compared to the A/Pan/99-WT control (see 
supplementary table S.1 for a complete list of significantly changed protein groups). For 
both viral strains, all viral proteins that were included in the MS data analysis were 
identified, and PB2 was the most significant and most abundant protein. For infor-
mation about p values and t-test differences of viral proteins see supplementary tables 
S.2 and S.3. 
 
 
Figure 3.7. Significance and t-test difference of identified proteins. Volcano plot analysis 
for A A/Pan/99-PB2-Strep and B A/Thai/04-PB2-Strep samples was performed using Perseus 
software. One-sample t-test values were calculated for M/L and H/L ratios (log2) of 4 replicates 
and plotted as –log of p values on the y axis. The t-test difference was plotted on the x axis. 
Dots represent protein groups. Significantly changed protein groups with a t-test difference of >0 
are depicted in blue. Detected viral proteins of A/Pan/99 and A/Thai/04 with a p-value of < 0.05 
are encircled in red whereas viral proteins with a p-value of > 0.05 are encircled in black. 
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3.1.4 Protein classification 
Evaluation of MS data revealed 487 protein groups significantly changed in abundance 
with a t-test difference of > 0 in A/Pan/99-PB2-Strep or A/Thai/04-PB2-Strep eluates 
(referred to as filtered list/filtered protein groups or UA, see supplementary table S.1 for 
a complete list of these protein group). 
Out of these proteins, 131 (representing 26.9 %) were also found in other proteomic 
screens that looked for interaction partners of the PB2 protein of other influenza virus 
strains, either expressed alone or as part of the viral polymerase complex (figure 
3.6) 138-142.  
 
 
Figure 3.8. Comparison of MS data with different PB2/polymerase complex interactome 
screens. The list of significantly changed proteins with a t-test difference of > 0 (UA, depicted 
above in red) was compared to protein lists from other publications (depicted in blue) that fo-
cused on the interactome of influenza PB2 or polymerase complex. Studies used for compari-
son are: Heaton et al., Bradel-Tretheway et al., Watanabe et al., Wang et al. and York et al. 138-
142. In the case of studies that were also investigating protein interactomes of other influenza 
virus proteins, comparison was performed only with AP-MS data of PB2- or “PB2 as part of the 
polymerase complex”-samples. Venn diagrams were generated 
ing http://bioinformatics.psb.ugent.be/webtools/Venn/. Numbers represent number of proteins. 
The largest overlap of PB2/polymerase complex interactome proteins (71 proteins) was 
found with the Watanabe et al. screen (figure 3.8; Watanabe, UA). However, when the 
overlap between interactomes was calculated as the percentage of the number of pro-
teins of the interactome screen used for comparison, the largest overlap was found 
with the Bradel-Tretheway et al. screen (figure 3.8; Bradel, UA). 8 proteins were de-
tected in both screens, which represent 23.5 % of the 34 proteins identified as hit pro-
teins in the Bradel-Tretheway et al. screen after stringent filtering. This screen aimed to 
identify interaction partners of the viral polymerase of A/Vietnam/1203/04 (H5N1). 
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Overall, the majority of proteins detected in all of the screens (925 out of 1192; 77.6 %) 
were identified in only one of the six compared screens. 
To gain insight into the biological function of the filtered protein groups identified in this 
study, the protein list was subjected to gene ontology (GO) term analysis with the “Pro-
tein Analysis Through Evolutionary Relationships (PANTHER)” classification system 
online tool. For the 487 detected protein groups, 515 gene IDs were discovered and 
classified according to their protein class. The majority of the proteins in the filtered list 
(25.3 %) belong to a class of nucleic acid binding proteins, followed by proteins belong-
ing to the class of oxidoreductase proteins (12.9 %) or hydrolase proteins (10.3 %) (fig-
ure 3.9). 
The predominance of interactions with nucleic acid binding proteins was not unex-
pected since PB2, as part of the viral replication and transcription machinery, is a nu-
cleic acid binding protein itself. In addition, interplay of cellular nucleic acid binding pro-
teins with the polymerase complex has already been described (see section 1.2.3).  
 
 
Figure 3.9. Functional classification of proteins in the filtered protein list. Filtered proteins 
were classified according to their protein class. GO term analysis was performed using the 
PANTHER classification system. The majority of proteins belong to the protein classes framed 
in red. 
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3.1.5. Hit protein classification and network analysis 
In order to identify specific cellular interaction partners of PB2, first the filtered protein 
list with 487 protein groups was further condensed by adding another filter criterion as 
follows: in addition to being statistically significant and showing a t-test difference of > 
0, protein groups needed to have a t-test difference of ≥ 1 in at least 2 out of 4 experi-
mental replicates. A t-test difference of ≥ 1 (log2) equates to a fold increase in protein 
abundance of at least 2 compared to the A/Pan-99-WT control. Adding this criterion 
increased the likelihood of the further examined protein groups being specific binding 
partners of PB2 and shortened the list from 487 filtered protein groups to 20 hit protein 
groups. These 20 hit protein groups are detailed in table 3.2. 
Table 3.2. List of hit proteins. Eluted proteins with a t-test difference of >0 in the 4 experi-
mental replicate and a t-test difference of ≥ 1 in at least 2 replicates were defined as hit proteins. 
Bibliography: interactome screens of PB2/polymerase complex in which the protein was also 
identified in PB2 or “PB2 as part of the polymerase complex”-samples 138-142. 
 
Gene name 
 
Protein name 
 
Function 
 
Bibliography 
 
AGR2 
 
Anterior gradient protein 
2 homolog 
 
Required for MUC2 
post-transcriptional 
synthesis and secre-
tion 
 
- 
 
BAG2 
 
BAG family molecular 
chaperone regulator 2 
 
Co-chaperone for 
HSPA8 and HSP70 
 
Heaton et al./ Wa-
tanabe et al./ York 
et al. 
 
CAST 
 
Calpastatin 
 
Inhibition of Calpain 
 
- 
 
CKMT1A 
CKMT1B 
 
Creatine kinase U-type 
 
Catalyzes the transfer 
of phosphate between 
ATP and various 
phosphogens 
 
- 
- 
 
CPS1 
 
Carbamoyl-phosphate 
synthase 
 
Enzyme involved in 
the urea cycle 
 
Heaton et al./ 
Wang et al. 
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Gene name 
 
Protein name 
 
Function 
 
Bibliography 
 
EPHX1 
 
Epoxide hydrolase 1 
 
Catalyzes the hydroly-
sis of epoxides to di-
hydrodiols 
 
- 
 
GGH 
 
Gamma-glutamyl hydro-
lase 
 
Hydrolyzes the poly-
glutamate sidechains 
of pteroylpolygluta-
mates 
 
- 
 
HIST1H2B 
 
Histone H2B type 1 
 
Core component of 
nucleosome 
 
Watanabe et al. 
 
HIST1H4A 
 
Histone H4 
 
Core component of 
nucle-osome 
 
Watanabe et al. 
 
HIST2H3A 
 
Histone H3.2 
 
Core component of 
nucle-osome 
 
- 
 
HNRNPC 
 
Heterogeneous nuclear  
ribonucleoproteins 
C1/C2 
 
Binds pre-mRNA and 
nucleates the assem-
bly of 40S hnRNP par-
ticles 
 
- 
 
HSPA2 
 
Heat shock-related 70 
kDa protein 2 
 
Molecular chaperone 
 
Watanabe et al. 
 
HSPA8 
 
Heat shock cognate 71 
kDa protein 
 
Molecular chaperone 
 
Watanabe et al./ 
York et al. 
 
KCNJ8 
 
ATP-sensitive inward 
rectifier potassium 
channel 8 
 
Potassium channel 
 
- 
 
LXN 
 
Latexin 
 
Inhibitor of CPA1, 2, 4 
 
- 
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Gene name 
 
Protein name 
 
Function 
 
Bibliography 
 
PABPC1 
PABPC3 
 
Polyadenylate-binding 
protein 1; 3 
 
Binds the poly(A) tail 
of mRNA (1/3) 
Function in transla-
tional initiation regula-
tion (1) 
 
Watanabe et al. 
- 
 
RCN2 
 
Reticulocalbin-2 
 
Calcium-binding pro-
tein 
 
Watanabe et al./ 
York et al. 
 
SLC12A2 
 
Solute carrier family 12 
member 2 
 
Na-K-Cl cotransporter 
 
- 
 
SNRNP200 
 
U5 small nuclear ribo-
nucleoprotein 200 kDa 
helicase 
 
Component of the U5 
snRNP and U4/U6-U5 
tri-snRNP complexe 
 
- 
 
TOP2A 
 
DNA topoisomerase 2-
alpha 
 
Control of topological 
states of DNA 
 
Watanabe et al./ 
Bradel-Tretheway 
et al. 
 
For CKMT1A/B (Creatine kinase U-type A and Creatine kinase U-type B) and 
PABPC1/3 (Polyadenylate-binding protein 1 and Polyadenylate-binding protein 3), 
MaxQuant could not clearly differentiate between the two proteins. Even though en-
coded by different genes, the amino acid sequences are highly similar for CKMT1A and 
CKMT1B, and PBPC1 and PBPC3, respectively. Hence, all four proteins were included 
in the hit list which therefore contains 22 proteins (table 3.1). 
Out of these 22 proteins, 13 proteins (GGH, CKMT1B, HIST2H3A, EPHX1, CKMT1A, 
PABPC3, SLC12A2, LXN, SNRNP200, CAST, KCNJ8, hnRNPC1, AGR2) were not 
found in the 5 previously published interactome screens used for comparison 138-142.  
Since proteins interact with other proteins and usually work in complexes, a “Search 
Tool for the Retrieval of Interacting Genes/Proteins (STRING)” database network anal-
ysis was conducted in order to visualize relationships between hit proteins. STRING is 
an online database of predicted and known protein-protein interactions. It is based on 
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data from numerous sources such as the Molecular Interaction Database (MINT), Kyo-
to Encyclopedia of Genes and Genomes (KEGG) or GO. STRING also includes text 
mining, experimental data and computational predictions to create protein interaction 
networks. 
 
 
Figure 3.10. STRING network of PB2 interactome screen hit proteins. STRING database 
analysis (https://string-db.org/) of hit proteins from table 3.2. MCL inflation parameter for cluster-
ing of the network = 2. Line colors indicate: light blue = known interactions from curated data-
bases; pink = known interactions experimentally determined; green = predicted interactions by 
gene neighborhood; dark blue = predicted interactions by gene co-occurrence; yellow = text 
mining; black = co-expression; light purple = protein homology. 
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The obtained interaction network for the hit proteins was clustered using the Markov 
Cluster algorithm (MCL) with the inflation parameter set to 2 (figure 3.10). Six proteins 
(CAST, RCN2, KCNJ8, AGR2, LXN and GGH) showed no relationship to other proteins 
while the remaining 16 proteins grouped together in two clusters. The smaller cluster 
comprised the three histone proteins (light green) while the second cluster encom-
passed the remaining 13 proteins (red). Except for BAG2, SLC12A2 and EPHX1 all 
proteins of the larger cluster could be assigned to the molecular function “nucleotide 
binding”. 
Interestingly, for the majority of hit proteins (with the exception of SLC12A2 and the 6 
proteins that showed no interactive relationship to other proteins) an experimentally 
determined protein interaction to at least one other hit protein is known. HSPA8 repre-
sents the clear center of the larger protein cluster with 10 experimentally determined 
protein interactions. 
3.2 Data validation 
To support the findings of the MS screen, 13 proteins from the hit list were selected 
and used for validation by polymerase activity assay (minigenome assay) and co-
immunoprecipitation (co-IP). This selection was based on the molecular functions and 
reagent availability of the proteins. The following proteins were used for analysis: 
AGR2, BAG2, CAST, EPHX1, GGH, hnRNPC1, HSPA2, HSPA8, LXN, PABPC1, 
PABPC3, RCN2, SLC12A2. 
3.2.1 Co-immunoprecipitation  
To validate the co-precipitation of PB2 with selected hit proteins, 293T cells were trans-
fected with expression plasmids for PB2, PB1 and PA of either A/Thai/04 or A/Pan/99 
and the plasmid coding for the FLAG- or V5-tagged protein of interest. 
In the case of control samples the empty vector, coding only for the tag sequence, was 
transfected in addition to PB2, PB1 and PA. 24 h post transfection, cells were lysed 
and proteins were immunoprecipitated by use of either α-V5 or α-FLAG antibodies 
coupled to protein G agarose beads. After washing and elution, co-immunoprecipitation 
of PB2 with the investigated protein was determined by immunoblot analysis.  
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Figure 3.11. Validation of the co-precipitation of A/Thai/04 PB2 with selected hit proteins. 
293T cells were transfected with plasmids encoding V5 or FLAG-tagged hit proteins, or the cor-
responding empty tag vector (control), and expression plasmids for A/Thai/04 PB2, PB1 and 
PA. 24 hours p.t., cells were lysed and immunoprecipitation was performed using protein G 
agarose beads coupled to A α-V5 or B/C α-FLAG antibodies. Bound proteins (IP) and cell ly-
sates (WCL) were analyzed by SDS PAGE and immunoblotting using the indicated antibodies. 
Red asterisk indicate specific protein bands according to their calculated molecular masses. 
Representative experiment of N ≥ 2. 
Co-IP analysis confirmed the co-precipitation of A/Thai/04 PB2 with BAG2, GGH, 
HSPA2, HSPA8, PABPC3, EPHX1, LXN and SLC12A2. The co-precipitation with 
PABPC1 could not be validated with certainty since the PB2 band was only slightly 
more increased compared to the control (figure 3.11). In case of A/Pan/99, co-
precipitation with PB2 was verified for BAG2, HSPA8, PABPC1, PABPC3, EPHX1, 
LXN and SLC12A2 (figure 3.12). The A/Pan/99 PB2 band in the co-precipitate of GGH 
and HSPA2 samples was only slightly more intense compared to the control sample, 
indicating a possibly very weak interaction. Co-precipitation of A/Thai/04 or A/Pan/99 
PB2 with AGR2, CAST, hnRNPC1 or RCN2 could not be confirmed under applied con-
ditions. 
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Figure 3.12. Validation of the co-precipitation of A/Pan/99 PB2 with selected hit proteins. 
293T cells were transfected with expression plasmids for A/Pan/99 PB2, PB1 and PA, and 
plasmids encoding V5 or FLAG-tagged hit proteins, or the corresponding empty tag vector (con-
trol). After 24 h, cells were lysed and immunoprecipitation was performed using protein G aga-
rose beads coupled to A α-V5 or B α-FLAG antibodies. Bound proteins (IP) and cell lysates 
(WCL) were analyzed by SDS PAGE and immunoblotting using the indicated antibodies. Red 
asterisk indicate specific protein bands according to their calculated molecular masses. Repre-
sentative experiment of N ≥ 2. 
3.2.2 Polymerase activity assay 
The polymerase activity assay, also known as minigenome assay, is a reporter based 
assay that allows for determination of the influence of e.g. mutation, knock down or 
overexpression of proteins, on viral polymerase activity (see figure 3.13). The MS 
screen was conducted in order to identify cellular interaction partners of PB2 that have 
an impact on polymerase activity. Therefore, the minigenome assay was used to inves-
tigate the functional relevance of the PB2 cellular interaction partners on viral polymer-
ase activity as it is a relatively fast screening method. 
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Figure 3.13. Schematic representation of the influenza polymerase activity assay. The 
minigenome plasmid (pPolI-SapI-A-NS-Luc) contains the firefly Luciferase gene flanked by the 
5` and 3`untranslated region of an influenza genomic segment (in this case the NS segment) 
and the intracellular synthesis of the firefly RNA in negative orientation is driven by pPolI. The 
viral proteins PA, PB1, PB2 and NP, their expression enabled by a constitutive promoter (for 
example the CAG-promoter), bind the (-) RNA and facilitates transcription. An increase in firefly 
Luciferase activity, based on viral polymerase induced protein expression, indicates influenza 
polymerase activity. The constitutively expressed Renilla Luciferase (encoded on the pTK-
plasmid) allows for normalization of transcription levels and protein expression. 
293T cells were transfected with expression plasmids encoding PB2, PB1, PA and NP 
of either A/Pan/99 or A/Thai/04, a firefly luciferase reporter plasmid under the control of 
the UTRs of the NS segment of Influenza A, and a constitutively expressed Renilla 
luciferase reporter plasmid as an internal transfection and expression control. In addi-
tion, either 100 ng or 500 ng of the plasmid encoding the investigated cellular protein 
was co-transfected. The total amount of DNA between samples was kept constant with 
empty expression plasmids corresponding to the analyzed protein. For positive con-
trols, 500 ng of the analogous empty vector was co-transfected.  
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Figure 3.14. Functional investigation of MS data by polymerase activity assay. 293T cells 
were transfected with expression plasmids encoding the components of the minigenome assay 
and the cellular proteins of interest: A A/Pan/99 or B A/Thai/04 PB2, PB1, PA and NP, the firefly 
luciferase reporter plasmid as well as 100 ng or 500 ng of plasmids coding for the proteins of 
interest. In case of the 100 ng samples, 400 ng of the corresponding empty vector was co-
transfected to keep the total amount of DNA constant. The constitutively expressed Renilla lu-
ciferase reporter plasmid was also co-transfected and served as an internal control. For the 
positive control samples, empty expression vectors corresponding to the investigated proteins 
were co-transfected. 24 h after transfection, cells were lysed and luciferase activity was meas-
ured. The displayed values are the mean + SD of 3 independent experiments conducted in du-
plicates. The p values were determined by the Wilcoxon signed rank test. Proteins framed by 
boxes were verified for PB2 interaction by Co-IP (figure 3.9 and 3.10). 
After 24 h, cells were lysed and luciferase activity was measured. The activity of the 
firefly luciferase was normalized to the activity of the Renilla luciferase, then the nor-
malized luciferase activity was calculated as an x-fold activation in comparison to the 
corresponding positive control (set to 100 %). These results are shown in figure 3.14. 
Overexpression of AGR2, CAST, hnRNPC1, LXN, PABPC1 and PABPC3 had no sig-
nificant effect on the polymerase activity of A/Pan/99 (figure 3.14.A). In contrast, over-
expression of AGR2, PABPC1 and PABPC3 led to a dose dependent decrease in 
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A/Thai/04 polymerase activity, while overexpression of hnRNPC1 increased polymer-
ase activity (figure 3.14.B). On the other hand, while overexpression of SLC12A2 had 
no significant effect on A/Thai/04 polymerase activity, it led to a decrease in A/Pan/99 
polymerase activity when transfected in the same quantities. The effect of overexpres-
sion of the remaining cellular proteins was similar for both viral strains (see figure 3.14). 
BAG2, EPHX1, GGH and HSPA2 overexpression had a negative effect on polymerase 
activity of both influenza virus strains while overexpression of RCN2 and HSPA8 in-
creased polymerase activity. The impact on polymerase activity was dose dependent 
for each protein except for RCN2, which had a significant influence on A/Pan/99 only 
when 100 ng was transfected and a stronger significant effect on A/Thai/04 also when 
100 ng was transfected. Overall, the results of the minigenome assay strongly support-
ed the functional relevance of the MS data since overexpression of all proteins except 
for CAST and LXN had an impact on the polymerase activity of at least one viral strain. 
Results of the co-immunoprecipitation and polymerase activity assay validation exper-
iments are summarized in table 3.3. 
Table 3.3. Combined results of the co-immunoprecipitation and polymerase activity as-
say experiments. Listed are the investigated proteins, whether or not they co-precipitated 
A/Pan/99 or A/Thai/04 PB2, and if their overexpression significantly increased (↑) or decreased 
(↓) viral polymerase activity or had no significant effect (-). 
 
Protein 
 
Co-precipitation with PB2    
confirmed by co-IP 
 
Significant effect on polymerase         
activity 
 A/Pan/99 A/Thai/04 A/Pan/99 A/Thai/04 
   100 ng 500 ng 100 ng 500 ng 
 
AGR2 
 
No 
 
No 
 
- 
 
- 
 
↓ 
 
↓ 
 
BAG2 
 
Yes 
 
Yes 
 
- 
 
↓ 
 
- 
 
↓ 
 
CAST 
 
No 
 
No 
 
- 
 
- 
 
- 
 
- 
 
EPHX1 
 
Yes 
 
Yes 
 
- 
 
↓ 
 
↓ 
 
↓ 
 
GGH 
 
Weak 
 
Yes 
 
↓ 
 
↓ 
 
- 
 
↓ 
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Protein 
 
Co-precipitation with PB2    
confirmed by co-IP 
 
Significant effect on polymerase         
activity 
 A/Pan/99 A/Thai/04 A/Pan/99 A/Thai/04 
   100 ng 500 ng 100 ng 500 ng 
 
hnRNPC1 
 
No 
 
No 
 
- 
 
- 
 
- 
 
↑ 
 
HSPA2 
 
Weak 
 
Yes 
 
- 
 
↓ 
 
↓ 
 
↓ 
 
HSPA8 
 
Yes 
 
Yes 
 
↑ 
 
↑ 
 
- 
 
↑ 
 
LXN 
 
Yes 
 
Yes 
 
- 
 
- 
 
- 
 
- 
 
PABPC1 
 
Yes 
 
No 
 
- 
 
- 
 
↓ 
 
↓ 
 
PABPC3 
 
Yes 
 
Yes 
 
- 
 
- 
 
↓ 
 
↓ 
 
RCN2 
 
No 
 
No 
 
↑ 
 
- 
 
↑ 
 
↑ 
 
SLC12A2 
 
Yes 
 
Yes 
 
- 
 
↓ 
 
- 
 
- 
3.3 Characterization of HSPA8 as a novel PB2 
interaction partner 
The SILAC based MS analysis of A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep pre-
cipitations resulted in a hit list of 22 PB2 interaction partners. Co-immunoprecipitation 
analysis then confirmed the interaction of PB2 with 9 out of 13 proteins selected for 
data validation. Overexpression of 11 out of these 13 proteins also had an impact on 
polymerase activity as determined by minigenome assay. Hence, the MS data was 
confirmed to be of functional relevance. In a final set of experiments a target interacting 
protein of PB2 was selected for further exemplary analysis. Among hit proteins, HSPA8 
was especially of interest. Not only could the interaction of HSPA8 with PB2 of both 
viral strains be confirmed by co-immunoprecipitation, HSPA8 was also one of only 
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three tested proteins whose overexpression had a positive effect on viral polymerase 
activity. In addition, HSPA8 was the center of the hit protein network (figure 3.10). 
HSPA8, also known as Hsc70, belongs to the heat shock protein family HSP70 and 
carries out a wide range of biological functions. For example, HSPA8 plays a role in 
clathrin-mediated endocytosis, protein folding, and nuclear import and export of pro-
teins 118. In addition to its importance for Turnip mosaic virus and herpes simplex virus 
type 1 (HSV-1) replication, it has been reported to interact with the influenza A virus M1 
protein and is believed to play a role in the nuclear export of the influenza virus ribonu-
cleoprotein complex 62,122,125,151. HSPA8 was also found to be a potential PB2 interac-
tion partner of the lab adapted influenza viral strain A/WSN/33 (H1N1) in the MS 
screens of York et al. and Watanabe et al. 141,142. However, both studies did not confirm 
this interaction with additional experiments. 
3.3.1 Co-precipitation of PB2 with Endogenous HSPA8 
To further characterize and confirm the co-precipitation of PB2 with HSPA8, co-IP 
analysis of the endogenous protein expressed in A549 cells was employed. A549 cells 
infected with A/Pan/99-WT or A/Thai/04-WT virus were lysed and endogenous HSPA8 
was immunoprecipitated by use of protein G agarose beads coupled to α-HSPA8 anti-
body. As a negative control, α-c-Myc antibody coupled protein G agarose beads were 
used. The Co-IP of PB2 was determined by immunoblot analysis. 
 
 
Figure 3.15. Co-precipitation of PB2 with endogenous HSPA8. A549 cells were infected with 
A/Pan/99-WT (A) or A/Thai/04-WT virus (B) at an MOI of 5. 16h p.i. cells were lysed and Co-IP 
was performed with α-HSPA8 or α-c-Myc (control) antibodies coupled to protein G agarose 
beads. Precipitated proteins (IP) and 10 % of whole cell lysates (WCL) were analyzed by SDS 
PAGE and immunoblotted using the indicated antibodies. Displayed data is from a representa-
tive experiment of N ≥ 2. 
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Co-IP experiments showed the co-precipitation of A/Pan/99 and A/Thai/04 PB2 with 
endogenous HSPA8 in infected A549 cells (figure 3.15.A and B, respectively). These 
data therefore confirm the results of co-IP in hit protein overexpressing cells (figure 
3.11 and 3.12) and MS analysis. 
3.3.2 HSPA8 relocates into the nucleus in infected cells 
HSPA8 is constitutively expressed and mainly localized in the cytoplasm of cells under 
physiological conditions. Under stress conditions such as e.g. heat shock, HSPA8 con-
centrates in the nucleus 152. Watanabe et al. demonstrated that HSPA8 also relocates 
into the nucleus of influenza virus infected cells at late time points of infection 125. How-
ever, in the study conducted by Watanabe et al. the relocation of HSPA8 during influ-
enza virus infection was only shown for the lab adapted strain A/WSN/33. To determine 
if this relocation also occurs in cells infected with A/Pan/99 and A/Thai/04 strains, 
which have unlike A/WSN/33 not been subjected to multiple passages, and to thereby 
further characterize the role of HSPA8 in influenza virus infected cells, the localization 
of HSPA8 was analyzed by immunofluorescence staining during A/Pan/99 and 
A/Thai/04 infection. 
A549 cells were infected with A/Pan/99-WT or A/Thai/04-WT at an MOI of 1. After 4 h 
or 8 h p.i. cells were fixed and HSPA8 was visualized by staining with an α-HSPA8 
antibody and fluorescently labelled secondary antibody. Since staining of PB2 with all 
commercially available antibodies tested under different conditions was unfortunately 
not successful, staining with α-NP antibodies and fluorescently labelled secondary an-
tibodies was used to locate influenza virus infected cells. The sub-cellular localization 
of HSPA8 was then determined using confocal microscopy. 
At 4 h p.i., HSPA8 was almost equally distributed in the cytoplasm and the nucleus of 
uninfected cells as well as of cells infected with A/Pan/99-WT or A/Thai/04-WT (figures 
3.16.A and 3.17.A, respectively). This is illustrated in the corresponding intensity pro-
files of the HSPA8, NP and DAPI channels (see bottom left corner of the panels in fig-
ure 3.13 and 3.14). If one follows the green line, representing the HSPA8 signal, a simi-
lar intensity of the signal in the nucleus (characterized by an increase in intensity of the 
blue DAPI signal) and the cytoplasm can be seen. This equates to the distribution of 
HSPA8 in cells 0 h after infection (data not shown). The red influenza virus NP signal 
peaked in the nuclear region of the infected cells at 4 h post infection. 
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Figure 3.16. HSPA8 relocates into the nucleus at late time points of A/Pan/99-WT infec-
tion. A549 cells were infected with A/Pan/99-WT at an MOI of 1. A 4 h or B 8 h p.i. cells were 
fixed and HSPA8 and influenza virus NP visualized by staining with antibodies for the indicated 
proteins. The square area of the inset is digitally magnified (enlarged). The white arrow indi-
cates the area used for intensity profiles of the green (HSPA8), red (NP) and blue (DAPI) chan-
nel. Scale bar =10 µm. 
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Figure 3.17. HSPA8 relocates into the nucleus at late time points of A/Thai/04-WT infec-
tion. A549 cells were infected with A/Thai/04-WT at an MOI of 1. A 4 h or B 8 h p.i. cells were 
fixed and HSPA8 and influenza virus NP were visualized by staining with antibodies for the indi-
cated proteins. The square area of the inset is digitally magnified (enlarged). The white arrow 
indicates the area used for intensity profiles of the green (HSPA8), red (NP) and blue (DAPI) 
channel. Scale bar =10 µm. 
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8 h post infection, a relocation of HSPA8 into the nucleus of A/Pan/99-WT and 
A/Thai/04-WT infected cells was observed (figure 3.16.B and 3.17.B, respectively). The 
intensity profiles showed a clear increase of the green HSPA8 signal in the nucleus of 
infected cells (characterized by an increase of the red influenza virus NP signal) when 
compared to the intensity of the cytoplasmic HSPA8 signal. In contrast, the green 
HSPA8 signal in neighboring uninfected cells remained constant in nuclear and cyto-
plasmic areas of the cell. NP was located in the nucleus as well as in the cytoplasm at 
8 h post infection.  
Hence, confocal microscopy analysis revealed that HSPA8 also relocates into the nu-
cleus of A549 cells infected with non-lab adapted influenza virus strains of the subtypes 
H3N2 and H5N1. This HSPA8 relocation was also observed at late time points of infec-
tion (16 h p.i., data not shown). 
3.3.3 siRNA mediated depletion of HSPA8 expression influences 
A/Panama/2007/99 and A/Thailand/(KAN-1)/04 replication 
To investigate the role of HSPA8 in viral replication, viral growth curve analysis was 
performed in A549 cells after siRNA mediated HSPA8 depletion.  
A549 cells were transfected with an HSPA8 siRNA mix, composed of four individual 
HSPA8 siRNAs, or non-target (NT) control siRNA, then infected with A/Pan/99-WT or 
A/Thai/04-WT viruses at an MOI 0.1, 48 hours post siRNA transfection. The time point 
for infection was previously determined in optimization experiments (data not shown). 
In addition cell viability was monitored over the time frame of the experiment by MTT 
assay. 
The viability of HSPA8 knock down cells was stable over time and similar to cells trans-
fected with non-target siRNA (figure 3.18.A). Therefore, it could be excluded that the 
effects of the HSPA8 knock down on viral growth were due to changes in cell viability. 
To ensure that the depletion in HSPA8 protein expression remained stable during the 
course of the experiment, cell lysates were taken for analysis at 0 h and 72 h post in-
fection (48 h and 120 h post siRNA transfection). These time points represent the start 
and end point of viral growth curve analysis, where HSPA8 protein depletion was con-
firmed by immunoblot analysis (figure 3.18.B). 
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Figure 3.18. Depletion of HSPA8 influences A/Pan/99-WT and A/Thai/04-WT replication. 
A549 cells were transfected with NT siRNA or a HSPA8 siRNA mix. After 48 h, cells were in-
fected with A/Pan/99-WT or A/Thai/04-WT viruses at an MOI of 0.1. A Influence on cell viability 
of HSPA8 depletion monitored by MTT assay. Displayed values represent the mean +SD of 
N=2 in duplicate. B The integrity of the HSPA8 depletion at 0 h and 72 h p.i. was confirmed by 
immunoblot analysis. Viral titers (log PFU/ml) of C A/Pan/99-WT and D A/Thai/04-WT strains 
over time were determined by standard plaque titration assay. Displayed values represent the 
mean +SD of N=2 in duplicates. Viral titers of E A/Pan/99-WT and F A/Thai/04-WT strains at   
72 h p.i. were also depicted as absolute values. 
siRNA mediated depletion of HSPA8 led to a slight decrease in A/Pan/99-WT viral 
growth from 16 h p.i. onwards (figure 3.18.C). Viral titers were decreased between  
41.7 % and 69.6 % compared to viral titers from non-target A549 cells. The strongest 
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effect was observed at 72 h post infection. While A/Pan/99-WT virus grew to a mean of 
81.875 PFU/mL in non-target siRNA transfected cells, it grew only to a mean of 24.875 
PFU/mL in HSPA8 knock down cells (figure 3.18.E). 
Viral growth of A/Thai/04-WT in HSPA8 knock down cells was slightly decreased at 0 h 
and 16 h p.i. (figure 3.18.D). However, while titers were almost identical at 24 h p.i., at 
48 h and 72 h p.i. viral titers from HSPA8 depleted cells were marginally increased in 
comparison to virus titers from non-target siRNA transfected cells. Hence, no clear 
trend for the influence of HSPA8 depletion on A/Thai/04-WT growth during the time 
course of infection could be observed, while HSPA8 depletion showed a negative effect 
on A/Pan/99-WT growth from 16 h to 72 h post infection. The effect of HSPA8 deple-
tion on viral growth was however not statistically significant. 
3.3.4 Knock down of HSPA8 leads to a depletion of 
A/Panama/2007/99 PB2 
Since the knock down of HSPA8 had a slight effect on viral growth, and overexpression 
of HSPA8 led to an increase in polymerase activity of A/Pan/99 and A/Thai/04 (see 
section 3.2.2), the minigenome assay was also performed in siRNA knock down cells 
to further investigate the role of HSPA8 in the viral replication cycle. 
293T cells were transfected with NT siRNA or the HSPA8 siRNA mix. After 24 h, cells 
were transfected with expression plasmids encoding PB2, PB1, PA and NP of either 
A/Pan/99 or A/Thai/04, a firefly luciferase reporter plasmid under the control of the UTR 
of the NS segment of influenza A virus, and a constitutively expressed Renilla lucifer-
ase reporter plasmid. For the negative control, the PB2 expression plasmid was re-
placed by the corresponding empty plasmid. 24 h later, cells were lysed and luciferase 
activity was measured. Normalized luciferase activity was calculated as x-fold activa-
tion in comparison to non-target siRNA transfected samples (set to 100 %). 
The polymerase activity of the A/Thai/04 strain was slightly increased to 111.7 % in 
HSPA8 depleted cells (figure 3.19. B). In contrast, depletion of HSPA8 led to a 39.8 % 
reduction in A/Pan/99 polymerase activity in comparison to NT siRNA transfected cells 
(figure 3.19.A). These data correlate well with the overexpression (figure 3.14.A) and 
virus growth curve analysis data (figure 3.18.C and E). 
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Figure 3.19. Knock down of HSPA8 leads to a depletion of A/Pan/99 PB2. 293T cells were 
transfected with the siRNA mix for HSPA8 or NT siRNA. After 24 h cells were transfected with 
expression plasmids encoding A A/Pan/99 or B A/Thai/04 PB2, PB1, PA and NP, as well as the 
firefly luciferase minigenome plasmid. The constitutively expressed Renilla luciferase reporter 
plasmid served as the internal control. The PB2 expression plasmid was replaced by the corre-
sponding empty vector in negative control samples. 24 h after minigenome transfection, cells 
were lysed and luciferase activity was measured. Displayed values represent the mean + SD of 
3 independent experiments. Expression levels of the indicated proteins were determined by 
immunoblot analysis of minigenome lysates of C A/Pan/99 and D A/Thai/04 samples. Depicted 
are immunoblot data representing 2 out of 3 experiments. 
Depletion of HSPA8 was confirmed by immunoblot analysis of minigenome expressing 
lysates. While HSPA8 depletion was similar for A/Pan/99 and A/Thai/04 samples (fig-
ure 3.19.B and D, respectively), expression levels of PB2 differed dramatically between 
strains. While A/Thai/04 PB2 expression levels were similar in NT and HSPA8 siRNA 
transfected cells, A/Pan/99 PB2 protein was strongly depleted in HSPA8 knock down 
cells. This effect was not due to differences in whole protein amounts, as measured 
actin levels were similar between NT and HSPA8 siRNA transfected cells in A/Thai/04 
and A/Pan/99 samples. This observation hints at a role for HSPA8 in A/Pan/99 PB2 
protein stability. 
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4. Discussion 
4.1 Mass spectrometric analysis revealed the PB2 
interactome of non-laboratory adapted seasonal and 
highly pathogenic avian influenza virus strains 
All viruses are obligate intracellular parasites, meaning they are entirely reliant on their 
host cell and its resources for their own reproduction. Hence, to understand the replica-
tion cycle of a virus it is essential to not only analyze viral proteins but viral proteins in 
their host cell environment. This includes the identification of cellular binding partners 
of viral proteins. Only the interaction with cellular proteins enables the virus to access 
cellular pathways and thereby allows for effective virus replication. In addition the con-
trol of viral replication by the innate or adaptive immune system is based on the interac-
tion of viral and cellular factors. 
The influenza virus protein PB2 is part of the trimeric viral polymerase complex. It is 
crucial for viral genome transcription and replication and was shown to be linked to the 
viral host range 57,71,137. Hence, the host cell interactome of PB2 has been the subject 
of several studies focusing on influenza virus polymerase activity or host range deter-
minants. However, many of these studies were performed with laboratory-adapted in-
fluenza strains, e.g. A/PR8/34 or A/WSN/33 139,141,142. To enable efficient replication in 
mice (which are not natural hosts for influenza virus but represent a low-cost, easy-
husbandry and well established model) these viruses underwent multiple passages in 
mice 153. Hence, the PB2 interactomes determined in studies using A/PR8/34 or 
A/WSN/33 do not necessarily reflect the PB2 interactome of human isolates and there-
by the natural situation. Other studies have analyzed the PB2 interactome of human 
isolates of seasonal and highly pathogenic influenza virus strains, however these stud-
ies were carried out not in the context of infected cells, but in cells in which PB2 or the 
complete polymerase complex was expressed by transient transfection 138,143,144. Viral 
proteins that are expressed in non-infected cells are not in the environment of a com-
plete virus replication cycle and lack the influence of other viral and cellular proteins 
that are expressed or differentially regulated in infected cells. This thesis represents the 
first study in which the PB2 interactome of viral strains representing human isolates 
was determined in infected cells. We aimed to identify the PB2 interactome, including 
direct as well as indirect interaction partners of PB2, of seasonal (represented by 
A/Pan/99 (H3N2)) and highly pathogenic (represented by A/Thai/04 (H5N1)) viral 
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strains and to characterize the effect of selected interaction partners on viral replica-
tion. 
Mass spectrometric analysis 
Protein interactions of PB2 were identified in a SILAC based affinity-purification mass 
spectrometry (AP-MS) approach. AP-MS was selected due to several different charac-
teristics of this approach. Firstly, mass spectrometry allowed for the highly sensitive 
detection of protein-protein interactions (PPI) under physiological conditions in a rele-
vant biological context 149, in this case human alveolar epithelial cells (A549) infected 
with influenza virus. By means of affinity purification upstream of MS, PB2 and its cellu-
lar interaction partners were enriched and non-specific contaminants were reduced. 
Secondly, the use of SILAC labeled cells made it possible to perform a quantitative 
comparison between cells infected with A/Pan/99-PB2-Strep, A/Thai/04-PB2-Strep and 
the internal control A/Pan/99-WT. This enabled the further exclusion of false positives 
and external protein contaminants, which increased confidence in the identified interac-
tion partners of A/Pan/99- and/or A/Thai/04-PB2 proteins. 
The experimental setup of the MS screen needed to take several important factors into 
account. For example, the choice of influenza virus strains, the cell type used for infec-
tion, and the time period cells were infected for prior to affinity purification of PB2-strep. 
The human influenza virus strain A/Pan/99 (H3N2) was chosen because it represents a 
classical seasonal influenza virus, it was part of the influenza vaccine from 2000 to 
2004 154, and the eight-plasmid-based rescue system of this strain was established in 
the laboratory. Of the available rescue systems for a highly pathogenic influenza virus 
strain that originated from a human isolate, the A/Thai/04 strain was chosen because 
its PB2 protein harbors a glutamic acid residue at position 627, and therefore repre-
sents an avian-type PB2. Even though it was shown that A/Thai/04 acquired an adap-
tive mutation in its NEP protein to compensate for the lack of a mammalian-type K-627 
PB2 155 in order to enhance its polymerase activity, it is not yet known whether avian-
type PB2 of highly pathogenic human isolates interacts with host factors different to the 
mammalian-type PB2 of seasonal strains. Therefore, the comparison of these influenza 
virus strains was of particular interest. Both recombinant WT and Strep-tagged viruses 
were propagated in embryonated chicken eggs. Due to the need for responsible han-
dling of animal material, virus stocks were limited. To allow for a maximum number of 
biological replicates cells could only be infected at an MOI of 1.5 and no experimental 
set-ups using A/Thai/04-WT as internal control was included. In order to maximize the 
amount of PB2 protein available for affinity purification, whilst still being within the time 
frame of a monocyclic infection, cell lysis was performed 16 hours post infection. In 
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addition, growth analysis showed a major attenuation of the A/Thai/04Strep-PB2 virus 
compared to the WT virus from 24 h on (see figure 3.2.B). Even though it cannot be 
explained why the virus showed attenuation only from 24 h onwards, this observation 
reinforced the decision to infect cells for 16 h. Human alveolar epithelial cells (A549 
cells) represent an in vitro model for type II pneumocytes, the primary target cells for 
influenza viruses in the human lung 95, and are widely used in influenza virus research; 
therefore they were selected as the host cell line of choice in the MS study.  
In total, data from 4 experimental replicates were collected in order to identify cellular 
interaction partners of A/Pan/99 and A/Thai/04 PB2 proteins, resulting in the detection 
and quantification of 1842 protein groups. 
Evaluation of MS data 
Replicates showed a relatively strong Pearson correlation of 0.569 to 0.823 for 
A/Pan/99-PB2-Strep, and from 0.858 to 0.922 for A/Thai/04-PB2-Strep samples (figure 
3.6.A-3.6.B). Hence, M/L and H/L ratios of protein groups were very similar between 
replicates, indicating stable proportions of the individual protein groups between 
A/Pan/99-PB2-Strep; A/Thai/04-PB2-Strep and the internal A/pan/99-WT control were 
affinity purified and detected across the 4 experiments. 
Volcano plot analysis revealed 487 cellular protein groups that were significantly more 
abundant in PB2-Strep samples compared to the internal WT control (see supplemen-
tary table S.1). Of these, 83 protein groups were significantly more abundant in both 
A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep eluates, while 106 and 298 protein 
groups were solely significantly more abundant in either A/Pan/99-PB2-Strep or 
A/Thai/04-PB2-Strep eluates, respectively. This could lead to the assumption that PB2 
of the A/Thai/04 strain specifically interacts with a greater number of cellular proteins. 
However, analysis of the H/M ratio of PB2 peptides in the 4 replicates revealed that 
A/Thai/04 PB2 was 2.7 to 10.9 times more abundant than A/Pan/99 PB2 (data not 
shown). This correlated with the observation that PB2 expression levels were higher in 
A/Thai/04 infected A549 cells compared to A/Pan/99 infected cells (see figure 3.1 as an 
example). In addition, A/Thai/04 infection led to more profound cytopathic effects (CPE) 
at 16 hours post infection and viral titers were up to 3 times higher compared to 
A/Pan/99 (see figure 3.2 as an example). Over a 72 h time course of infection, 
A/Thai/04 viral titers were increased by up to 7 times compared to the A/Pan/99 strain, 
indicating a more potent replication of A/Thai/04 influenza virus in A549 cells, an ob-
servation that has also been described before by Matthaei et al. and Gabriel at 
al. 156,157. Hence, even though equal overall protein amounts of the 3 cell states infect-
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ed with the 3 different viral strains were mixed together and then used for co-
precipitation, the proportion of viral proteins was supposedly higher in the A/Thai/04-
PB2-Strep than in the A/Pan/99-PB2-Strep lysates. Therefore, it is likely that binding 
sites on the Strep-Tactin resin were relatively stronger occupied by A/Thai/04-PB2-
Strep protein and its interaction partners, leaving less space for A/Pan/99-PB2-Strep 
protein and its interaction partners to bind. This could have shifted the M/L; H/L ratio 
equilibrium in the direction of A/Thai/04 PB2. Subsequently, protein groups that were 
found to be significantly more abundant only in A/Thai/04-PB2-Strep eluates cannot 
generally be excluded as potential A/Pan/99 PB2 binding partners. As a result, the fil-
tered protein group list was considered as a whole, rather than being divided into 
A/Thai/04 and A/Pan/99, in the analyses that followed. Hence, the experimental condi-
tions were not optimal for a comparative analysis of A/Pan/99 and A/Thai/04 PB2 inter-
action partners using mass spectrometry. 
Regarding future AP-MS studies, an adjustment of tagged-protein levels, or the appli-
cation of two separate affinity purifications, one for each viral strain in combination with 
its internal control, would be strongly advisable.  
The limited amount of available binding sites on the Strep-Tactin resin, highlighted by 
the fact that PB2 protein was also found in the non-bound fraction (see figure 3.5), 
combined with the unequal amounts of A/Thai/04 and A/Pan/99 PB2 proteins applied to 
the resin, could also explain the slightly lower Pearson correlation of the A/Pan/99-
PB2-Strep data. The likelihood that a protein will bind to the Strep-Tactin resin in simi-
lar amounts across 4 individual experiments decreases with decreasing numbers of 
available binding sites. 
All viral proteins that were included in the database used for protein identification by 
MaxQuant were found to be more abundant in Strep eluates compared to the WT con-
trol (see figure 3.7). Except for the M1 and M2 protein of A/Pan/99, the change in pro-
tein abundance was significant for all proteins (see supplementary table S.2 and S.3). 
PB2 showed the highest significance and fold-change in A/Pan/99-PB2-Strep (t-test 
difference 358.29) as well as in A/Thai/04-PB2-Strep (t-test difference 992.55) eluates 
compared to the internal control, confirming the functionality of the experimental setup 
and the significance of data evaluation. Overall, viral proteins were at least 3 times 
more abundant in Strep eluates, indicating that they co-purified with PB2-Strep. PB2 
forms vRNPs together with PA, PB1, NP and vRNA 13. Hence the co-purification of 
these proteins with PB2-Strep in an infectious context could be predicted, while the co-
purification of PB2 with e.g. the transmembrane proteins NA and HA was less ex-
pected. However, the M1 protein is presumed to interact with the cytoplasmic tails of 
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NA, HA and M2 as well as with NEP and vRNPs 48,158-160. Given that all viral proteins 
are present at 16 hours post infection, M1 presumably served as a linker and the whole 
protein complex was precipitated. The same mechanism could explain the abundance 
of NS1, which is known to interact with NP 161, in the PB2-Strep eluates. 
The filtered list of cellular proteins significantly more abundant in PB2-Strep eluates 
was compared to data from 5 other previously published proteome screens that looked 
for interaction partners of PB2, either expressed alone or as part of the viral polymer-
ase complex (figure 3.8) 138-142. The largest data overlap (71 of the same cellular pro-
teins identified in both studies) was found with the Watanabe et al. screen (figure 3.8; 
Watanabe, UA). This is probably due to the fact that the Watanabe et al. protein list, 
generated by MS analysis, was not subjected to a stringent data filtering process be-
fore additional experimental analyses were performed 141. Hence, this list of 388 poten-
tial PB2 interaction partners was the longest used for comparison, which thereby facili-
tated the observed largest data overlap.  
However, when the data overlap was calculated as a percentage of the number of pro-
teins of the interactome screen used for comparison, the largest overlap was found 
with the Bradel-Tretheway et al. screen (figure 3.8.A; Bradel, UA). The same 8 proteins 
were detected in both screens which represent 23.5 % of 34 hit proteins of the Bradel-
Tretheway et al. screen, which aimed to identify interaction partners of the viral poly-
merase of A/Vietnam/1203/04 (H5N1) 138. Two of these proteins, ANP32A and B, are 
known to be crucial for viral polymerase activity. Especially a 33 long aa sequence pre-
sent in avian but not mammalian ANP32A plays a role in the suboptimal polymerase 
activity of avian H5N1 or H7N9 polymerase in mammalian cells (see section 1.2.4) 68. 
The fact that this screen also analyzed the interactome of a H5N1 strain presumably 
contributes to the number of overlap proteins. In addition, strict filter criteria were ap-
plied, thus lowering the likelihood of false positives, which promotes the number of pro-
portional overlap proteins. 
The majority of all compared protein groups, namely 925 out of 1192 (77.6 %), were 
found in only 1 screen. The discrepancy between various studies using AP-MS and 
other systems-level technologies like RNAi screens to identify host-pathogen interac-
tions has been shown to be high 162. Possible reasons for this low overlap include dif-
ferent experimental setups, false positives and negatives, divergent applications of 
statistical analysis 163 and individual filter criteria. As shown in Table 4.1, even though 
AP-MS techniques were used to identify interaction partners of PB2 or the polymerase 
complex, each experimental setup was unique in the combination of cell type, viral 
strain e.t.c, all of which contributes to differences in the obtained results. 
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Table 4.1. Experimental setups of proteome screens used for comparison with our fil-
tered protein list. The AP-MS screens aimed to identify interaction partners of the influenza 
virus PB2 protein expressed in isolation (Heaton et al., Wang et al., Watanabe et al. and York et 
al.) or as part of the polymerase complex (Bradel-Tretheway et al.). 
 
 
Heaton et al. 
 
Bradel-
Tretheway     
et al. 
 
Wang et al. 
 
Watanbe 
et al. 
 
York et al. 
 
Cell type 
 
A549 
 
A549 
 
293T 
 
293T 
 
293T 
Viral 
Strain 
A/PR/8/34 (H1N1) A/VN/1203/04 
(H5N1) 
A/PR/8/34 
(H1N1); 
A/WSN/33 
(H1N1); 
A/NY/18/2009 
(H1N1); 
A/VN/1203/04 
(H5N1) 
A/WSN/33 
(H1N1) 
A/WSN/33 
(H1N1) 
Tag FLAG TAP FLAG FLAG Strep 
Transfec-
tion 
- PA-TAP + PB2 
PA-TAP + PB1 
+ PB2 
PB2-FLAG PB2-FLAG - 
Infection MOI 3 
10 hours 
- MOI 1  
16 hours 
(no VN/04 inf.) 
- MOI 5 
7 hours 
 
Nonetheless, 2 proteins were found in our filtered protein list and in the Heaton et al.; 
Watanabe et al. and the York et al. screens. SLC25A6, also known as ANT3, is known 
to interact with the viral protein PB1-F2, which triggers the intrinsic apoptosis pathways 
in the host cell 164. The second protein, BAG2, is known to stimulate the ADP/ATP ex-
change rate of HSPA8 and to act as an inhibitor of its CHIP-dependent ubiquitin ligase 
activity165. However a role for BAG2 in the influenza virus replication cycle has not yet 
been described. 
A total of 30 proteins (6.2 %) were also found in 2 out of 4 previously published 
screens. Among them are proteins that have not yet been described in the context of 
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influenza virus infection, as well as proteins that are known to be required for the effi-
cient polymerase activity of H1N1 and H5N1 subtypes, e.g. DDB1 and DDX5 127. While 
an additional 98 proteins were also found in 1 of the compared screens (20.1 %), the 
majority of identified proteins (356; 73.1 %) were only found in the screen performed in 
this study. This comparative analysis on one hand highlights the significance of the 
retrieved data by displaying proteins that were found in multiple screens and are known 
to play a role in the influenza virus replication cycle. On the other hand, the comparison 
also points out the need for further data filtering to decrease the number of false posi-
tives, and to increase the likelihood of identifying specific interaction partners of PB2. 
GO term analysis of the protein list using the PANTHER online tool to gain further in-
sight into the biological functions of the identified protein groups led to the same con-
clusion (figure 3.9). Classification according to their protein class showed that the ma-
jority of proteins (25.3 %) belong to the class of nucleic acid binding proteins. This was 
consistent with expectations, since PB2 is part of the viral RNA replication and tran-
scription machinery; hence, it is plausibly that PB2 might interact with cellular proteins 
also involved in nucleic acid binding. The interaction of PB2 with representatives of the 
third most prominent protein class, hydrolysis proteins (10.3 % of interaction partners 
identified in our screen), was less predictable. However, nucleases belong to a class of 
hydrolases, which could explain the occurrence of this protein class in an interactome 
screen of a viral polymerase protein. The cellular proteins MCM2/3/4/6 and 7 identified 
in our screen, also belong to a class of hydrolase proteins, and form the minichromo-
some maintenance complex, which has previously been shown to interact with influen-
za virus PA protein and to regulate virus genome replication, thus supporting the rele-
vance of the data set 67. On the other hand, proteins belonging to the second most 
prominent protein class, oxidoreductase proteins (12.9 %), as well as to other catego-
ries revealed in PANTHER analysis (such as extracellular matrix proteins and cell junc-
tion proteins), highlight the need to apply more stringent filter criteria, even though the 
involvement of these proteins in PB2 function cannot be excluded with absolute cer-
tainty. 
In order to obtain a more stringent list of potential PB2 interaction partners, another 
filter criterion was added to the analysis. In addition to being statistically significant, 
protein groups needed to have a t-test difference of ≥ 1 (log2) in at least 2 out of 4 ex-
periments, equating to a fold increase in protein abundance of at least 2 compared to 
the A/Pan-99-WT control. This shortened the list from 487 filtered protein groups to 22 
protein hits (hit list; table 3.2) and increased the ratio of proteins overlapping with the 
other proteome screens from 22.4 % to 40.9 %. The proteins GGH, CKMT1B, 
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HIST2H3A, EPHX1, CKMT1A, PABPC3, SLC12A2, LXN, SNRNP200, CAST, KCNJ8, 
hnRNPC1, and AGR2 were, not found to interact with PB2 in the 5 published interac-
tome screens used for comparison and thereby represent potential novel binding part-
ners of PB2 138-142. For example, it is known that the ubiquitously expressed protein 
hnRNPC1 associates with pre-mRNAs in the nucleus and potentially influences splicing 
regulation166. The influenza virus proteins NEP and M2 are produced by splicing of the 
NS1 and M1 mRNAs, a process which is controlled by the cellular proteins RED and 
SMU1. This protein complex is recruited by PB2 and PB1 to splicing sites of viral 
mRNA 167. Hence, the interaction of PB2 with other cellular splicing regulators is possi-
ble, and may have functional relevance to the influenza virus replication cycle. In addi-
tion, the importance of hnRPC1 for the replication of other viruses has already been 
shown in the context of dengue, hepatitis C and poliovirus infection 168. 
GO term analysis assigned 11 of 22 hit proteins to the molecular function “nucleotide 
binding”, indicating the relevance of hit proteins. A STRING database network analysis 
revealed 2 clusters of protein interaction networks (see figure 3.10). The smaller cluster 
comprised 3 histone proteins while the second cluster encompassed 13 proteins with 
HSPA8 as the center. All of the 10 connections of HSPA8 shown in figure 3.10 repre-
sent experimentally determined protein interactions. This could lead to the assumption 
that a single large complex of interacting proteins has been precipitated with PB2. 
However, since HSPA8 is a member of the heat shock protein 70 (HSP70) family and 
plays a role in nascent protein folding and cellular transport of proteins 118 it is likely that 
it binds to a wide variety of proteins. Therefore, this large cluster does not necessarily 
represent a single large protein complex, but potentially reflects the chaperone function 
of HSPA8 and/or a network of smaller protein complexes that are not all physically 
linked inside cells, but that all contain HSPA8 (see section 4.2 for further discussion of 
HSPA8 and its role in the influenza replication cycle). The fact that some of the proteins 
are mainly located in the nucleus (for example SNRNP200 and TOP2A) while others 
are located in the cytosol (for example BAG2), the mitochondrion (CKMT1A/B) or the 
endoplasmic reticulum (EPHX1) also speaks against a single large protein complex. 
The possible precipitation of several small protein complexes is supported by the fact 
that for the majority of hit proteins (excluding SLC12A2, PABPC3 and the 6 proteins 
that showed no relationship to other proteins) an experimentally determined protein 
interaction to at least one other hit protein in addition to HSPA8 is known. Overall, 
these results were in line with expectations. The overlap with other proteome screens, 
the assigned molecular functions of identified proteins and the identification of known 
PB2 interaction partners such as PABPC1 61 indicated the functional relevance of the 
AP-MS data. Nevertheless, the performed interactome screen enabled the identifica-
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tion of potentially novel PB2 interaction partners which, until now, have not yet been 
reported. 
Validation of protein hits 
To further support the findings of the MS screen, 13 proteins from the hit list were se-
lected for validation based on their molecular functions and reagent availability. AGR2, 
CAST, EPHX1, GGH, hnRNPC1, LXN, PABPC3 and SLC12A2 were selected as can-
didates representing potentially novel PB2 interaction partners. In addition BAG2, 
HSPA2, HSPA8 and RCN2 served as representatives of proteins already found in oth-
er PB2 interactome screens, but not yet further investigated in terms of their potential 
role in polymerase interaction or function. For example, the BAG2 protein was not only 
found in 3 out of the 4 proteome screens used for comparison 139,141,142 but is also 
known to have a regulatory function within the chaperone activity of Hsp70 family 
members, of which 2, HSPA2 and HSPA8, were also found in the AP-MS screen. 
Hence, further investigation of these interacting proteins seemed logical. 
The 13th protein selected for validation, PABPC1, is a known interaction partner of  
PB2 61 and served as a positive control for the Co-IP validation experiment. This 3’-
poly(A) tail binding protein is known to be part of the translation pre-initiation complex. 
PABPC1 interacts with the translation initiation factor eIF4G which is, in turn, part of the 
cap-binding complex which is recruited to mRNA through interaction of the complex 
component eIF4E with the 5’-cap 169. Hence, the interaction of PABPC1 and eIF4G 
forms a protein bridge between 3′- and 5′-mRNA-termini 170. The formation of this so 
called “closed loop structure” promotes recruitment of the small ribosomal subunit to 
the mRNA 5′ terminus 171. It has been shown that the influenza virus NS1 protein not 
only interacts with PABPC1 and eIF4G, but is also associated with viral but not cellular 
mRNA, suggesting that NS1 promotes the specific recruitment of the translation initia-
tion complex to viral mRNAs 172. However, viral mRNAs are nonetheless selectively 
translated in influenza virus mutants lacking the NS1 protein, hinting at an additional 
mechanism for selective translation of viral mRNAs 173. Even though the interaction of 
the viral polymerase with viral mRNAs that have already been transported to the cyto-
plasm is highly controversial, Yángüez et al. showed that PB2 interacts with eIF4G and 
proposed a model in which PB2 mediates the association of the 5’-cap with the cap-
binding complex in an eIF4E independent manner 174. Since infection with influenza 
leads to the dephosphorylation and inactivation of eIF4E 175, it was suggested that PB2 
promotes the formation of the “closed-loop” structure, thereby helping to initiate viral 
mRNA translation. Since the interaction of PB2 with PABPC1 has also been shown 61, 
the formation of the “closed-loop structure” is potentially even independent of the inter-
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action of NS1 with PABPC1, supporting the hypothesis of an additional role for PB2 in 
the influenza virus replication cycle. Alternatively, the interaction of PB2 with PABPC1 
could also occur in the nucleus where the cellular protein is known to bind un-spliced 
and partially spliced pre-mRNA 176. The role of PABPC1 in nuclear events is however 
still unclear 177. The Co-IP analysis showed co-precipitation of A/Pan/99 PB2 with over-
expressed, tagged PABPC1 protein, verifying the functionality of the MS experimental 
setup (see figure 3.12). Interestingly, PABPC1 overexpression had however only a 
significant influence on the activity of the A/Thai/04 polymerase for which co-
precipitation of PB2 could not be verified with certainty (see figure 3.11. and 3.14). 
However, the fact that overexpression had an effect on polymerase activity supports an 
interaction of PABPC1 with PB2. A decrease in polymerase activity of A/Thai/04 was 
not only observed after PABPC1 overexpression but also after overexpression of the 
second poly(A)-binding protein analyzed, PABPC3. The inhibitory effect of PABPC1/3 
overexpression on A/Thai/04, but not on A/Pan/99 polymerase activity hints at an inhib-
itory effect of PABPC proteins on the activity of avian-type viral polymerases. It would 
be worthwhile testing if the same difference in effects of PABPC proteins on polymer-
ase activity can be observed in other seasonal and highly pathogenic avian/avian-type 
influenza virus strains.  
Overall, the co-precipitation of A/Thai/04 PB2 with 8 (BAG2, GGH, HSPA2, HSPA8, 
PABPC3, EPHX1, LXN, SLC12A2), and the co-precipitation of A/Pan/99 PB2 with 7 
(BAG2, HSPA8, PABPC1, PABPC3, EPHX1, LXN, SLC12A2) out of 13 examined hit 
proteins could be verified in overexpression experiments (see figures 3.11 and 3.12). 
This validation rate is very high for a high-throughput screen, indicating the robustness 
of the chosen method. Moreover, minigenome assay revealed an effect with 11 out of 
13 overexpressed proteins on the polymerase activity of either A/Pan/99 or A/Thai/04 
strains (figure 3.14). In addition to PABPC1 and 3, AGR2, hnRNPC1 and SLC12A2 
overexpression had different effects on the viral polymerase activity of the 2 influenza 
virus strains. While AGR2 overexpression slightly inhibited A/Thai/04 polymerase ac-
tivity whilst not affecting A/Pan/99 polymerase activity, SLC12A2 only showed an in-
hibitory effect on the activity of the A/Pan/99 polymerase, leaving the A/Thai/04 poly-
merase unaffected. The membrane protein SLC12A2 transports sodium (Na), potassi-
um and chloride into cells 179. It has been shown that an increase in intracellular Na+ 
leads to a decline in influenza virus titers 180. Given that overexpression of SLC12A2 
leads to a decrease in A/Pan/99 polymerase activity, an inhibitory effect of Na+ is feasi-
ble while the A/Thai/04 polymerase is maybe less sensitive to elevated Na+ concentra-
tions. 
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The ribonucleoprotein hnRNPC1 had a positive effect on polymerase activity, however 
this was only observed for A/Thai/04 strain. Interestingly, the interaction of hnRNPC1, 
as well as the interaction of the polymerase influencing proteins AGR2 and RCN2 with 
PB2 could not be verified by co-IP (see table 3.3.). This may hint at a possible role of 
NP in the interaction with some of these proteins since NP was present in the MS ex-
periment as well as in the minigenome assay, but not during the Co-IP with the tagged, 
overexpressed cellular proteins. For example, the NP interacting splicing factor UAP56 
has been shown to facilitate the NP-RNA interaction that likely serves as the viral pol-
ymerase template. Hence, it was suggested that the UAP56-NP interaction could lead 
to enhanced viral RNA synthesis 178. A potentially similar function for the splicing factor 
hnRNPC1 in A/Thai/04 replication represents an interesting topic for further investiga-
tion. 
The co-precipitation of the polymerase inhibiting proteins GGH and HSPA2 (detrimen-
tally influences both A/Pan/99 and A/Thai/04 polymerase activity) with A/Pan/99 PB2 
protein could not be verified with certainty. The PB2 bands in these eluates were only 
slightly more prominent than in the control eluate. However, when combined with the 
results of the minigenome assay, an interaction of these proteins (as it was shown for 
A/Thai/04 PB2) with A/Pan/99 is plausible. Furthermore, the inhibitory effect of HSPA2 
on the polymerase activity of A/Pan/99 and A/Thai/04 is similar to findings regarding 
HSPA1A of the Hsp70 family: HSPA1A was shown to interact with PB2 as well as with 
PB1 of the A/WSN/33 influenza strain, and its overexpression also inhibited viral poly-
merase activity. This resulted in significantly reduced transcription and replication of 
viral RNA due to the interference of HSPA1A with RNP integrity, which is thought to be 
achieved by HSPA1A blocking the interaction of PB1 with vRNA 181. 
Overall, validation experiments confirmed the co-precipitation of PB2 with a large num-
ber of the cellular proteins identified in the SILAC AP-MS screen, which had been fur-
ther streamlined through the appliance of stringent filter criteria. The question of 
whether the interaction of these proteins with PB2 is direct or mediated through viral 
PB1, PA or additional cellular proteins could not be clarified in this experimental setup 
and should be the subject of further investigation. Proteins usually work in complexes 
and the MS setup was designed to identify cellular factors influencing viral polymerase 
function. Hence, the focus of this study was not on details of the protein interaction 
itself, but on the functional influence of these interacting cellular proteins on viral poly-
merase activity. The observation that overexpression of 11 out of 13 proteins selected 
for validation had a significant influence on the polymerase activity of A/Thai/04 and/or 
A/Pan/99 strains indicates the suitability of the MS analysis for this purpose. Several of 
4. Discussion 105 
 
 
these proteins, for example HSPA2 and hnRNPC1, have not yet been reported to have 
an influence on influenza virus polymerase activity. Hence, this study has uncovered 
variety of cellular proteins for further experimental trials investigating the influenza virus 
polymerase and its interplay with host cell factors. The obtained data also suggests 
differences in the impact of these identified proteins on the polymerase activity of sea-
sonal and highly pathogenic influenza virus strains. 
4.2 HSPA8 is a novel regulator of the non-laboratory 
adapted seasonal influenza virus polymerase 
HSPA8, also known as Hsc70 or HSP73, belongs to the 70 kDa heat shock protein 
(HSP70) family 119. In addition to its various cellular functions in protein folding 182, pro-
tein degradation 183 and protein transport into organelles 184 (amongst other functions, 
see figure 4.1), HSPA8 has also been shown to play a role in regulating the replication 
of a variety of different viruses. For example, HSPA8 functions as a receptor for Japa-
nese encephalitis virus 123, is important for formation of the pre-replicative site of her-
pes simplex virus type 1 (HSV-1) 122 and interacts with the RNA-dependent RNA poly-
merase of turnip mosaic virus 124. 
 
 
Figure 4.1. Cellular functions of HSPA8. The heat shock protein HSPA8 has a large variety of 
cellular functions during optimal as well as during stress conditions. For more detailed infor-
mation on HSPA8 and its cellular functions see section 1.4. 
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In addition, HSPA8 has also been described in the context of the Influenza virus repli-
action cycle. Watanabe et al. showed that the depletion of HSPA8 leads to reduced 
titers of A/WSN/33 in HeLa cells, presumably due to its interaction with the influenza 
virus M1 protein, and the potential role of this interaction in the nuclear export of 
vRNPs 62,125,126. Furthermore, Bortz et al. identified HSPA8 as an enhancer of 
A/WSN/33 and A/VN/1203/04 (H5N1) polymerase activity in 293T cells 127. However, 
this was only observed in the infection-based minigenome assay and not in the con-
ventional minigenome assay, leading them to the conclusion that the influence of 
HSPA8s on viral polymerase activity was due to its function in the cellular stress re-
sponse. 
In contrast, our study showed a positive effect of HSPA8 overexpression on A/Pan/99 
as well as A/Thai/04 polymerase activity in minigenome expressing, non-infected A549 
cells (see figure 3.14), suggesting a non-stress related role for HSPA8 in polymerase 
function. Already interesting in itself, it was also observed that overexpression of BAG2 
(a co-factor of HSPA8) resulted in the downregulation of both A/Pan/99 and A/Thai/04 
polymerase activity. BAG2 belongs to the Bcl-2-associated athanogene (BAG) family of 
proteins which are characterized by the presence of at least one BAG domain located 
at the C-terminus 185. The BAG domain mediates the binding of these proteins to the 
ATPase domain of Hsp70 family members, which accelerates the chaperones 
ADP/ATP exchange rate and thereby encourages substrate release 118. The family 
member BAG2, identified in this and in 3 other PB2/polymerase interactome screens, 
binds the ATPase domain of HSPA8 with high affinity in a 2:2 stoichiometry 186. Given 
that endogenous HSPA8 is present in BAG2 overexpression cells, it is plausible that 
additional, overexpressed BAG2 proteins throws the BAG2-HSPA8 equilibrium out of 
balance, leading to reduced HSPA8 function and therefore inhibited viral polymerase 
activity. The presence of an HSPA8 co-factor in the hit list and an effect on this factor 
on viral polymerase activity supported the decision to analyze HSPA8 and its role in 
viral replication in more detail 
Role of HSPA8 in the replication cycle of A/Pan/99 and A/Thai/04  
To further investigate the role of HSPA8 in the context of an influenza virus infection in 
more detail, co-IP of PB2 with cellular HSPA8 was performed. The co-precipitation of 
A/Pan/99 and A/Thai/04 PB2 with endogenous HSPA8 from infected A549 cells was 
confirmed (see figure 3.15). This is in keeping with observations concerning other heat 
shock proteins. Li et al. described the interaction of HSPA1A, another member of the 
HSP70 family, with PB2 and PB1 of the A/WSN/33 influenza strain 181 and an interac-
tion with the same viral proteins, in this case of the A/PR8/33 influenza strain, was 
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shown for Hsp90 by Naito et al. 64. The question whether HSPA8 interacts only/directly 
with PB2 or also with/through other proteins of the viral polymerase complex needs to 
be further investigated. However, the co-precipitation of PB2 with HSPA8 in 
PA/PB1/PB2 and HSPA8 transfected 293T cells indicated that the heat shock protein 
interacts with the viral polymerase complex without the need of additional viral proteins 
(see figure 3.11 and 3.12). Taken together with the minigenome assay results in 
HSPA8 overexpressing cells (figure 3.14), the direct involvement of HSPA8 in viral pol-
ymerase functionality is plausible.  
Unlike HSPA1A, HSPA8 is constitutively expressed and only mildly induced during 
cellular stress 118. Even though mainly located in the cytosol, HSPA8 shuttles between 
the nucleus and cytoplasm under normal conditions and concentrates in the nucleus 
under stressful conditions 118. Watanabe et al. showed an accumulation of HSPA8 in 
the nucleus of A/WSN/33 and A/PR8/33 infected MDCK and HeLa cells, respective-
ly 125. To determine if the concentration of HSPA8 in the nucleus is a common feature 
of influenza virus infected cells, the localization of HSPA8 was analyzed by immunoflu-
orescence staining in A549 cells infected with the seasonal A/Pan/99 and the highly 
pathogenic A/Thai/04 strains of influenza virus. In both cases HSPA8 was evenly dis-
tributed between the cytoplasm and the nucleus of infected cells 4 hours p.i., while 
HSPA8 was then observed to be concentrated in the nucleus of infected cells after 8 
hours of infection (see figure 3.16 and 3.17). This is in agreement with the results from 
Watanabe et al. which showed a relocation of HSPA8 into the nucleus at 9 h but not 3 
h post infection 125. Watanabe et al. proposed a regulatory role for HSPA8 in the nucle-
ar export of newly formed vRNPs through its interaction with the viral M1 protein 62. In 
terms of viral polymerase activity, the presence of HSPA8 in the nucleus at late time 
points of infection indicates an influence of this heat shock protein on newly formed 
polymerase proteins, rather than on polymerase complexes that are part of the incom-
ing vRNPs. 
HSPA8 depletion using a mixture of 4 different siRNAs slightly decreased A/Pan/99 
titers from 16 h p.i. onwards, with a peak of viral titer decline at 72 h p.i. (figure 3.18.C 
and E), compared to negative control siRNA treated cells. These results are in accord-
ance with the effect of overexpression of HSPA8 on viral polymerase activity (figure 
3.14.A) and the observation by Watanabe et al. that HSPA8 depletion results in a de-
crease in viral titer of A/WSN/33 in HeLa cells 125. Interestingly, the influence of HSPA8 
on A/Thai/04 replication was less clear. Viral titers were decreased at 16 h p.i. in 
HSPA8 depleted cells, however titers were almost identical at 24 h p.i., and then in-
creased at 48 h and 72 h p.i. in comparison to negative control siRNA treated cells (see 
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figure 3.18.D and F). These data could hint at different functions for HSPA8 in early 
and late time points of the A/Thai/04 viral replication cycle, or alternatively could be a 
result of the unintentional use of lower viral titers for the initial infection of cells treated 
with HSPA8 specific siRNA. Even though complications during infection of A549 cells 
cannot be excluded, the same pipetting error in 2 experiments performed in duplicates 
is very unlikely. Therefore it is more plausible to suspect that the lower titers at 0 h and 
16 h p.i. in HSPA8 depleted cells were perhaps due to an impact of HSPA8 depletion 
on viral attachment and/or endocytosis. It has been shown that influenza virus H5N1 
can enter host cells through clathrin mediated endocytosis 187, during which HSPA8 
acts as a clathrin-uncoating ATPase 119. In this case, the depletion of HSPA8 could 
result in a reduction in clathrin mediated endocytosis, which could in turn lead to a re-
duction in virus entry, and reduced viral titers. 
The reason for the enhancing effect of HSPA8 depletion on A/Thai/04 replication at late 
time points of infection (48 h and 72h p.i.) is a subject of speculation. One possible 
explanation could be related to the function of HSPA8 in protein degradation through 
the ubiquitin-proteasome pathway 119. The interaction of HSPA8 with STUB1/CHIP 
leads to the coupling of ubiquitin side chains to the chaperones protein substrate and 
the substrates subsequent degradation. Hence, decreased HSPA8 levels may result in 
the rescue of viral proteins from HSPA8/ubiquitin dependent proteasomal degradation, 
thus resulting in enhanced viral titers. The involvement of increased viral polymerase 
activity in elevated viral replication in HSPA8 depleted cells seems unlikely, given the 
stimulating effect of HSPA8 overexpression on A/Thai/04 polymerase activity. Howev-
er, siRNA depletion of HSPA8 in 293T cells did lead to a slight increase in viral poly-
merase activity to 111.7 % (figure 3.19.B) which is maybe also due to decreased 
HSPA8 mediated viral protein degradation. Unfortunately, a clear conclusion regarding 
the influence of HSPA8 on A/Thai/04 polymerase activity and viral replication cannot be 
made based on these results. 
Results concerning the involvement of HSPA8 in the A/Pan/99 replication cycle were 
however, more in agreement with each other. While HSPA8 overexpression increased 
viral polymerase activity, HSPA8 depletion decreased A/Pan/99 replication to 30.4 % 
and viral polymerase activity down to 60.2 % in comparison to cells treated with nega-
tive control siRNA (figure 3.19.A). Intriguingly, HSPA8 depletion led to a strong deple-
tion of A/Pan/99 PB2 protein (figure 3.19.C). Given that HSPA8 functions as a molecu-
lar chaperone for a variety of proteins, it is likely that PB2 is also dependent on HSPA8 
for proper folding and protein stability. The lack of HSPA8 presumably leaves PB2 in a 
premature state, resulting in the reduced activity of PB2 and/or its degradation by the 
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cellular ubiquitin-proteasome system (UPS) or by lysosomal degradation. A small 
amount of PB2 was however still detectable by immunoblot analysis, perhaps explain-
ing the remaining activity of the viral polymerase complex, and was presumably due to 
the fact that small amounts of HSPA8 were still present inside cells. To test whether 
reduced viral polymerase activity is linked to inaccurate folded PB2, HSPA8 knock 
down cells could be treated with inhibitors of the lysosomal or ubiquitin-proteasome 
degradation system. This should lead to a rescue of PB2 protein amounts in immunob-
lot assay while the polymerase activity should still be decreased. To further character-
ize the influence of HSPA8 on viral polymerase activity, the minigenome assay was 
performed in the presence of the HSP70 inhibitor YM-01 (data not shown). Addition of 
the inhibitor resulted in a concentration dependent increase in viral polymerase activity. 
Even though this seems to be contradictory to the knock down results, one has to con-
sider that YM-01 not only modulates the activity of HSPA8, but also of other Hsp70 
family members such as HSPA1A, which has previously been shown to have an inhibi-
tory effect on influenza virus polymerase activity 181. Hence, it could not be determined 
which HSP70 member led to the increase in viral polymerase activity when cells were 
treated with YM-01. Moreover, it cannot be excluded that the inhibitor has previously 
undocumented off target effects that interfere with viral replication. Given that siRNA 
treatment is much more specific when investigating the role of individual HSP70 family 
members in viral replication and polymerase activity, these results were considered to 
have more relevance. 
Role of HSPA8 as a PB2 chaperone 
As previously mentioned, the relocation of HSPA8 to the nucleus at late time points of 
infection does not support a role for this chaperone on incoming viral polymerase pro-
teins. Early transcription from incoming vRNPs leads to expression of the early gene 
products PA, PB1, PB2 and NP which are then subsequently transported into the nu-
cleus after translation in the cytoplasm 62. PB1 and PA form a dimeric complex in the 
cytoplasm which is imported into the nucleus by RanBP5, while PB2 is imported into 
the nucleus separately by the importin α/β pathway 63. In the nucleus, PB2 and the 
PB1-PA dimer assemble to form the polymerase complex which in turn forms new 
vRNPs together with viral RNA and NP. Newly formed vRNPs then serve as a template 
for transcription of the late genes HA, NA, NEP, M2 and M1 62. Watanabe et al. pro-
posed that the nuclear export of newly formed vRNPs is regulated by HSPA8 via the 
formation of a CRM1-HSPA8-M1-vRNP complex mediated by the HSPA8 nuclear ex-
port sequence (see figure 1.7), thus supporting a role for HSPA8 at later time points 
during influenza virus infection 62. 
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Figure 4.2. Proposed model for the role of HSPA8 in the influenza virus replication cycle. 
The polymerase protein PB2 is expressed early in influenza virus infection. After translation, 
cytosolic HSPA8 acts as a chaperone to promote A/Pan/99 PB2 maturation and stability which 
is necessary for efficient viral replication (A). Even though HSPA8 can presumably also act as a 
chaperone for A/Thai/04 PB2, the high expression rate of PB2 allows for the generation of suffi-
ciently high concentrations of correctly folded protein even in the absence of the chaperone 
protein (B). Hence, A/Thai/04 is less dependent on HSPA8 for viral replication. Correctly folded 
PB2 and the PB1-PA dimer are separately transported into the nucleus where they form the 
trimeric polymerase complex. After formation of vRNPs together with newly synthesized vRNA 
and NP, HSPA8 (which relocates into the nucleus at late time points of infection) regulates the 
nuclear export of vRNPs via the formation of a CRM1-HSPA8-M1-vRNP complex 62. 
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The data presented in this thesis combined with the results from Watanabe et al. hint at 
a dual role for HSPA8 in the replication cycle of seasonal influenza viruses (see figure 
4.2). It is thought that cytosolic HSPA8 acts as a chaperone for newly translated poly-
merase protein PB2, facilitating protein maturation and stability, before PB2 is imported 
into the nucleus and united with the PA-PB1 heterodimer to form the functional viral 
polymerase complex. This theory is supported by the observation that HSPA8 deple-
tion leads to a depletion of PB2 and downregulation of viral polymerase activity, whilst 
viral polymerase activity is also decreased by overexpression of the HSPA8 co-factor 
BAG2 (figure 3.19 and 3.14). Fislová et al. obtained similar results regarding PB2 lev-
els and viral growth after depletion of the chaperonin containing TCP-1 (CCT) protein, 
proposing that CCT might act as a chaperone for PB2 in the cytoplasm 188. A similar 
role in maintaining the activity of influenza virus polymerase subunits before the for-
mation of mature vRNP complexes was also described for the heat shock protein 
Hsp90 64. After successful formation of new vRNPs in the nucleus, the viral M1 protein 
is expressed and transported into the nucleus, where M1 plays a role in the nuclear 
export of vRNPs. At this point HSPA8, no longer essential in the cytoplasm since ex-
pressed PB2 is now already part of newly formed vRNPs in the nucleus, accumulates 
in the nucleus and regulates vRNP export through its interaction with M1. Since HSPA8 
is also known to aid the import of cytoplasmic proteins into the nucleus 119, an addition-
al role for HSPA8 in the nuclear import of newly translated PB2 and/or M1 is also pos-
sible. 
As there were seemingly contradictory results, a clear cut role for HSPA8 in A/Thai/04 
polymerase activity is less obvious. A feature of H5N1 viruses is their ability to replicate 
to high viral titers 189. This was also observed in the present study; A/Thai/04 grew to 
higher viral titers, led to more profound CPE in infected cells and exhibited higher PB2 
expression levels than seasonal A/Pan/99. Given that H5N1 viruses replicate to high 
viral loads in several mammalian species without adaptation 189, a lower dependency 
on host cell factors and a less balanced interplay with the host cell can be assumed. 
Hence, the sheer amount of PB2 generated in the host cell during infection may abolish 
their dependency on host cell chaperone proteins. Therefore even though HSPA8 may 
support correct protein folding when supplied by overexpression, the lack of HSPA8 
may not necessarily result in lower viral polymerase activity. The likelihood of sufficient 
numbers of correctly folded PB2 protein to support high levels of viral polymerase activ-
ity being generated by chance is expected to be increased when high amounts of new-
ly synthesized proteins are produced. Under these circumstances, the decrease in 
HSPA8 mediated proteasomal degradation of highly abundant PB2 may outdo the 
slightly inhibitory effects of HSPA8 depletion on protein folding, thus resulting in a small 
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increase of A/Thai/04 polymerase activity in HSPA8 depleted cells. Whether the inhibi-
tory effect on protein folding becomes more important in an infectious/cellular stress 
context as suggested by Bortz et al. 127 cannot be elucidated with the results at hand. 
However, decreased viral titers in HSPA8 depleted cells at 16 hours p.i. may support 
this hypothesis. 
HSPA8 is a constitutively expressed protein of the HSP70 heat shock protein family 119. 
In addition to its various functions in normal cellular processes, HSPA8 has also been 
shown to play a role in several aspects of the replication cycle of different viruses, in-
cluding HSV-1 122, Japanese encephalitis 123 and turnip mosaic virus 124. With regards 
to the potential role of HSPA8 in the influenza virus replication cycle, an influence on 
influenza virus polymerase activity due to the function of HSPA8 in cellular stress re-
sponse 127, as well as a regulatory role in vRNP nuclear export through the interaction 
of HSPA8 with viral M1 protein, have previously been proposed 62,125,126. In this study, 
HSPA8 was shown to co-precipitate with PB2 of the seasonal A/Pan/99 and the highly 
pathogenic A/Thai/04 influenza virus strains. In addition, it was demonstrated that 
HSPA8 is important for A/Pan/99 PB2 integrity and, as a result, for its polymerase ac-
tivity. Thus, a role for the chaperone activity in facilitating PB2 maturation and increas-
ing PB2 stability, in addition to the role of HSPA8 in vRNP export, is proposed.  
The data presented in this thesis demonstrates that mass spectrometry is a powerful 
approach for identifying cellular interaction partners of viral proteins and, in combina-
tion with classical virological and molecular methods, a valuable tool for unravelling 
new cellular regulators of viral replication. 
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Supplementary information 
Table S.1. Cellular protein groups identified in the MS screen with a p-value of < 0.05 and 
a t-test difference of > 0. They represent protein groups that are significantly changed and are 
more abundant in A/Pan/99-PB2-Strep and/or A/Thai/04-PB2-Strep samples compared to the 
A/Pan/99-WT control. 
№ Gene Statistically significant and t-test difference 
of > 0 in 
1 ABCC1 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
2 ABCC3 A/Thai/04-PB2-Strep 
3 ACAA1 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
4 ACAA2 A/Thai/04-PB2-Strep 
5 ACACA A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
6 ACADM A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
7 ACAT1 A/Thai/04-PB2-Strep 
8 ACO1 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
9 ACO2 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
10 ACOT1;ACOT2 A/Thai/04-PB2-Strep 
11 ACOT9 A/Thai/04-PB2-Strep 
12 ACOX1 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
13 AGFG1 A/Pan/99-PB2-Strep 
14 AGL A/Pan/99-PB2-Strep 
15 AGR2 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
16 AIFM1 A/Thai/04-PB2-Strep 
17 AK2 A/Thai/04-PB2-Strep 
18 AKR1A1 A/Pan/99-PB2-Strep 
19 AKR1B1 A/Pan/99-PB2-Strep 
20 AKR1B10 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
21 AKR1C2 A/Pan/99-PB2-Strep 
22 AKR1D1 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
23 ALDH18A1 A/Thai/04-PB2-Strep 
24 ALDH1A1 A/Pan/99-PB2-Strep 
25 ALDH1B1 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
26 ALDH2 A/Thai/04-PB2-Strep 
27 ALDH3A1 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
28 ALDH3A2 A/Thai/04-PB2-Strep 
29 ANP32A A/Thai/04-PB2-Strep 
30 ANP32B A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
31 ANXA1 A/Pan/99-PB2-Strep 
32 ANXA4 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
33 ANXA5 A/Pan/99-PB2-Strep 
34 ANXA6 A/Pan/99-PB2-Strep 
35 APEH A/Pan/99-PB2-Strep 
36 APOBEC3C A/Pan/99-PB2-Strep 
37 AQR A/Thai/04-PB2-Strep 
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38 ARF1;ARF3 A/Pan/99-PB2-Strep 
39 ARF4 A/Pan/99-PB2-Strep 
40 ARL1 A/Thai/04-PB2-Strep 
41 ARPC5 A/Pan/99-PB2-Strep 
42 ASPH A/Thai/04-PB2-Strep 
43 ATP2A2 A/Thai/04-PB2-Strep 
44 ATP2B1 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
45 ATP5A1 A/Thai/04-PB2-Strep 
46 ATP5B A/Thai/04-PB2-Strep 
47 ATP5C1 A/Thai/04-PB2-Strep 
48 ATP5D A/Thai/04-PB2-Strep 
49 ATP5F1 A/Thai/04-PB2-Strep 
50 ATP5O A/Thai/04-PB2-Strep 
51 BAG2 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
52 BCAP31 A/Thai/04-PB2-Strep 
53 BLVRB A/Pan/99-PB2-Strep 
54 BPHL A/Thai/04-PB2-Strep 
55 C19orf10 A/Thai/04-PB2-Strep 
56 C1QBP A/Thai/04-PB2-Strep 
57 C21orf33 A/Thai/04-PB2-Strep 
58 CALM1;CALM2 A/Pan/99-PB2-Strep 
59 CALR A/Thai/04-PB2-Strep 
60 CALU A/Thai/04-PB2-Strep 
61 CAND1 A/Pan/99-PB2-Strep 
62 CANX A/Thai/04-PB2-Strep 
63 CAPG A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
64 CARS A/Pan/99-PB2-Strep 
65 CAST A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
66 CBR1 A/Pan/99-PB2-Strep 
67 CBR3 A/Pan/99-PB2-Strep 
68 CBR4 A/Thai/04-PB2-Strep 
69 CBX3 A/Thai/04-PB2-Strep 
70 CCDC58 A/Thai/04-PB2-Strep 
71 CECR5 A/Thai/04-PB2-Strep 
72 CKMT1A; CKMT1B A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
73 CLTC A/Pan/99-PB2-Strep 
74 CMAS A/Thai/04-PB2-Strep 
75 CMBL A/Pan/99-PB2-Strep 
76 CMPK1 A/Pan/99-PB2-Strep 
77 COPA A/Pan/99-PB2-Strep 
78 COPS4 A/Thai/04-PB2-Strep 
79 COX4I1 A/Thai/04-PB2-Strep 
80 CPD A/Thai/04-PB2-Strep 
81 CPS1 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
82 CRAT A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
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83 CRIP2 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
84 CROCC A/Pan/99-PB2-Strep 
85 CRYZ A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
86 CS A/Thai/04-PB2-Strep 
87 CST3 A/Thai/04-PB2-Strep 
88 CTSA A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
89 CTSB A/Thai/04-PB2-Strep 
90 CTSC A/Thai/04-PB2-Strep 
91 CTSC A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
92 CTSZ A/Thai/04-PB2-Strep 
93 CYB5B A/Thai/04-PB2-Strep 
94 CYC1 A/Thai/04-PB2-Strep 
95 CYCS A/Thai/04-PB2-Strep 
96 CYFIP2 A/Pan/99-PB2-Strep 
97 DAP3 A/Thai/04-PB2-Strep 
98 DBT A/Thai/04-PB2-Strep 
99 DDB1 A/Thai/04-PB2-Strep 
100 DDOST A/Thai/04-PB2-Strep 
101 DDX17 A/Thai/04-PB2-Strep 
102 DDX23 A/Thai/04-PB2-Strep 
103 DDX5 A/Thai/04-PB2-Strep 
104 DECR1 A/Thai/04-PB2-Strep 
105 DECR2 A/Thai/04-PB2-Strep 
106 DEK A/Thai/04-PB2-Strep 
107 DHCR7 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
108 DHTKD1 A/Thai/04-PB2-Strep 
109 DHX15 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
110 DHX9 A/Thai/04-PB2-Strep 
111 DIABLO A/Thai/04-PB2-Strep 
112 DIAPH1 A/Pan/99-PB2-Strep 
113 DLD A/Thai/04-PB2-Strep 
114 DLST A/Thai/04-PB2-Strep 
115 DNAJB11 A/Thai/04-PB2-Strep 
116 DTD2 A/Pan/99-PB2-Strep 
117 DYNC1H1 A/Pan/99-PB2-Strep 
118 ECH1 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
119 ECHS1 A/Thai/04-PB2-Strep 
120 ECI1;DCI A/Thai/04-PB2-Strep 
121 EFTUD2 A/Thai/04-PB2-Strep 
122 EML4 A/Pan/99-PB2-Strep 
123 EPDR1 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
124 EPHX1 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
125 ERP29 A/Thai/04-PB2-Strep 
126 ERP44 A/Thai/04-PB2-Strep 
127 ESYT2 A/Pan/99-PB2-Strep 
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128 ETFA A/Thai/04-PB2-Strep 
129 ETFB A/Thai/04-PB2-Strep 
130 ETHE1 A/Thai/04-PB2-Strep 
131 EZR A/Pan/99-PB2-Strep 
132 FAH A/Pan/99-PB2-Strep 
133 FAM21C;FAM21A A/Pan/99-PB2-Strep 
134 FARSB A/Pan/99-PB2-Strep 
135 FASN A/Pan/99-PB2-Strep 
136 FBL A/Thai/04-PB2-Strep 
137 FH A/Thai/04-PB2-Strep 
138 FIS1 A/Thai/04-PB2-Strep 
139 FKBP3 A/Pan/99-PB2-Strep 
140 FN1 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
141 FTH1 A/Thai/04-PB2-Strep 
142 FTL A/Thai/04-PB2-Strep 
143 G6PD A/Pan/99-PB2-Strep 
144 GAA A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
145 GALM A/Pan/99-PB2-Strep 
146 GCLM A/Pan/99-PB2-Strep 
147 GGH A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
148 GLA A/Thai/04-PB2-Strep 
149 GLB1 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
150 GLUD1;GLUD2 A/Thai/04-PB2-Strep 
151 GOLGA3 A/Pan/99-PB2-Strep 
152 GOT2 A/Thai/04-PB2-Strep 
153 GPC1 A/Thai/04-PB2-Strep 
154 GRHPR A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
155 GSS A/Pan/99-PB2-Strep 
156 GSTK1 A/Pan/99-PB2-Strep 
157 GTF2I A/Thai/04-PB2-Strep 
158 GTF3C1 A/Thai/04-PB2-Strep 
159 H3F3B A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
160 HADH A/Thai/04-PB2-Strep 
161 HADHA A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
162 HADHB A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
163 HEXA A/Thai/04-PB2-Strep 
164 HEXB A/Thai/04-PB2-Strep 
165 HIBADH A/Thai/04-PB2-Strep 
166 HIBCH A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
167 HINT2 A/Thai/04-PB2-Strep 
168 HIST1H2AJ A/Thai/04-PB2-Strep 
169 HIST1H2BL A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
170 HIST1H4A A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
171 HK1 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
172 HMGN1 A/Thai/04-PB2-Strep 
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173 HMGN2 A/Thai/04-PB2-Strep 
174 HNRNPA1;L2 A/Thai/04-PB2-Strep 
175 HNRNPC A/Thai/04-PB2-Strep 
176 HNRNPM A/Thai/04-PB2-Strep 
177 HNRNPU A/Thai/04-PB2-Strep 
178 HNRNPUL1 A/Thai/04-PB2-Strep 
179 HNRNPUL2 A/Thai/04-PB2-Strep 
180 HSD17B10 A/Thai/04-PB2-Strep 
181 HSD17B4 A/Thai/04-PB2-Strep 
182 HSD17B8 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
183 HSP90B1 A/Thai/04-PB2-Strep 
184 HSPA1A; HSPA1B A/Thai/04-PB2-Strep 
185 HSPA2 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
186 HSPA4 A/Thai/04-PB2-Strep 
187 HSPA5 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
188 HSPA6 A/Thai/04-PB2-Strep 
189 HSPA8 A/Thai/04-PB2-Strep 
190 HSPA9 A/Thai/04-PB2-Strep 
191 HSPD1 A/Thai/04-PB2-Strep 
192 HTATIP2 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
193 HTATSF1 A/Thai/04-PB2-Strep 
194 HYOU1 A/Thai/04-PB2-Strep 
195 IARS A/Pan/99-PB2-Strep 
196 IARS2 A/Thai/04-PB2-Strep 
197 ICT1 A/Thai/04-PB2-Strep 
198 IDH1 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
199 IDH2 A/Thai/04-PB2-Strep 
200 IDH3A A/Thai/04-PB2-Strep 
201 IDH3B A/Thai/04-PB2-Strep 
202 IL18 A/Pan/99-PB2-Strep 
203 ILF3 A/Thai/04-PB2-Strep 
204 ILKAP;ILKAP3 A/Pan/99-PB2-Strep 
205 IQGAP1 A/Pan/99-PB2-Strep 
206 ISOC2 A/Thai/04-PB2-Strep 
207 ITGA6 A/Thai/04-PB2-Strep 
208 ITGAV A/Thai/04-PB2-Strep 
209 ITGB5 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
210 KCNJ8 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
211 KDELR1 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
212 KIAA1598 A/Pan/99-PB2-Strep 
213 KIF5B A/Pan/99-PB2-Strep 
214 KRT18 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
215 KTN1 A/Thai/04-PB2-Strep 
216 KYNU A/Pan/99-PB2-Strep 
217 LACTB2 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
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218 LAMB1 A/Thai/04-PB2-Strep 
219 LAMC1 A/Thai/04-PB2-Strep 
220 LAMP1 A/Thai/04-PB2-Strep 
221 LDHB A/Pan/99-PB2-Strep 
222 LGALS3 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
223 LGALS3BP A/Thai/04-PB2-Strep 
224 LMAN1 A/Thai/04-PB2-Strep 
225 LRPPRC A/Thai/04-PB2-Strep 
226 LRRFIP1 A/Pan/99-PB2-Strep 
227 LTA4H A/Pan/99-PB2-Strep 
228 LXN A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
229 LYPLAL1 A/Pan/99-PB2-Strep 
230 MANF A/Thai/04-PB2-Strep 
231 MATR3 A/Thai/04-PB2-Strep 
232 MB A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
233 MCCC2 A/Thai/04-PB2-Strep 
234 MCM2 A/Thai/04-PB2-Strep 
235 MCM3 A/Thai/04-PB2-Strep 
236 MCM4 A/Thai/04-PB2-Strep 
237 MCM6 A/Thai/04-PB2-Strep 
238 MCM7 A/Thai/04-PB2-Strep 
239 MCU A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
240 MDH1 A/Pan/99-PB2-Strep 
241 MDH2 A/Thai/04-PB2-Strep 
242 ME1 A/Pan/99-PB2-Strep 
243 MESDC2 A/Thai/04-PB2-Strep 
244 MGST1 A/Thai/04-PB2-Strep 
245 MLEC A/Thai/04-PB2-Strep 
246 MPST A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
247 MRE11A A/Thai/04-PB2-Strep 
248 MRPL17 A/Thai/04-PB2-Strep 
249 MRPL18 A/Thai/04-PB2-Strep 
250 MRPL19 A/Thai/04-PB2-Strep 
251 MRPL20 A/Thai/04-PB2-Strep 
252 MRPL21 A/Thai/04-PB2-Strep 
253 MRPL30 A/Thai/04-PB2-Strep 
254 MRPL43 A/Thai/04-PB2-Strep 
255 MRPL46 A/Thai/04-PB2-Strep 
256 MRPS24 A/Thai/04-PB2-Strep 
257 MRPS28 A/Thai/04-PB2-Strep 
258 MRPS34 A/Thai/04-PB2-Strep 
259 MRRF A/Thai/04-PB2-Strep 
260 MT-CO2 A/Thai/04-PB2-Strep 
261 MVP A/Pan/99-PB2-Strep 
262 MYH10 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
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263 MYO1B A/Pan/99-PB2-Strep 
264 NANS A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
265 NCBP1 A/Thai/04-PB2-Strep 
266 NCBP2 A/Thai/04-PB2-Strep 
267 NCL A/Thai/04-PB2-Strep 
268 NCSTN A/Thai/04-PB2-Strep 
269 NDUFA12 A/Thai/04-PB2-Strep 
270 NDUFA6 A/Thai/04-PB2-Strep 
271 NDUFS1 A/Thai/04-PB2-Strep 
272 NDUFS3 A/Thai/04-PB2-Strep 
273 NHP2L1 A/Thai/04-PB2-Strep 
274 NIPSNAP1 A/Thai/04-PB2-Strep 
275 NIPSNAP3A A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
276 NME2;NME1 A/Pan/99-PB2-Strep 
277 NME3 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
278 NME4 A/Thai/04-PB2-Strep 
279 NOMO1;2;3 A/Thai/04-PB2-Strep 
280 NONO A/Thai/04-PB2-Strep 
281 NPEPL1 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
282 NPLOC4 A/Pan/99-PB2-Strep 
283 NPM1 A/Thai/04-PB2-Strep 
284 NQO2 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
285 NUDT21 A/Thai/04-PB2-Strep 
286 NUP155 A/Thai/04-PB2-Strep 
287 NUP210 A/Thai/04-PB2-Strep 
288 OGDH A/Thai/04-PB2-Strep 
289 P4HB A/Thai/04-PB2-Strep 
290 PABPC1;PABPC3 A/Thai/04-PB2-Strep 
291 PAFAH1B2 A/Pan/99-PB2-Strep 
292 PARK7 A/Pan/99-PB2-Strep 
293 PC A/Thai/04-PB2-Strep 
294 PCCA A/Thai/04-PB2-Strep 
295 PCCB A/Thai/04-PB2-Strep 
296 PCK2 A/Thai/04-PB2-Strep 
297 PDHA1 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
298 PDHB A/Thai/04-PB2-Strep 
299 PDIA3 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
300 PDIA4 A/Thai/04-PB2-Strep 
301 PDIA6 A/Thai/04-PB2-Strep 
302 PGD A/Pan/99-PB2-Strep 
303 PHB A/Thai/04-PB2-Strep 
304 PHB2 A/Thai/04-PB2-Strep 
305 PIR A/Pan/99-PB2-Strep 
306 PLD3 A/Thai/04-PB2-Strep 
307 PLOD3 A/Thai/04-PB2-Strep 
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308 PLXNB2 A/Thai/04-PB2-Strep 
309 POFUT1 A/Thai/04-PB2-Strep 
310 POLR1A A/Thai/04-PB2-Strep 
311 PON2 A/Thai/04-PB2-Strep 
312 POR A/Thai/04-PB2-Strep 
313 PPA2 A/Thai/04-PB2-Strep 
314 PPIB A/Thai/04-PB2-Strep 
315 PPP2R4 A/Pan/99-PB2-Strep 
316 PRDX1 A/Pan/99-PB2-Strep 
317 PRDX3 A/Thai/04-PB2-Strep 
318 PRDX4 A/Thai/04-PB2-Strep 
319 PRDX5 A/Thai/04-PB2-Strep 
320 PRKDC A/Thai/04-PB2-Strep 
321 PRPF19 A/Thai/04-PB2-Strep 
322 PRPF8 A/Thai/04-PB2-Strep 
323 PSMA3 A/Pan/99-PB2-Strep 
324 PSMB1 A/Thai/04-PB2-Strep 
325 PSMB5 A/Thai/04-PB2-Strep 
326 PSMD5 A/Pan/99-PB2-Strep 
327 PSME2 A/Pan/99-PB2-Strep 
328 PTCD3 A/Thai/04-PB2-Strep 
329 PYCARD A/Pan/99-PB2-Strep 
330 RAB10 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
331 RAB11A;B A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
332 RAB1A A/Thai/04-PB2-Strep 
333 RAB27B A/Thai/04-PB2-Strep 
334 RAB2A;B A/Thai/04-PB2-Strep 
335 RAD50 A/Thai/04-PB2-Strep 
336 RAP1B;A A/Thai/04-PB2-Strep 
337 RBM12 A/Thai/04-PB2-Strep 
338 RBM12B A/Thai/04-PB2-Strep 
339 RBMX;L1 A/Thai/04-PB2-Strep 
340 RCN1 A/Thai/04-PB2-Strep 
341 RCN2 A/Thai/04-PB2-Strep 
342 RDH11 A/Thai/04-PB2-Strep 
343 RDX A/Pan/99-PB2-Strep 
344 RECQL A/Pan/99-PB2-Strep 
345 REEP5 A/Thai/04-PB2-Strep 
346 RNPEP A/Pan/99-PB2-Strep 
347 RPL12 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
348 RPL13a A/Pan/99-PB2-Strep 
349 RPL17 A/Pan/99-PB2-Strep 
350 RPL24 A/Pan/99-PB2-Strep 
351 RPL28 A/Pan/99-PB2-Strep 
352 RPL30 A/Thai/04-PB2-Strep 
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353 RPL35 A/Thai/04-PB2-Strep 
354 RPL9 A/Thai/04-PB2-Strep 
355 RPN2 A/Thai/04-PB2-Strep 
356 RPP25 A/Thai/04-PB2-Strep 
357 RPP30 A/Thai/04-PB2-Strep 
358 RPS11 A/Pan/99-PB2-Strep 
359 RPS12 A/Pan/99-PB2-Strep 
360 RPS15A A/Pan/99-PB2-Strep 
361 RPS18 A/Pan/99-PB2-Strep 
362 RPS24 A/Pan/99-PB2-Strep 
363 RPS27A;UBB;P4C;UBA52 A/Thai/04-PB2-Strep 
364 RPS6 A/Pan/99-PB2-Strep 
365 RPS6KA3 A/Pan/99-PB2-Strep 
366 RRAGB;RRAGA A/Pan/99-PB2-Strep 
367 RRBP1 A/Thai/04-PB2-Strep 
368 RTN3 A/Thai/04-PB2-Strep 
369 SAE1 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
370 SARS2 A/Thai/04-PB2-Strep 
371 SART3 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
372 SCARB2 A/Thai/04-PB2-Strep 
373 SCO1 A/Thai/04-PB2-Strep 
374 SCP2 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
375 SDF2 A/Thai/04-PB2-Strep 
376 SDF2L1 A/Thai/04-PB2-Strep 
377 SDHB A/Thai/04-PB2-Strep 
378 SEC11A A/Thai/04-PB2-Strep 
379 SEC22B A/Thai/04-PB2-Strep 
380 SEC23A A/Pan/99-PB2-Strep 
381 SEC31A A/Pan/99-PB2-Strep 
382 SEL1L A/Thai/04-PB2-Strep 
383 SERPINB1 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
384 SERPINH1 A/Thai/04-PB2-Strep 
385 SET A/Thai/04-PB2-Strep 
386 SF3A1 A/Thai/04-PB2-Strep 
387 SF3A3 A/Thai/04-PB2-Strep 
388 SF3B1 A/Thai/04-PB2-Strep 
389 SF3B2 A/Thai/04-PB2-Strep 
390 SF3B3 A/Thai/04-PB2-Strep 
391 SFPQ A/Thai/04-PB2-Strep 
392 SFXN1 A/Thai/04-PB2-Strep 
393 SGTA A/Thai/04-PB2-Strep 
394 SIN3A A/Thai/04-PB2-Strep 
395 SLC12A2 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
396 SLC25A1 A/Thai/04-PB2-Strep 
397 SLC25A5 A/Thai/04-PB2-Strep 
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398 SLC25A6 A/Thai/04-PB2-Strep 
399 SLC4A1AP A/Thai/04-PB2-Strep 
400 SMARCC2 A/Thai/04-PB2-Strep 
401 SMC1A A/Thai/04-PB2-Strep 
402 SMEK1 A/Thai/04-PB2-Strep 
403 SNRNP200 A/Thai/04-PB2-Strep 
404 SNRNP70 A/Thai/04-PB2-Strep 
405 SNRPA1 A/Thai/04-PB2-Strep 
406 SNRPB;SNRPN A/Thai/04-PB2-Strep 
407 SNRPB2 A/Thai/04-PB2-Strep 
408 SNRPD1 A/Thai/04-PB2-Strep 
409 SNRPD2 A/Thai/04-PB2-Strep 
410 SNRPD3 A/Thai/04-PB2-Strep 
411 SOD1 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
412 SPCS2 A/Thai/04-PB2-Strep 
413 SPCS3 A/Thai/04-PB2-Strep 
414 SPR A/Pan/99-PB2-Strep 
415 SRC A/Thai/04-PB2-Strep 
416 SRP14 A/Thai/04-PB2-Strep 
417 SRRT A/Thai/04-PB2-Strep 
418 SRSF1 A/Thai/04-PB2-Strep 
419 SRSF2 A/Thai/04-PB2-Strep 
420 SRSF3 A/Thai/04-PB2-Strep 
421 SRSF6 A/Thai/04-PB2-Strep 
422 SSB A/Thai/04-PB2-Strep 
423 SSBP1 A/Thai/04-PB2-Strep 
424 SSR4 A/Thai/04-PB2-Strep 
425 SSRP1 A/Thai/04-PB2-Strep 
426 STAG2 A/Thai/04-PB2-Strep 
427 SUB1 A/Thai/04-PB2-Strep 
428 SUCLA2 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
429 SUCLG1 A/Thai/04-PB2-Strep 
430 SUCLG2 A/Thai/04-PB2-Strep 
431 SUMO1 A/Thai/04-PB2-Strep 
432 SUMO2 A/Thai/04-PB2-Strep 
433 SUPT16H A/Thai/04-PB2-Strep 
434 SUPT5H A/Thai/04-PB2-Strep 
435 SUPT6H A/Thai/04-PB2-Strep 
436 SWAP70 A/Pan/99-PB2-Strep 
437 SYNGR2 A/Thai/04-PB2-Strep 
438 TALDO1 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
439 TBCB A/Pan/99-PB2-Strep 
440 TCERG1 A/Thai/04-PB2-Strep 
441 TCOF1 A/Thai/04-PB2-Strep 
442 THOC1 A/Thai/04-PB2-Strep 
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443 THOP1 A/Pan/99-PB2-Strep 
444 TIGAR A/Pan/99-PB2-Strep 
445 TKT A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
446 TLN1 A/Pan/99-PB2-Strep 
447 TMED10 A/Thai/04-PB2-Strep 
448 TMED2 A/Thai/04-PB2-Strep 
449 TMED3 A/Thai/04-PB2-Strep 
450 TMED9 A/Thai/04-PB2-Strep 
451 TMEM106B A/Pan/99-PB2-Strep 
452 TMEM70 A/Thai/04-PB2-Strep 
453 TOMM20 A/Thai/04-PB2-Strep 
454 TOP2A A/Thai/04-PB2-Strep 
455 TOP2B A/Thai/04-PB2-Strep 
456 TPM1 A/Pan/99-PB2-Strep 
457 TPP2 A/Pan/99-PB2-Strep 
458 TPR A/Thai/04-PB2-Strep 
459 TPT1 A/Pan/99-PB2-Strep 
460 TRAP1 A/Thai/04-PB2-Strep 
461 TRAPPC3 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
462 TRMT61A A/Thai/04-PB2-Strep 
463 TST A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
464 TTBK2 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
465 TUFM A/Thai/04-PB2-Strep 
466 TXNDC12 A/Thai/04-PB2-Strep 
467 TXNDC5 A/Thai/04-PB2-Strep 
468 UBA1 A/Pan/99-PB2-Strep 
469 UBA2 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
470 UGDH A/Pan/99-PB2-Strep 
471 UGGT1 A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
472 UGP2 A/Pan/99-PB2-Strep 
473 UQCRC1 A/Thai/04-PB2-Strep 
474 UQCRC2 A/Thai/04-PB2-Strep 
475 UQCRFS1;P1 A/Thai/04-PB2-Strep 
476 USO1 A/Pan/99-PB2-Strep 
477 USP7 A/Thai/04-PB2-Strep 
478 UTRN A/Pan/99-PB2-Strep and A/Thai/04-PB2-Strep 
479 VAPA A/Thai/04-PB2-Strep 
480 VCP A/Pan/99-PB2-Strep 
481 VPS29 A/Pan/99-PB2-Strep 
482 WDR5 A/Thai/04-PB2-Strep 
483 XRCC5 A/Thai/04-PB2-Strep 
484 YWHAB A/Pan/99-PB2-Strep 
485 YWHAG A/Pan/99-PB2-Strep 
486 YWHAZ A/Pan/99-PB2-Strep 
487 ZC3HAV1 A/Thai/04-PB2-Strep 
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Table S.2. t-test difference and p-values of A/Pan/99 viral proteins identified in MS 
screen. Data was calculated using Perseus 1.5.0.31. 
Protein t-test difference p value 
PB2 358.29 0.000041 
PB1 24.10 0.000656 
PA 214.38 0.000062 
HA 5.27 0.005236 
NA 3.15 0.041400 
NP 76.11 0.000394 
M1 9.02 0.080168 
M2 6.35 1.000000 
NS1 5.02 0.013032 
 
Table S.3. t-test difference and p-values of A/Thai/04 viral proteins identified in MS 
screen. Data was calculated using Perseus 1.5.0.31. 
Protein t-test difference p value 
PB2 992.55 0.000033 
PB1 318.03 0.001205 
PA 601.74 0.001371 
HA 118.44 0.002851 
NA 5.94 0.043551 
NP 125.80 0.000916 
M1 206.36 0.002938 
M2 97.68 0.002360 
NS1 217.22 0.000220 
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